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Abstract 
Hepatitis C virus (HCV) infects an estimated 170 million people and is 
responsible for considerable morbidity and mortality worldwide. Successful 
resolution of infection is achieved naturally in approximately 30% of infected 
individuals and correlates with a strong T cell response. Furthermore, treatment 
with interferon (IFN)a achieves sustained virologic response in approximately 
50% of chronically infected individuals. Conventional dendritic cells (cDCs), as 
the most potent antigen presenting cells, and plasmacytoid DCs (pDCs), as the 
principal IFNa/|3 producing cells, serve as potential targets for both immune 
evasion and therapeutic strategies. In order to evaluate the effects of HCV on DC 
function, we compared phenotypic and functional characteristics of DCs from 
chronically infected patients to DCs from healthy donors. Our results suggest 
that despite non-specific decreases in total numbers, DC phenotypic and 
functional integrity is maintained. Consequently, we propose that other factors 
associated with HCV immunity may act on DCs to regulate pathogenesis and 
immunity. In light of the important roles of IFNa/p and CD4+ T cells in the 
clinical response to HCV, we focused on the interplay of these factors with DCs 
during CD8+ T cell priming. Using a human in vitro cross-presentation system, 
we found that IFNa/p acts on immature DCs (iDCs) to inhibit CD8+ T cell 
activation by cross-presentation. Further analysis revealed that ST ATI-
dependent inhibition of CD40-induced IL-12 was responsible for this block. In 
contrast, a switch from STAT1 to STAT4 signaling enabled an immune enhancing 
effect of IFNa/p on mature DCs (mDCs) that potentiated CD8+ T cell activation. 
In order to evaluate this latter effect in vivo, we monitored the ability of pDC 
IFNa/p production to substitute for CD4+ T cells in CD8+ T cell priming. The 
results revealed that pDC activation overcomes the need for CD4 'help' in 
priming CD8+ T cell responses in an IFNa/p receptor-dependent manner. 
Importantly, IFNa/p produced by non-pDCs did not provide similar priming 
signals. These results provide support for HCV immunotherapy trials and offer 
a unique mechanism to account for the dual effects of IFNa/p in pathogenesis 
and immunity. 
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Chapter 1: Defining a role for D C s in H C V pathogenesis 
1.1 Introduction 
Hepatitis C virus (HCV) infects an estimated 170 million people worldwide and, 
as a leading cause of cirrhosis and liver disease, is associated with considerable 
morbidity and mortality. In order to develop vaccine strategies to reduce disease 
burden, a comprehensive understanding of the components of effective HCV 
immunity is needed. Two important discoveries have been critical in this regard. 
First, extensive characterization of the immune response to HCV infection 
revealed that strong cell-mediated immunity correlates with resolution of 
infection. Second, interferon-alpha (IFNa) is a highly effective treatment for 
chronic HCV infection. In light of these findings, I have focused on the role that 
two important dendritic cell (DC) subsets play in these 
phenomena—conventional DCs (cDCs) as potent stimulators of the adaptive 
immune response and plasmacytoid DCs (pDCs) as the main producers of IFNa. 
Moreover, I will discuss the mechanisms of IFNa/p production and signaling 
involved in its effects on adaptive immunity. A better understanding of the role 
of DCs in orchestrating effective HCV immunity will provide insight into the 
pathogenesis of and therapeutic strategies for HCV. 
1.2. H C V Immunology 
The immune system evolved to protect multicellular organisms from invading 
pathogens. Like any good security system, the immune system has surveillance 
and effector divisions to deal with these intruders; but, it is not just search and 
destroy. The immune systems must also strive to 'do no harm' to the host. 
Kilting the pathogen at the expense of the host would not be evolutionarily 
advantageous. Similarly, invading pathogens have evolved in keeping with 
these rules; they maintain a vested interest in host survival to allow for 
replication and transmission. As such, they have evolved intricate mechanisms 
of immune evasion in order to maintain their survival. These mechanisms of 
evasion may either be direct antagonism of the immune response or 
immunologic jujitsu (using the host response for its own benefit). An 
understanding of these mechanisms offers insight into the important aspects for 
pathogen survival, key targets for therapeutic intervention, and fundamental 
mechanisms of the host immune response. 
It is with these goals that I have considered the over-riding question of 
hepatitis C virus (HCV) immunology: Why do some people naturally clear HCV 
infection and some people progress to chronic infection? In order to address the 
question fully, I focus not only on the host's ability to respond, but also on the 
virus' ability to evade. 
Pathogenesis and public health impact of HCV 
Current estimates suggest that 3% of the world's population (approximately 170 
million people) is infected with HCV1. Although HCV less commonly causes 
acute hepatitis (10-40% of infections), more than 70% of infected persons 
progress to chronic infection2 (Fig. 1.1). Chronic H C V is a major cause of chronic 
liver disease and hepatocellular carcinoma (HCC). According to the World 
Health Report of 2004, liver cirrhosis and HCC accounted for 1.4 million deaths, 
20% of which are likely attributable to HCV infection3. In addition, HCV 
infection is linked to numerous co-mordibities (e.g. type II cyroglobulinemia) 
and is a leading cause of liver transplant in the USA and Europe. 
The development of identification tools for hepatitis A and hepatitis B 
over 30 years ago allowed for the identification of non-A, non-B hepatitis 
transmissible by infected blood and blood products4. The causative agent was 
identified as HCV in 1989 by expression cloning of cDNAs from the serum of an 
infected patient5. Until effective screening measures where implemented in July 
1992, infection was commonly passed through blood transfusions, hemodialysis, 
and organ transplantation2. Furthermore, the use of contaminated needles for 
vaccination campaigns from the 60's-70's are thought to have been responsible 
for high rates of exposures in some areas6. Worldwide public health initiatives 
to screen the blood supply for HCV and to provide clean medical supplies 
significantly reduced the incidence of HCV infection. According to the Center for 
Disease Control, the incidence of HCV infection dropped from 240,000/year in 
the 1980s to 30,000 in 20037. Today, the highest incidence of HCV is among 
intravenous drug users. Shared risk factors with HIV make co-infection quite 
common. In fact, 50-90% of HIV infected injection drug users are co-infected and 
show more rapid progression to liver disease 8. 
>30 years: female, young age at infection 
N o r m a l 
Liver 
Acute 
Infection 
1 
Chronic 
Infection 
Develops 
in 7 0 % 
H C C risk 
is 1-4% 
per year 
< 20 years: alcohol use, 
H I V coinfection 
Figure 1.1 H C V Pathogenesis. Following exposure, acute H C V 
infection ensues. Although previous estimates underestimated the 
percentage of resolvers, chronic infection develops in the majority of 
infections and cirrhosis develops in 2 0 % of those chronically infected. 
Progression to cirrhosis is usually slower in females and those 
infected at younger age. Progression to cirrhosis is generally 
accelerated in those with concomitant alcohol use or HIV co-
infection. In patients with H C V cirrhosis, the risk of developing 
hepatocellular carcinoma (HCC) is 1-4% per year (adapted from 
Lauer and Walker, NEJM, 2001). 
H C V — T h e stealth virus 
HCV is often termed the stealth virus for its ability to establish chronic infection 
without efficient detection and clearance by the immune system. In addition, 
this name also describes its penchant for evading experimental systems that 
would allow for the characterization of its structure, function, and interaction 
with its host. Notably, HCV research has been limited by inefficient cell culture 
systems and the lack of a small animal model. 
Despite these limitations, considerable details of genome structure and 
protein function have been elucidated. cDNA cloning of the HCV genome 
revealed a single-stranded RNA with positive polarity eventually determined to 
be 9.6kb and placed into the Flaviviridae family due to sequence similarity5. In 
lieu of a 5'-cap structure, the 5'-non coding region (NCR) of HCV has been 
shown to have IRES activity9 and binds directly to ribosomal 40S subunit and 
translational initiation factor eIF3 10 enabling translation from entering RNA. All 
ten HCV proteins are translated as a single polyprotein and processed by auto-
catalytic cleavage or proteolytic cleavage (Fig. 1.2). 
The amino-terminal section of the polyprotein contains the structural 
proteins (Core, El, and E2) followed by a small integral membrane protein p7 
which may function as an ion channel. Core protein is a highly conserved basic 
protein existing in 19- and 21-kd forms. Similar to other structural core proteins, 
HCV core protein promotes virion formation by binding viral RNA and 
associating with membranes at the cytoplasmic surface of the ER11. Envelope 
glycoproteins El and E2 likely play an important role in mediating viral entry. 
Biochemical data suggests that E2 binds to CD81, a tetraspanin expressed on 
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of the H C V polyprotein. The polyprotein is cleaved as indicated in 
the figure. The putative functions of the proteins in the H C V life 
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various cell types including hepatocytes and B cells12. However, the lack of an 
infectious cell culture system prevented the functional evaluation of E2 and 
CD81 in veritable infection. The development of HCV pseudoparticles (HCVpp) 
with HCV E1/E2 glycoproteins on the surface of a replication deficient HIV 
particle enabled the functional assessment of this association and confirmed the 
importance of E2 interaction with CD81 to mediate infection13"15. More recently, 
the development of an infectious HCV cell culture (HCVcc) system further 
validated the importance of E2, as well as CD81, in mediating viral entry16~18. El 
may also play a role in entry. Sequence similarity of El residues 264-290 with 
fusion peptides from related virus glycoproteins suggest that El may play an 
analogous role in mediating entry 19. 
The remainder of the genome encodes the non-structural (NS) proteins 
(NS2, NS3, NS4A, NS4B, NS5A, NS5B) that play a crucial role in viral processing 
and replication. NS3 is a 70kd protein with a serine protease domain and an 
NTPase/helicase domain. NS3 is required for infectivity in vivo and acts with 
NS4A co-factor to cleave NS3-4A, NS4A-4B, and NS4B-5A. NS5A-5B cleavage 
does not require NS4A co-factor activity20. The role of NS3 helicase activity in 
viral replication is not clear; however, mutations disrupting helicase function are 
not infectious 21. Adaptive mutations in NS4B, NS5A, and NS5B strongly 
enhance replication, suggesting that these proteins are important in the HCV 
replication machinery22. NS5A is a membrane associated zinc metalloprotein 
protein that exists in different phosphorylation states (56- and 58-kd). Zinc 
coordination is required for NS5A function in the HCV replication complex23,24, 
but its exact function remains unclear. Finally, NS5B is the RNA-dependent 
RNA polymerase (RdRP) responsible for viral replication. Mutation of the 
highly conserved G D D motif ablates in vivo infectivity21. The high error rate of 
the RdRP enables escape mutations and quasispecies to develop within the 
infected individual25. 
Understanding effective HCV immunity 
Although the lack of a small animal model for HCV precludes extensive probing 
of host immunity, an important human model exists for the study of effective 
HCV immunity—natural resolvers. Recent estimates suggest that nearly 30% of 
those exposed to HCV clear the infection naturally and extensive work has been 
done to characterize the nature of the immune response to HCV in humans. 
Current results suggest that CD4+ and CD8+ T cells play an important role in 
controlling acute infection, but significant data also exist for the involvement of 
other cells. Moreover, chimpanzees also succumb to HCV infection. Studies 
with these animals have enabled extensive probing of the immune cells involved 
in protective immunity. 
The role for B cells in HCV immunity is complex. The high prevalence of 
mixed cryoglobulinemia and lymphoma in chronic HCV has directed several 
groups to investigate the role for HCV in driving B cell abnormalities26. One 
study suggested a direct link between these abnormalities and HCV infection 
showing that 7 out of 7 patients with splenic lymphoma with villous 
lymphocytes in the setting of chronic HCV went into remission following 
treatment of their HCV with IFNa therapy27. E2 binding of CD81, a component 
of the B cell co-receptor complex, provided a possible mechanism for HCV 
antigen driving B cell abnormalities12; however, despite accumulation of naive B 
cells in the peripheral blood of H C V patients, antigenic stimulation does not 
seem to be responsible for B cell activation and differentiation28. 
Neutralizing antibodies play an important role in protective immunity to 
many viral infections;29 however, the importance of antibodies in HCV immunity 
is not clear. HCV-specific antibodies usually appear 7-8 weeks after infection 
and there is evidence to suggest that they may neutralize infection both in vitro30 
and in vivo 31. The putative target of some of these neutralizing antibodies is the 
N-terminal region of E2 which contains a hypervariable region (HVR1)30. 
Sequence changes in the HVR-1 of E2 that occurred simulataneously with 
antibody seroconversion suggest that antibody drives viral mutations. However, 
early studies in chimpanzees and humans suggest that antibody seroconversion 
does not protect against re-infection32,33. Furthermore, resolution may occur in 
the absence of antibody seroconversion34,35. Specific qualitative properties of B 
cell function and antibody specificity may be important parameters for 
conferring protection in vivo. A more extensive evaluation of neutralizing 
antibodies with the recently developed HCVcc system may offer new insight into 
their importance. 
Natural Killer (NK) cells may play an important role in mediating 
effective innate immunity in HCV infection. When activated by virally infected 
cells, NK cells release IFNy and cytolytic granules. In vitro studies suggest that 
E2 engagement of CD81 on NK cells may modulate cytokine production and NK 
cell effector function36. A recent study aimed at identifying genetic susceptibility 
to chronic HCV infection showed that patients with a specific NK inhibitory 
receptor (KIR2DL3) and HLA haplotype (HLA-C) were more likely to clear 
infection37. The inability of HLA-C to interact with KIR2DL3 may lower the 
threshold for N K cell activation. One caveat of this study is that the correlation 
only held for patients infected from "low dose" exposures. 
Considerable effort has been made to understand the role of HCV-specific 
T cells in viral clearance. Specifically, CD8+ T cells are crucial in host defense 
against viral infection. CD8+ 'killer' T cells or cytotoxic T lymphocytes (CTLs) 
recognize infected cells in an antigen specific manner by T cell receptor 
engagement of foreign peptides bound to MHC class I (MHCI) molecules on the 
cell surface of the infected cell. Thus engaged, the cytotoxic effect can be 
achieved by release of apoptosis inducing granzymes or pore forming peforins as 
well as a membrane-bound apoptosis-inducing ligand called Fas. In addition, 
CTLs can also produce IFNy which can inhibit viral replication, induce MHCI 
upregulation, and activate macrophage effector functions38. Consequently, both 
the cytolytic and noncytolytic functions of CTLs are important in controlling 
viral infection39. 
Early work showed that CD8+ T cell immune responses are important 
prognostic indicators in acute infections40 (Fig. 1.3). Similarly, protective 
immunity in chimpanzees correlates with HCV-specific cellular immunity, not 
antibody response M. Numerous studies have offered correlative support for the 
role of T cell immunity in HCV clearance41. Direct evaluation of the role for 
CD8+ T cells by in vivo depletion resulted in prolonged viremia offering proof 
that CD8+ T cells play a crucial role in mediating resolution42. However, CD8+ T 
cell responses are also seen in chronic infection and do not always correlate with 
clinical outcome43. As such, differences in CTL effector function in the tissue may 
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Figure 1.3. T cell immunity plays a key role in the outcome of H C V 
infection. Liver injury is observed weeks to months following initial 
viremia as evidenced by the rise in transaminase levels. A. Although 
T cell responses are variable during progression to chronic infection, 
both the CD8+ and CD4+ T cell responses are generally blunted. B. 
In contrast, robust CD8+ and CD4+ T cell responses correlate with 
viral resolution and normal transminase (adapted from Bowen and 
Walker, 2005 Nature). 
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account for their variable efficacy in viral clearance. Several reports have 
suggested impaired cytokine secretion and cytotoxic function in vitro44,45; 
however, the function of CD8+ T cells in situ is not known. Further, differences 
in the differentiation of HCV specific memory T cells may account for limited 
effector functions46. 
Several studies suggest that CD4+ T cells are an important determinant 
for effective CD8+ T cell immunity to HCV. In vivo depletion of CD4+ T cells in a 
chimpanzee that had previously resolved infection prevented effective CD8+ T 
cell immunity in a subsequent infection and allowed escape mutations to 
develop47. Although the elimination of CD4+ T cells is not possible in humans, 
studies in HIV/HCV co-infected patients offer similar data suggesting that the 
diversity of the CD4 response is an important determinant for the magnitude 
and breadth of the CD8+ T cell response to HCV48. A unique instance in which 
two patients infected from a single source resulted in different clinical outcomes 
also suggests that CD4+ T cell diversity is important in supporting CD8+ T cell 
responses during acute infection49. Finally, development of regulatory T (Treg) 
cells, CD4+/CD25+ T cells that inhibit T cell activation50, may also modulate 
HCV specific T cell function51, but the antigen specificity of Treg cell activity is still 
unclear. 
The strong evidence suggesting the importance of cell-mediated immunity 
in an effective HCV immune response has raised many questions concerning the 
components involved in generating this response. In order to explore these 
questions, I have focused on two aspects of HCV immunity: the role of dendritic 
cells (DCs) and the effect of IFNa/p. First, we will consider the DC as a pivotal 
player in the priming of a T cell response. 
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1.3. Dendritic Cells 
The 'sentinels' of the immune system 
The initiation of an immune response is a complex process. The invading 
antigens and the lymphocytes that respond to their assault have long been 
appreciated as crucial components of the host/pathogen interaction. However, 
the spatial separation between the antigen in the site of infection or tumor and 
the lymphocytes in the lymph nodes creates the need for a messenger 
system—the antigen presenting cell (APC). Although not appreciated as such 
originally, these APCs were first visualized in the skin by Paul Langerhans in 
1868. DCs are considered the most potent APCs and exist throughout the skin, 
mucousal surfaces, and peripheral tissue52. They can efficiently stimulate both B 
and T lymphocytes. Importantly, DCs are required for priming naive T 
lymphocytes 52. The existence of a DC 'sentinel' system offers the immune system 
the ability to receive information of potential dangers in a centralized lymph area 
where it can subsequently identify and prime antigen specific effectors. 
Maturation alters DC phenotype, function, and location 
Two distinct differentiation states of DCs have been described that facilitate their 
ability to act as 'sentinels' of the immune system (Fig. 1.4). In tissue, DCs are 
present in what has been termed the 'immature' state. Immature DCs (iDCs) are 
characterized by their primary role—antigen capture53. iDCs utilize four main 
pathways to capture antigen: phagocytosis (via receptors including avP5, 
phosphatidylserine receptor, and CD36), micropinocytosis, macropinocytosis, 
and receptor mediated endocytosis (via receptors including MMR, DEC-205, 
13 
•Inflammatory cytokines: 
TNFa, PGE-2, IL-6, IL1p L y m p h N o d e 
Pathogen Recognition: 
ssRNA, dsRNA, LPS 
Apoptotic Cell 
Virus 
Bacteria 
Peripheral Tissue 
Figure 1.4. D C s are the 'sentinels' of the immune system. DCs 
serve as the messenger between the site of infection and the priming 
of the adaptive immune response in the lymph node. Immature DCs 
(iDCs) in the periphery are uniquely suited to capture antigen. In 
response to maturation stimuli, DCs migrate through the afferent 
lymph to the lymph node where they can present antigen to T cells in 
secondary lymphoid organs. Mature DCs (mDCs) are aptly suited 
for priming T cells with high levels of surface M H C and co-
stimulatory molecule expression. 
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FcRy and FcRe). iDCs are characterized immunohistochemically by their lack of 
macrophage markers such as CDM, absence of the mature DC marker CD83 and 
low surface expression of co-stimulatory molecules and MHC II (consistent with 
their primary role being antigen capture). Upon exposure to inflammatory 
cytokines (e.g.TNFa, IL-lp) or microbial stimuli (e.g. LPS, SAC, dsRNA), DCs 
undergo a programmed phenotypic and functional change termed 'maturation' 
that reflects the shift in their role from antigen capture to antigen processing and 
presentation. As DCs mature, they differentiate into stellate, non-adherent cells 
thus providing increased surface area for T cell engagement. These mature DCs 
(mDCs) are characterized by the surface expression of CD83 as well as high 
levels of co-stimulatory molecules and MHC II reflecting their potent antigen 
presentation capacity52. Functional activity of mDCs can be evaluated in vitro by 
assaying their ability to prime allogeneic T lymphocytes54. DCs are 100-1000 fold 
more potent allostimulators than bulk leukocytes. No one molecule has been 
identified to explain the potency of mDCs; upregulation of MHCII (10-100-fold), 
co-stimulatory molecules (e.g. CD80 and CD86), and cytokine production (e.g. 
IL-12)55'56 all may play a role. 
Coincident with these maturation changes, DCs upregulate CCR7 to 
facilitate migration from the tissue to the lymph node57. Physiologically, this 
migration puts mDCs in proximity of both naive and central memory T cells. As 
such, the location and unique phenotypic profile puts the mDC in the right place 
with all the tools for initiating a T cell response, be it activation or tolerance. 
Accordingly, I focus in depth in chapter 2 on the maturation profiles of DCs 
during chronic HCV and the role they may play in HCV immunity. 
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DCs specialize in antigen capture and presentation 
The central feature of the DC 'sentinel' system is the endowment with a unique 
ability to capture, process, and present antigen for an effective immune response. 
The ability of iDCs to capture antigen is not unique—in fact, macrophages 
phagocytose more efficiently than DCs. However, while macrophages 
phagocytose and subsequently degrade antigen, DCs sequester antigen in 
MHCII-rich compartments (MIICs). These MIICs convert from late-endosomal to 
non-lysosomal compartments upon maturation, enabling MHCII-peptide 
complex discharge to the surface58. A recent report suggests that low levels of 
lysosomal proteases allow DCs to sequester and process antigen, thus facilitating 
antigen presentation59. 
DCs also have specialized machinery for MHCI presentation. In contrast 
to MHCII presentation, MHCI presentation is classically restricted to 
endogenously expressed antigens processed by the proteasome and loaded onto 
MHCI in the ER. This classical model however fails to account for the generation 
of CD8+ T cell responses to tissue-restricted antigen (e.g. tumor antigen or 
antigen from viruses that do not infect APCs). Early work by Michael Bevan 
challenged the classical model for MHCI antigen presentation by showing that 
exogenous antigen can be used to generate epitopes for CD8+ T cell priming60. 
This mechanism was termed cross-priming due to the crossing of the canonical 
boundaries of MHCI antigen presentation. This pathway plays an important role 
in generating CD8+ T cell responses to tissue-restricted antigen61"63. Notably, 
DCs have a unique capacity to cross-present antigen on MHCI in order to prime 
a CTL response64. In addition to apoptotic cells, antigen from viral particles as 
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well as immune complexes may be cross-presented to engage antigen-specific 
CD8+ T cells65. 
The mechanism by which HCV is presented to the immune system by 
APCs is not clear. In the following chapters, I review and evaluate the ability of 
HCV to directly infect APCs. Furthermore, in chapter 4,1 detail the development 
of an in vivo system to evaluate cross-presentation of full length HCV. 
Immunologic ouctomes of antigen presentation 
Following antigen processing and presentation, DCs engage and activate T cells. 
Initial models suggested that T cell activation requires two signals: 'signal 1' 
(MHC-peptide complex) to engage antigen specific T cells and 'signal 2' (co-
stimulation) to enable T cell activation. Co-stimulatory molecules CD80 and 
CD86 are uniquely expressed on APCs and provide 'signal 2' via CD28 
engagement on T cells. However, more recent data argues that the generation of 
effective CTLs requires 'signal 3' or 'help,' provided either by "danger" signals66 
or in an antigen specific fashion by CD4+ T helper cells67 (Fig. 1.5). Although 
immune response to several infectious agents were traditionally characterized as 
helper-independent, recent studies suggest that CD4+ T cell help is an absolute 
requirement for the generation of CD8+ T cell memory68,69. In vivo models of 
cross-priming (via i.v. injection of irradiated OVA-loaded P2 microglobulin-/-
spleen cells) require CD4+ T cell 'help' to generate antigen-specific CTLs70. The 
requirement for CD4+ T cell 'help' for cross-priming CTLs suggests two potential 
scenarios: (1) A three-
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Figure 1.5. D C s mediate activation and tolerance of CD8+ T cells. 
Antigen presentation by m D C s can result in distinct immunologic 
outcomes: activation or tolerance. In the absence of C D 4 help or 
other danger signals, cross-presentation of antigen to CD8+ T cells 
leads to tolerance via division and death. Production of TGF-P by 
DCs following phagocytosis of apoptotic cells or IL-10 production by 
T may skew towards tolerance. In contrast, in the presence of 
'help' provide by CD40L ligation from C D 4 T cells, LPS engagement 
of TLR4, or dsRNA engagement of TLR3, DCs are licensed to prime 
CD8+ T cells. IL-12 and IL-6 from the D C as well as IL-2 produce by 
C D 4 helper cell are important cytokines for priming the CD8+ T cell 
response. 
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cell interaction (DC, CD4+ and CD8+ T cell) in the lymph node suggesting a role 
for short-range signals (e.g. IL-2) or (2) a 'licensed' DC which may serve as a 
"temporal bridge between a CD4+ T-helper and a T-killer."71 This latter 
hypothesis implies that CD4+ T cells impart a 'license' to DCs that enables them 
to activate CTLs. CD40L is expressed on the surface of activated CD4+ T helper 
cells and its engagement of CD40 on the DC is sufficient to generate effective 
CTLs, supporting the second model72"74. Although CD40 stimulation is known to 
lead to the upregulation of co-stimulatory molecules and the secretion of 
cytokines (including TNFa, IL-ip, and IL-12)75, the signaling pathway in DCs 
responsible for this functional switch remains unclear. Other TNF superfamily 
members in addition to CD40L may also activate DCs to produce 'signal 3.'62 
There is strong evidence to suggest that IL-12 produced by the DC may be an 
important component of 'signal 3' in allowing full activation of naive CD8 T 
cells76. 
In addition to playing a central role in priming a T cell response, DCs can 
also induce antigen specific T cell tolerance77. Although most self-reactive T cells 
are deleted during development in the thymus in a process called central 
tolerance, peripheral tolerance is thought to be responsible for inactivating T cells 
reactive to developmentally expressed and tissue-restricted antigens. The 
induction of T cell anergy, deletion, and cytokine skewing are all mechanisms of 
functional tolerance. All three mechanisms require engagement of T cell with 
MHC-peptide complex. Due to the suggestion that naive T cells do not 
circulate78, peripheral CD8+ T cell tolerance to tissue restricted antigens depends 
on a cross-presenting APC to deliver antigen to the lymph node79. In vitro 
studies have identified the DC as the crucial APC required for CD8+ T cell 
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tolerance to cross-presented antigen62; this finding is supported by the recent in 
vivo work of others80. 
Some reports suggest that the maturation state of the DC controls the 
immunologic outcome of the T cell response81. In other words, in the steady state 
iDCs capture antigens and silence T cell responses either by deleting them or 
expanding Treg cells. However, this poses two problems regarding T cell tolerance 
by DCs in vivo. First, as mentioned above, since naive T cells do not circulate, 
peripheral CD8+ T cell tolerance likely occurs in the T cell rich regions of the 
lymph node or secondary lymphoid tissue. However, DC chemotaxis into the T 
cell areas of the draining lymph organs, enabled by the upregulation of CCR7, 
requires a maturation stimulus57. Second, DC / T cell engagement is required 
for active induction of antigen specific T cell tolerance. However, iDCs do not 
acidify their endosomal system and as a result the antigen captured is 
maintained in an unprocessed holding compartment until a maturation signal is 
received82. Therefore, it is difficult to envision how antigen captured in the 
periphery can be efficiently presented to T cells for the induction of antigen 
specific tolerance by iDCs. 
Instead, it has been demonstrated that mDCs can mediate both activation 
and tolerance depending on the presence of 'signal 3' stimuli62. Using an in vitro 
cross-presentation system, both activation (defined by proliferation and CTL 
activity) and tolerance (defined by T cell division and death) required 
phenotypically (i.e. CD83+, CD25+, CD%6^, HLA DR *&) and functionally (i.e. 
potent inducers of allogeneic mixed leukocytes reaction) mature DCs62. The 
crucial switch between DCs inducing T cell activation or tolerance is not 
maturation, but rather 'signal 3' provided by CD40 engagement on the DC. IL-12 
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production in response to CD40 engagement may act as a 'signal 3' in skewing 
cross-tolerance to cross-priming76,83. 
The regulation of T cell activation versus T cell tolerance in HCV infection 
is not well understood. The lack of a small animal model creates a significant 
obstacle for extensive characterization of the immune response. In lieu of this 
model, I evaluate, in chapters 3 and 4, the role that CD4+ T cells and virally 
induced IFNa/p play in modulating these signals to control the immunological 
outcome. 
DC interaction with viruses 
Infection of DCs can alter function. Some viruses, such as influenza, 
promote maturation M. In the case of influenza, maturation may protect from 
viral cytopathicity as well as enable DC migration for T cell engagement. This 
maturation response, however, is not common to all viruses and may even 
depend on the multiplicity of infection. Infection of DCs with herpes simplex 
virus (HSV) and measles virus (MV) leads to submaximal DC maturation and 
impaired T cell activation85"87. In contrast, two flaviviruses, bovine viral 
diarrheal virus (BVDV) and classic swine fever virus (CSFV) do not induce 
maturation or disrupt the ability to stimulate T cells88,89. Similar results are seen 
with a related flavivirus, yellow fever 17D 90(see Appendix 3). 
There is precedent for DC-specific interactions with flaviviruses— 
specifically dengue virus (DV). DV selectively infects a DC population in the 
skin called langerhan cells (LCs) and causes infected LCs to migrate out of the 
tissue 91. DC specific ICAM-3 grabbing non-integrin (DC-SIGN) is sufficient for 
DV infection92 and accounts for the selectivity of DV for LCs and iDCs 93. 
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Interestingly, H C V E2 interacts with DC-SIGN94,95. One report suggests that VSV 
El /E2 pseudotype particles enter DCs via DC-SIGN 96, but the same results are 
not seen with HCVpp13"15. In addition to infection, binding of HCV to DCs may 
also play a role in pathogenesis. For example, interaction of HIV with DC-SIGN 
for binding but not for entry has suggested a mechanism whereby HIV migrates 
with DCs to the lymph node to gain access to CCR5 positive CD4+ T cells97. DC-
SIGN interaction is not, however, a general feature of flavivirus host interaction. 
It is not sufficient for yellow fever infection or necessary for West Nile virus 
(WNV) infection92. A recent report shows avP3 integrin as the receptor for 
WNV98. 
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1.4. Interferon (IFN)-o/p 
In addition to the data from natural resolvers, another patient population 
provides important data for understanding the components of a successful 
response—sustained virologic responders (SVRs). SVRs are defined as patients 
that have cleared HCV following IFNa therapy and remain HCV negative 6 
months after discontinuation of therapy. The second major aim of my thesis is to 
understand the role that IFNa may play in modulating the immune response at 
the DOT cell interface, during pathogenesis and therapy. 
IFNa: The standard of care 
Currently, the most effective treatment for HCV is pegylated IFNa. It 
slows progression of liver disease and eradicates virus in approximately 50% of 
cases99. IFNa was originally defined as an antiviral agent, but has been used 
therapeutically for the treatment of viral and non-viral diseases. The original 
IFNa monotherapy for chronic HCV with three injections per week was 
approved in 1990 and the latest regimen, combination of ribavirin and pegylated 
IFNa was approved in 2002 10°. Response rates to IFNa therapy stratify by 
genotype with SVR rates of 42-46% for genotypes 1 and 4; 76-80% for genotypes 
2 and 3 101,102. Analysis of sequence determinants correlating with response to 
IFNa therapy revealed an interferon sensitivity-determining region (ISDR) 
within genotype lb seen in some cohorts103,104 but not others105. 
IFNs were discovered by Alick Isaacs and Jean Lindemann in 1957 as an 
undefined substance with antiviral activity106. They showed that supernatant 
from influenza-infected chicken embryos cleared of virus was able to inhibit 
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influenza infection when added to a fresh set of chicken embryos. Work within 
the last several decades has defined this antiviral substance more carefully as 
type I IFNs in contrast to type II IFNs (IFNy). There are seven different classes of 
type I IFNs (a, p, 6, e, k, co, and x). IFNa and IFNp are best characterized of the 
type I IFNs. While most cells can produce both, depending on the stimulus, the 
primary producers of IFNa and IFNp are leukocytes and fibroblasts, 
respectively107. At least 14 IFNa subtypes exist, but only one IFNp. For the most 
part, the antiviral and antiproliferative effects of the multiple IFNa subtypes are 
functionally redundant; however, large differences exist in their ability to 
activate NK cells108. Nonetheless, all use a single IFNa/p receptor (IFNAR). 
The molecular mechanisms associated with IFNa/p's defining antiviral 
effect are numerous; however, four proteins play an important role—2,5-
oligoadenylate synthetase (2',5'-OAS), protein kinase R (PKR), myxovirus 
resistance protein A (MxA), and RNA-specific adenosine deaminases (ADAR). 
2',5'-OAS induces an antiviral state by activating RNase L, a cellular 
endoribonuclease, which degrades viral RNA 109. PKR is a double-stranded 
RNA-dependent protein kinase which inhibits peptide chain initiation and viral 
translation by phosphorylation of eIF-2a n0. MxA is an IFN-induced GTPase 
originally characterized by its ability to block influenza A infection111. Although 
the mechanism of its antiviral activity is not completely understood, MxA 
antagonizes viral polymerase activity112 and blocks redistribution of viral capsid 
proteins113. Finally, the activation of ADAR inactivates viral RNA by RNA 
editing114. 
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The signaling mechanisms associated with the induction of this antiviral 
response have been extensively characterized (Fig. 1.6). The IFNAR is a 
heteromdimeric receptor consisting of subunits IFNAR1 and IFNAR2. IFNAR2 
exists in three different forms: IFNAR-2a (short), IFNAR-2b (soluble), and 
IFNAR-2c (long)115. IFNAR1 and IFNAR2c are constitutively associated with 
intracellular Janus kinases 0AKs), Jakl and Tyk2, respectively116. IFNa/p 
engagement causes IFNAR dimerization and/or oligomerization. This 
rearrangement enables Jakl and Tyk2 activation by trans-phosphorylation. 
Subsequent phosphorylation of receptor cytoplasmic tails enables STAT2 
recruitment. In contrast to activation of ST ATI by IFNy, IFNa/p signaling 
requires STAT2 for ST ATI phosphorylation117. Tyrosine phosphorylation 
enables STAT1/STAT2 heterodimerization and interaction with p48 (IRF-9) 
forming interferon-stimulated gene factor-3 (ISGF-3). ISGF-3 translocates to the 
nucleus, binds to interferon stimulated response elements (ISRE), and activates 
transcription118. IFNa/p also activates STAT3 and STAT4. Similar to STAT2, 
STAT3 can form heterodimers with ST ATI to activate ISRE. In contrast, STAT4 
homodimerizes and binds to (IFN)-gamma-activated sequence (GAS) elements119. 
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Figure 1.6. IFNo/P signaling. Engagement of the IFNa/p receptor 
activates Jakl and Tyk2 which in turn phosporylate ST ATI and 
STAT2. Heterodimerization and association with IRF9 to form ISGF3 
results in translocation to the nucleus and activation of gene 
transcription from interferon stimulated response elements (ISRE). 
ISRE transcription drives the IFN priming loop as well as other anti-
viral and innate immunity effector functions. 
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IFNa/p production triggered by virus detection 
The production of IFNa/p by an infected cell is highly regulated by the 
activation of pre-existing transcription factors. Although nuclear factor-KB (NF-
kB) and ATF-2-c-Jun may play a role, an absolute requirement for interferon 
response factor (IRF) 3 has been demonstrated120 (Fig. 1.7). Inhibitor of NF-kB 
kinase-E (IKKe) and TANK-binding kinase 1 (TBK1) play an important role in 
IRF3 activation, which results in transcriptional activation of both IFNp and 
IFNa4 genes121. The production of IFNa4/p induces IRF7 transcription by both 
paracrine and autocrine signaling via canonical ST ATI signaling disccused 
above. Activation of IRF7 during viral infection enables cells to activate 
transcription of other IFNa genes besides the a4 subtype. This priming loop is 
crucial for robust production of IFNa 122. 
The host response has evolved several mechanisms to link viral detection 
with production of IFNa/p. This response is triggered by pathogen-associated 
molecular patterns (PAMPs) (e.g. single stranded (ss) or double stranded (ds) 
RNA) engagment of PAMP receptors on the host cell. Classically, toll receptor 
(TLR) 3 was thought to be important for viral detection as it was required to 
trigger IFNa/p production in response to dsRNA 123. However, the location of 
TLR3 facing the lumen of the endosome does not put it in prime location for 
detecting ssRNA viruses. Another toll receptor, TLR9 was originally defined to 
detect non- methylated CpG motifs specific for bacterial DNA124. Although TLR9 
agonists are a strong trigger for IFNa/p, it was not originally clear how they were 
involved in a viral response. Subsequently, it was found that in addition to 
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Figure 1.7. P A M P receptors detect viral infection and trigger 
IFNq/p response via the IFNo/P priming loop. Three key P A M P 
receptors, TLR3, TLR7, and TLR9, detect dsRNA, ssRNA, and C p G 
D N A , respectively, in endosomal compartments. Intracellular 
ssRNA triggers RIG-I and activation of IKKs as well as NF-kB via 
Cardif. TLR3 activates NF-kB and TBK1 via TRIF. Phosphorylation 
of IRF3 by IKKe and TBK1 allows for dimerization and interaction 
with CBP/p300 to trigger IFNp transcription. IFNP signaling triggers 
IRF7 expression. TLR7 and TLR9 signal via M y D 8 8 to activate NF-kB 
and phosphorylate IRF7. The molecules involved in M y D 8 8 
dependent IRF3 activation are not known. 
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bacterial C p G motifs, viral D N A from herpesviruses (eg. HSV-1 and M C M V ) can 
also directly engage TLR9 to trigger IFNa/p production125. Recently, TLR7 was 
proposed to play a key role in triggering IFNa/p production in response to 
ssRNA virus influenza and specific ssRNA motifs126. Adaptors MyD88, IRAK, 
and TRAF6 mediate signaling for TLR7 and 9; however, TLR3 may utilize 
Toll/IL-1 receptor domain-containing adaptor, TRIF, which has the potential to 
directly activate IKKe and TBK1127. 
Intracellular detection of PAMPs also plays a significant role in triggering 
IFNa/p production. As mentioned above, PKR can detect intercellular dsRNA 
and may also play an important role in triggering IFNa/p production128; 
however, recent reports have demonstrated the function of another crucial 
intracellular dsRNA sensor, retinoic-acid-inducible gene I (RIG-I)129 or melanoma 
differentiation-associated gene 5 (mda-5)130. RIG-I contains a N-terminal tandem 
caspase activation and recruitment domain (CARD) that signals IRF-3 and NF-kB 
activation and a C-terminal DEx/D box RNA helicase domain which binds HCV 
RNA131. A recently described CARD containing adaptor protein, Cardif /IPS-
1 /VISA/MAVS, binds to RIG-I and recruits IKKs for IRF3 and NF-kB 
activation . 
IFNa/p during HCV infection 
In light of the potent antiviral effects of IFNa/p on HCV replication, it is 
understandable why HCV has evolved numerous mechanisms to disrupt IFNa/p 
signaling. Both and NS5A 133 and E2 134 have been shown to inhibit PKR via direct 
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interaction. More recently, the NS3-4A protease has been shown to play a key 
role in disrupting IRF-3 phosphorylation135 by cleaving Cardif136 and TRIF137. 
Despite the multiple strategies to inhibit IFNa/p signaling, intrahepatic 
IFNa/p production during HCV infection is a unique characteristic of HCV 
infection. In contrast to hepatitis B virus (HBV) infection, HCV reaches high viral 
titers within 1 week of infection138 and induces a robust IFNa/p response 
detected by IFN stimulated gene (ISG) expression139. Notably, induction of ISGs 
following infection does not correlate with viral titer and outcome suggesting 
that other factors such as genetics or concomitant risk factors play an important 
role. Alternatively, other features of IFNa/p's complex role in immunoregulation 
may impact the outcome of HCV infection140. 
The main producers of IFNa/p during HCV infection have not been 
identified. Clearly, hepatocytes are the main target of infection141 and posses 
both RIG-I and TLR3 signaling pathways for triggering IFNa/p production142. 
However, although induction of ISGs are seen in liver tissue, IFNa/p transcripts 
are seen in PBMCs suggesting that a cellular component of PBMCs may be 
responsible for ISG induction in liver tissue during acute infection143. 
Plasmacytoid DCs: The Interferon Producing Cells 
Although many cells are capable of producing IFNa/p in response to 
appropriate stimuli, the natural interferon producing cell (NIPC) has long been 
recognized as the most potent producer of IFNa/p among PBMCs144. These cells 
remained poorly characterized until the observation was made that NIPCs were 
a DC subset called plasmacytoid DCs (pDCs)145. In humans, pDCs were first 
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described as a CDllc negative D C subset146147 and proposed to be the poorly 
characterized plasmacytoid T cells long described by pathologists in lymphoid 
tissue 148. These cells were originally characterized by their location in the T cell-
rich extra-follicular regions and high expression levels of IL-3Ra (CD123)149. 
Subsequent studies have shown that IL-3 acts as a survival factor, but the 
immunological significance of pDC location is not clear. 
Originally, pDCs were identifiable only by lineage negative and non-
specific markers CD4, CD 123, and HLA-DR. The generation of antibodies 
specific for pDCs allowed the direct enumeration, purification, and functional 
assessment of pDCs in circulating blood 150. One of these antibodies recognizes a 
type II C-type lectin called blood DC antigen (BDCA)-2 151. Importantly, BDCA-2 
is downregulated upon activation and antibodies to BDCA-2 inhibit IFNa/p 
production. Recently, antibodies against specific mouse pDC markers were 
developed (120G8 and PDCA-1)152. Hopefully, these reagents will give us a clear 
sense of pDC and pDC-derived IFNa/p in coordinating adaptive immunity. 
As the most potent producers of IFNa/p, these cells play an important role 
in the response to viral infection. Notably, they are capable of producing robust 
amounts of IFNa/p after exposure to DNA and RNA viruses as well as bacteria. 
Further work showed that human pDCs express TLR7 and TLR9 153, making 
them poised to respond to infectious pathogens. Interestingly, pDCs 
constitutively express IRF7 154 allowing faster IFNa/p production, independent of 
feedback. Following activation by TLR or CD40L engagement, pDCs move to 
lymph nodes and produce IFNa/p in the T cell-rich areas 155,156. A recent report 
describing the IRF7-/- mouse links a defect in pDC activity to a decrease in CpG 
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adjuvant effect on transgenic CD8+ T cells, but the immunologic significance of 
the pDC response in coordinating T cell activation is not well defined157. 
The role for pDCs in HCV pathogenesis is an area of intense research. As 
the main producers of IFNa/p, pDCs serve as a likely target for immune evasion 
strategies. As such, in chapter 2,1 evaluate pDC function during chronic HCV 
infection. The question of pDC function is critical not only for understanding 
pathogenesis but also for evaluating the rationale of TLR7 and TLR9 agonist 
therapies for chronic HCV. A better understanding of the role for pDCs and 
IFNa/p in regulating HCV-specific T cell immunity may offer insight into 
pathogenic and therapeutic strategies for HCV. 
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1.5. The questions 
In this thesis, I have endeavored to explore the role of DCs in HCV 
pathogenesis and the factors that act on DCs to regulate the immunologic 
outcome during HCV infection. I began these studies by setting up a clinical 
study at the Rockefeller University Hospital, CRI-0505, to explore the function of 
DCs in chronic HCV. The results of this study, discussed in chapter 2, pushed us 
to redefine the mechanisms by which HCV may affect DC function and 
immunologic outcome. In particular, I focused on the interplay between 
IFNa/p and CD4 help acting on DCs to regulate CD8+ T cell priming. Our 
surprising results, discussed in chapter 3, led us to explore the regulation of 
IFNa/p signaling by DC maturation and the implications of spatial location in 
dictating effects of cytokines on immunological outcome. In light of these 
results, I set up in vivo models to evaluate the ability of pDC IFNa/p production 
in the lymph node as a source of helper signals for CD8+ T cell priming, 
discussed in chapter 4. The results presented here offer significant support for 
HCV immunotherapy trials and provide a unique mechanism for IFNa/p in 
pathogenesis and immunity. It is my hope that these results will inspire support 
for new therapeutic strategies for HCV. 
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Chapter 2: Redefining the role for D C s in H C V pathogenesis: 
N o r m a l D C function in patients chronically infected with H C V 
2.1 Summary 
HCV-specific T cell responses and IFNa play important roles in HCV immunity. 
Since conventional DCs (cDCs) are required for priming T cells in vivo and pDCs 
(pDCs) are the principal cell type responsible for endogenous IFNa/p 
production158, an understanding DC function during HCV infection may offer 
insight into the crucial components of immunity. Initial reports showed 
impaired maturation and allostimulation of monocyte derived DCs159"161 and 
pDCs162 from chronic HCV patients suggesting a model of "DC dysfunction" to 
account for impaired immunity in chronic HCV. In order to evaluate the HCV 
specificity of these reports, we did a more careful analysis of absolute numbers, 
phenotypic markers, and functional activity of these DCs. In contrast to previous 
reports, we find no overt phenotypic or functional changes in monocyte derived 
DCs or circulating cDCs from chronically infected patients. Although our 
findings agree with previous reports of lower percentages of circulating pDCs in 
chronic HCV infection, single cell analysis suggests no overt defect in pDC IFNa 
production. This data challenges the old model of "DC dysfunction" in 
accounting for impaired HCV immunity. Furthermore, our analysis supports 
alternate models for weak T cell immunity in chronic HCV and offers data in 
support of cDC and pDC immunotherapy for chronic HCV. 
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2.2 Introduction 
Role for DC subsets in HCV infection 
As mentioned above the CD8+ T cell response has been identified to correlate 
with response to HCV infection. In light of the crucial role for cDCs in priming 
these CD8+ T cells, attention in the HCV field has been given to understanding 
the interaction of HCV with DCs (Fig. 2.1). The key questions in understanding 
this interaction center around infection of DCs as well as modulation of function. 
The prior lack of an infectious viral system and the technical difficulty in 
establishing reliable negative strand detection assays has precluded sound 
conclusions regarding DC infection141163. In contrast, many tools exist to study 
the function of DCs both in vitro and ex vivo—but the data remain controversial 
as to the effect of chronic HCV infection on DC function. 
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Figure 2.1. D C s play a pivotal role in H C V immunity. cDCs play a 
pivotal role in presenting antigen to the adaptive immune system. 
Antigen capture by direct infection or phagocytosis allow DCs to 
traffic antigen to the lymph node for T cell priming. pDCs are the 
main producers of IFNa/p and may influence infection in the tissue 
or immunity in the lymph node. 
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The old model: D C dysfunction in chronic H C V 
Several groups have reported a maturation defect in monocyte-derived 
DCs generated from chronic HCV-infected donors159"161. These observations led to 
a model where ineffective DC maturation results in the lack of HCV-specific 
CD8+ T cells in chronically infected patients160 (Fig. 2.2). However, this model 
does not account for the selective impairment of HCV-specific T cell responses as 
chronically infected HCV patients are immune competent. Additionally, in vivo 
data indicating the absence of HCV RNA in peripheral blood mononuclear cells 
(PBMCs) is inconsistent with a defective DC precursor141. In this chapter, we 
have re-examined the phenotype and function of monocyte-derived DCs 
generated from chronically infected HCV patients using more stringent criteria 
for the definition of DC maturation. In contrast to previous reports, we observe 
no defect in DCs from chronically infected HCV individuals and offer an 
alternate model for the role of DCs in HCV pathogenesis. 
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Figure 2.2. The "old model" for D C s in H C V pathogenesis. Previous 
reports have suggested that H C V inhibits D C maturation and 
consequently efficient T cell priming. However, this model does not 
account for the selective impairment of HCV-specific T cell responses 
as chronically infected H C V patients are immune competent. 
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Circulating cDCs and pDCs in human blood 
A significant caveat of all the studies mentioned above is that they focus on in 
vitro derived DCs. In fact, the majority of human DC studies are based on 
monocyte-derived DCs due to the low frequency of and paucity of positive 
markers for circulating blood DCs (BDCs)146. Recent characterization of the BDC 
groups showed that a CDllc+ subset expressed CDla (also referred to as 
BDCA-1)164,165. CDla is not unique to circulating DCs (e.g. it is highly expressed 
on B cells), but it can be used to differentiate CDllc+ from CD lie- DCs. 
Although these markers allow for the isolation of circulating cDCs, these cells 
make up only 0.5-1% of the total PBMC fraction and, thus, require large numbers 
of PBMCs for functional analysis. 
The other DC subset of interest in circulating blood is the pDC. pDCs 
recently received the spotlight in HCV biology in light of their robust IFNa/p 
production145. During the course of natural HCV infection, robust expression of 
IFNa/p response genes are seen in the liver139 and pDCs may play a role in this 
process143. HCV replication is very sensitive to IFNa, both in vitro and in vivo, 
but while HCV has numerous mechanisms to avoid the downstream effects of 
IFNa166, direct modulation of pDC function by HCV has not been shown. 
Furthermore, the immunoregulatory role of IFNa/p during HCV infection is not 
well understood. 
pDCs may be distinguished based on surface expression of CD123, BDCA-
2 or BDCA-4150. Although they exist at very low frequency (0.2 to 0.5% of 
PBMCs), cytometric analysis permits simultaneous gating of cell populations of 
interest and determination of functional activity (e.g. production of IFNa)167. In 
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this chapter, w e provide a careful analysis of both cell populations in chronic 
HCV infection and conclude that there are no phenotypic or functional defects in 
the cDCs and no decrease in the amount of IFNa produced on a per pDC basis. 
2.3 Study Design 
CRI-0505: Chronically Infected HCV Patients (see Appendix 3) 
Patient material was obtained as per Weill Medical College of Cornell University 
and The Rockefeller University Hospital Institutional Review Board approved 
protocols and all patients gave written informed consent. HCV infection was 
confirmed based on serology and/or plasma HCV titers. Chronic HCV was 
defined as detectable HCV viral load and sustained liver injury for greater than 6 
months (as monitored by liver function tests and/or liver biopsy). IFNa / 
ribavirin therapy had been discontinued at least 6 months prior to sample 
collection. In addition, patients had not received any immune modulators or 
suppressors within 30 days prior to study entry. All patients tested negative for 
HIV, syphilis, and HBV within 30 days prior to study entry and were free of 
uncontrolled medical illness (including decompensated cirrhosis and any 
rheumatologic or immunologic disease). Cohort 1 (n = 16) was used to analyze 
monocoyte derived DCs (Table 2.1) and cohort 2 (n = 17) was used to evaluate 
circulating DC populations (Table 2.2). Samples were also collected from 17 non-
HCV healthy donors. Sustained virologic responders (SVR, n=6) were HCV 
RNA negative six months after completion of pegylated-IFNa/ribavirin therapy. 
PBMCs were also obtained from patients with non-HCV liver disease (n=7) 
including hepatitis B, granulomatous hepatitis, and cirrhosis. 
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2.4 Materials and Methods 
Isolation and preparation of cells 
PBMCs, DCs, and T cells were prepared as previously described168. Briefly, 
PBMCs were isolated from whole blood by sedimentation over Ficoll-Hypaque 
(Amersham Pharmacia Biotech, NJ). T cell enriched and T cell depleted fractions 
were prepared by adherence to plastic in 1% single donor plasma. iDCs were 
prepared from the T cell depleted fraction by culturing cells in the presence of 
1000 U/mL GM-CSF (Berlex, Seattle, WA) and 500-1000 U/mL IL-4 (R&D 
Systems, Minneapolis, MN) for 6 days169,170. To generate mDCs, cultures were 
stimulated on day 6 with 50 ng/mL TNFa (Alexis Biochemicals) and O.IjjJVI PGE-
2 (Sigma) for 36-48 hrs171. cDCs were isolated using a BDCA-1 Isolation Kit 
(Miltenyi Biotec, Auburn, CA). Mature cDCs cultures were generated after 
purification with 50ng/mL TNFa (AlexisBiochemicals, San Diego, CA) and 
O.IjaM PGE-2 (Sigma, St. Louis, MO) for 36-48 hrs1 ,171 
Allogeneic Mixed Leukocyte Reaction (Allo-MLR) 
2 x 105 purified T cells/well were plated with cDCs at indicated ratios in 5% 
pooled human serum (Labquip LTD). Cultures were incubated for 4-5 days at 
37°C and pulsed with l^iCi 3H-thymidine during the last 14-16 hrs of culture. 3H-
thymidine incorporation was measured using a liquid scintillation counter 
(Packard Topcount). Allostimulatory index was generated by dividing the 
observed proliferation by the average maximal proliferation achieved when 
using mature cDCs at a ratio of 30 T cells : 1 DC. In all cases, maximal 
proliferation was > 100,000 counts per minute / IO6 T cells used. 
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Detection of influenza-specific T cells by ELISPOT 
mDCs were infected with influenza A/PR/8 (Spafas, Conn.) for lhr at 37°C, as 
described168. DCs and T cells were plated in 96-well Millipore plates coated with 
5mg/mL of anti-IFNy mAb (Mabtech, Mab-1-D1K). Cultures were incubated for 
24-36 hrs at 37°C, washed with mild detergent, and incubated with lfAg/mL 
biotin-conjugated anti-IFNy mAb (Mabtech, MAB 7BG-1). Spots were visualized 
using Vectastain Elite Kit (Vector Laboratories). Evaluation was performed in a 
blinded fashion by an independent service (Zellnet Consulting, Inc., NY) using 
an automated ELISPOT reader (Carl Zeiss, Inc., NY). Spots represent IFNy 
production by single cells and are reported as spot forming cells (SFCs)/106 cells. 
Cell enumeration 
Flow cytometric analysis was employed to enumerate different hematopoetic 
lineages in PBMCs using a Blood Dendritic Cell Enumeration Kit (Miltenyi 
Biotec, Auburn, CA). Briefly, scatter properties of the cells as well as CD 19 and 
CD 14 staining enabled enumeration of B cells and monocytes, respectively. 
Simultaneous labeling with anti-CDlc (BDCA-1) and anti-BDCA-2 monoclonal 
antibodies (mAb) allowed selection of CD19 negative cells and enumeration of 
the BDCA-1+ cDCs and the BDCA-2+pDC populations. Absolute numbers of the 
respective cell populations were normalized to the total number of PBMCs 
collected to obtain the relative percentage of each cell type. 
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IFNa production by Intracellular Cytokine Staining (ICCS) and ELISA 
PBMCs were resuspended in DMEM 10% FBS at 5 x 106/mL and stimulated with 
either media alone; 50 hemagglutinin units (HAU)/ml Influenza A/PR8/1976; or 
5ng/mL CpG (2216: 5'-GGGGGACGATCGTCGGGGGG-3'). Cultures were 
incubated for 5 hrs, harvested and fixed using Cytoperm/Cytofix kit (BD 
Pharmingen) and stained with anti-IFNa (MMHA-11, PBL Laboratories, 
Piscataway, NJ) followed by goat anti-mouse PE (Jackson Immunochemical, 
West Grove, PA). BDCA-2 FITC and BDCA-4 APC antibodies were used to label 
pDCs in the PBMC fraction, post-stimulation. To measure the quantity of total 
IFNa produced, supernatants from parallel cultures were collected after 24 or 48 
hrs and assayed using a human IFNa ELISA (PBL laboratories, Piscataway, NJ). 
Importantly, all PBMC samples used for IFNa assays were freshly prepared and 
used within 12 hrs as IFNa production was significantly affected by freeze-thaw 
(>10-fold decrease in IFNa production in parallel samples). IFNa production 
was normalized per pDC based on the percentage of pDCs in the PBMC fraction. 
Statistics 
Two tailed non-parametric comparisons (Mann-Whitney test) were used to 
calculate p values for differences in cDC and pDC enumeration, as well as total 
IFNa production by PBMCs, as this method allows for data with a non-Gaussian 
distribution, p values for normalized data in Fig. 2D was evaluated with a two-
tailed parametric comparison (unpaired t test, Welch corrected). 
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J6/JFH-1 chimeric infections 
High titer J6/JFH-1 chimeric HCV was obtained from Brett Lindenbach (Rice lab, 
RU). Briefly, this virus was created from the JFH-1 HCV cDNA (which can 
replicate in vitro without adaptive mutations18) recombined with core-NS2 region 
from a related genotype 2a strain, J616. iDCs and a hepatoma cell line (Huh7.5) 
were exposed to J6 / JFH chimeric HCV or mock virus supernatant for one hour 
at 37°C at 106/mL. DCs were washed and resuspended in 1% human serum with 
maturation cocktail TNFa / PGE-2. Huh7.5 cells were washed and fresh media 
was added. Infection was assayed by FACS analysis of NS5A expression. 
NS5A expression by FACS analysis 
Indicated cells were resuspended at 106/mL, washed in PBS, and fixed for 10 
minutes in lOOjxl cytoperm/cytofix (BD Pharmingen) per 105 cells at 4°C. Cells 
were washed twice in lx perm wash (BD Pharmingen) and stained with mouse 
monoclonal anti-NS5A (9E10, generated by Tim Tellinghuisen, Rice lab, RU) at 
1:50 for 15 minutes at 4°C and goat anti-mouse IgGs PE (Jackson 
Immunoresearch) at 1:400 for 15 minutes. 
2.5 Results 
Functional monocyte-derived DCs can be generated from patients with chronic HCV. 
PBMCs were isolated from chronic HCV patients (cohort 1, Table 2.1) and used 
for the generation of iDCs. Surface expression of CD14, CD25, CD40, CD54, 
CD83, CD86 and HLA-DR measured by FACS analsysis showed similarity to 
normal iDCs (Fig. 2.3A). Following exposure to TNFa and PGE-2, patient DCs 
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Table 2.1. Characteristics of study participants for monocyte-derived D C s 
(Cohort 1) 
Patient ID 
3 
(Chronic1') 
33 
(Chronic) 
51 
(Chronic) 
104 
(Chronic) 
126 
(Chronic) 
351 
(Chronic) 
402 
(Chronic) 
689 
(Chronic) 
794 
(Chronic) 
804 
(Chronic) 
812 
(Chronic) 
815 
(Chronic) 
936 
(Chronic) 
237 (SVR§) 
813 (SVR) 
976(SVR) 
Ape 
52 
52 
47 
53 
48 
61 
20 
69 
49 
22 
65 
68 
42 
52 
42 
41 
Sex 
M 
F 
M 
M 
M 
F 
M 
M 
F 
M 
F 
M 
F 
M 
F 
M 
Geno 
ty£e 
la 
la 
la 
lb 
2a 
lb 
N/A 
la 
N/A 
lb 
1 
N/A 
la 
la 
4a 
N/A 
ALT/ 
AST 
41/42 
NA 
76/48 
45/41 
59/31 
80/96 
41/31 
88/55 
35/70 
188/ 
113 
51/42 
247/ 
112 
19/14 
14/17 
5/9 
131/25 
Viral 
Load 
do*)-
189.0 
4.6 
6.9 
14.8 
NA 
5.2 
1.3 
47.1 
0.5 
11.6 
16.2 
4.5 
9.6 
BD** 
BD 
BD 
Histolosv 
Fibrosis: Stage 2 
Fibrosis: Grade 2, 
Stage 2 
Fibrosis: Grade 2, 
Stage 2 
Fibrosis: Grade 2, 
Stage 2 
No biopsy taken 
Fibrosis: Grade 2, 
Stage 3 
No biopsy taken 
Fibrosis: Grade 2, 
Stage 2-3 
Cirrhosis: Grade 3, 
Stage 4 
Advanced Fibrosis, 
Grade 2, Stage 4 
Fibrosis: Stage 1 
No biopsy taken 
Fibrosis 
Cirrhosis: Stage 4, 
Grade 4 
No biopsy taken 
No biopsy taken 
Date of Dx or Prior 
Jx 
Dx in 2/99; 
Peg-Ribavirin/IFN 
Unknown 
Dx in '96; 
Tx naive 
Dx in '65; 
Peg-Ribavirin x 3 
Tx Naive 
Tx Naive 
Dx '01; Tx naive 
Peg-Ribavirin/IFN 
Dx in '78; Tx naive 
Dx in 3/02; Tx 
naive 
Dx in '60s; 
Peg-Ribavirin/IFN 
Dxin9/01;Tx 
naive 
Dx in '95; Tx naive 
Dx '00; 
Peg-Ribavirin/IFN 
Dx in '97; 
Peg-Ribavirin/IFN 
Dx '79; 
Peg-Ribavirin/IFN 
+ Chronic patient defined as individual with H C V viral load and sustained liver injury for greater than 6 
months as monitored by ALT/AST and/or liver biopsy. 
§ Sustained Virologic Responder (SVR) defined as individual with evidence of H C V infection but 
maintained undetectable viral load more than 6 months after termination of therapy. 
* Viral load defined by quantitative PCR at time of blood draw (Roche Amplicor™). Data not available 
(NA) for PT #126; prior data confirmed status as chronically infected. 
** BD stands for below detection. 
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Figure 2.3. Monocyte-derived D C s from chronic H C V patients undergo 
normal TNF-a dependant maturation. A, B. Representative examples of 
iDCs (A) and m D C s (B) from a chronic H C V patient #3 are shown. 
Geometric mean fluorescence intensity (MFI) is indicated. C. Representative 
examples of m D C s from a normal donor and chronic H C V patient #804 are 
shown. Surface expression of the indicated marker (dark lines) is overlaid 
with the isotype control (dotted line). All antibodies were obtained from B D 
Biosciences. D. m D C s from chronic H C V patient #936 were adhered to 
Alcian blue treated coverslips, fixed with 3.4% PFA and stained with anti-
M H C I I (clone 93C9), followed by secondary anti-mouse IgG Alexa 488. 
Cells were visualized using a Zeiss Axioplan 200 microscope. 
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expressed surface markers characteristic of m D C s (Fig. 2.3B). Direct comparison 
of mDCs from chronic HCV patients and normal donors showed similar 
expression of CD83, CD86, HLA-DR, and CD54 (Fig. 2.3C). Furthermore, patient 
DCs displayed a stellate morphology characteristic of mDCs (Fig. 2.3D). 
Maturation was TNFa-dependent, as PGE-2 alone did not induce phenotypic 
maturation. 
We next evaluated patient DCs for their ability to prime allogeneic T 
lymphocytes as a measure of their functional capacity. Notably, proliferation 
was robust (>105 CPM at 90:1 T:DC ratio, Fig. 2.4A) and specific, as demonstrated 
by the lack of proliferation in syngeneic T cells (data not shown). Comparison of 
T cell priming capacity of phenotypically normal iDCs and mDCs from chronic 
HCV and normal donors provides functional data to support the normal TNFa-
dependent maturation in both patient populations (Fig. 2.4A). Normalized 
allostimulatory capacity of DCs from healthy versus chronic HCV-infected 
donors is shown (Fig. 2.4B). We conclude that monocyte-derived DCs generated 
from patients chronically infected with HCV are phenotypically and functionally 
normal. 
While it is difficult to demonstrate DC function in vivo, one measure 
employed is the evaluation of circulating memory T cells. We show that 
influenza-reactive T cells derived from patients can be effectively re-stimulated 
using syngeneic mDCs, as measured in an IFNy ELISPOT (Fig. 2.4C). Precursor 
frequency of influenza-reactive T cells in HCV patients (n=5), measured by spot 
forming cells (SFCs) / IO6 T cells, fell within the range of normal individuals 
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Figure 2.4. Mature DCs derived from chronic HCV patients prime 
allogeneic T cells and stimulate antigen specific syngeneic memory T 
cells. A. Allo-MLR T cell priming by iDCs and m D C s from normal (Nl) 
donor 3 and chronic H C V patient #794 are shown. Error bars indicate +/-
SD. B. Allostimulatory responses of m D C s from all tested normal donors 
and chronic H C V patients were normalized to values of the normal donor at 
30:1 to generate an allostimulatory index and plotted as thin lines with 
patient identification numbers noted. Thick black line represents mean 
allostimulatory capacity. C. IFN-y production by influenza-specific T cells 
stimulated with either uninfected (white portion of bar) or infected m D C s 
(black bar) from all patients tested. Data from normal, responder and 
chronic H C V patients are shown as spot forming cells (SFCs) per IO6 T cells, 
plotted on a logarithmic scale. N R indicates <50 SFC per IO6 T cells. 
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(pCTL range in humans is 0.02-0.15% based on seven control patients studied 
here and >350 ELISPOT assays performed in our laboratory). 
Lower numbers of circulating DCs in chronic HCV patients 
Despite the in vivo implications of this work, the caveat remains that these 
are data for in vitro derived cells. In order to explore the small populations of 
circulating DCs in vivo during chronic HCV infection (cohort 2, Table 2.2), we 
employed flow cytometric analysis. Using the scatter properties of the cells (size 
and granularity), as well as staining with anti-CD19 and anti-CD14 mAbs, it was 
possible to enumerate B cells (Fig. 2.5A, R2) and monocytes (Fig. 2.5A, R3), 
respectively. Cells were simultaneously labeled with anti-CDlc (BDCA-1) and 
anti-BDCA-2 mAbs, thus allowing selection of CD19- cells (Fig. 2.5A, R4) and 
enumeration of the BDCA-1+ cDCs (Fig. 2.5A, R5) and the BDCA-2+pDC (Fig. 
2.5A, R6) populations. Absolute numbers of the respective cell populations were 
normalized to the total number of PBMCs collected to obtain the relative percent 
of each cell type (Fig. 2.5B). Despite greater heterogeneity in the percentage of B 
cells in HCV patients, seen here, as well as previous studies28, we observed no 
statistical differences in the median percentage of B cells or monocytes. We did, 
however, reveal a small but marginally significant difference in the percentage of 
cDCs in chronic HCV compared to normals (0.62 vs. 0.83, p=0.05, respectively). 
In addition, the data indicate a reduction in the percentage of pDCs in chronic 
HCV patients (0.11 vs. 0.34, p=0.004) as compared to normal individuals. While 
potentially important to disease progression, this observation is not specific for 
chronic HCV infection. We find lower numbers of DCs in sustained virologic 
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Table 2.2. Characteristics of H C V patients in D C subset evaluation 
(Cohort 2) 
Patient 
1181° 
347°-d 
1142 '•" 
1060° 
107 
1128 
1127" 
959 
967 
1133 
840 
501 
522 
573d 
1166° 
1161° 
400d 
Age, 
years 
55 
51 
46 
38 
33 
57 
54 
29 
64 
47 
43 
58 
60 
52 
46 
70 
53 
Sex 
M 
F 
F 
F 
M 
F 
F 
M 
M 
M 
M 
F 
F 
M 
M 
F 
M 
Genotype 
NA 
1a 
1b 
1 
1a 
1b 
2a/c 
2b 
1a 
1a 
1b 
2b 
1b 
1a 
la/b 
1a 
1a 
ALT/AST score 
60/89 
207/145 
40/43 
129/77 
74/28 
51/NA 
138/93 
235/87 
48/31 
48/42 
66/40 
29/30 
82/60 
24/33 
63/51 
204/113 
104/106 
HCV load, lU/mL 
(X10')a 
62.5 
431 
128 
42.2 
2.5 
45 
14.6 
385 
NA 
182 
222.2 
>100 
27 7 
NA 
872 
264 
13 
Histological findingb 
NA 
Grade 3, stage 2 
Grade 2, stage 3-4 
Stages 1-2 
Grade 3, stage 3 
Stage 2 
Grade 1, stage 1 
Grade 3, stage 3 
Grade 3, stage 3 
NA 
Grade 1, stage 3 
Grade 3, stage 1 
Grade 2, stage 2 
Grade 2, stage 2 
NA 
Grade 2, stage 1 
Grade 3, stage 4 
Treatment 
Naive 
Peg-IFN/RBV 
Naive 
Naive 
Peg-IFN/RBV (treated in 2003) 
Naive 
Naive 
Naive 
Naive 
NA 
Naive 
Naive 
Naive 
Peg-IFN/RBV (treated in 2003) 
Naive 
Naive 
Naive 
NOTE, A patient with chronic HCV infection was defined as an individual with a detectable HCV load and sustained liver injury for >6 months, as monitored 
by liver function tests (alanine aminotransferase [ALT]/aspariate aminotransferase [AST]) anchor liver biopsy. IFN, interferon; NA, not available; PEG, pegylated; 
RBV, ribavirin. 
a HCV load defined by quantitative polymerase chain reaction at the time of collection of blood samples (Roche Amplicor). Data were not available for patients 
967 and 573; prior data confirmed that they had chronic HCV infection. 
b Histological criteria defined as in [16]. 
c Indicates leukapheresis sample. 
d Indicates fresh sample used for analysis of IFN-a production; no marking indicates a frozen sample. 
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Figure 2.5. D C Enumeration in chronic H C V . A. Cytometric-based 
enumeration strategy. P B M C s are gated in Rl based on Forward Scatter 
(FSC)/Side Scatter (SSC). B cells and monocytes are identified by CD19 and 
CD14 Cy5 labeling, respectively, and are differentiated based on SSC 
profile. B cells are gated by R2 and monocytes are gated by R3. CD19- and 
CD14 low cells are gated by R4 and used to enumerate BDCA-1 PE DCs (R5) 
and BDCA-2 FITC (R6). B. The percentage of monocytes and B cells are 
graphed for normal (filled triangles) or chronic H C V (filled circles) donors. 
The percentage of DCs (BDCA-1+) and plasmacytoid DCs (BDCA-2+) in 
normal, chronic H C V (HCV), sustained virologic responders (SVR, filled 
squares), and non-HCV liver disease (filled diamonds) are also displayed 
graphically. A Mann-Whitney test was used to generate p values for 
comparison of normal donors (n=17) and individuals with chronic H C V 
(n=17). 
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responders (n=6) as well as patients with non-HCV liver disease (n=7). L o w 
numbers of pDC have also been observed in patients with HIV/AIDS 172. 
Normal phenotype and function of circulating cDCs and pDCs 
In order to isolate cDCs and evaluate their functional characteristics, large 
numbers of PBMCs were collected by leukapheresis from four chronically 
infected patients. Surface expression of phenotypic markers was measured by 
flow cytometric analysis and indicated a phenotype suggestive of immature 
DCs—CD14", CD25", CD40", CD8310, CDSe1"' and HLA-DR"1 (Fig. 2.6A, gray line). 
Following exposure to TNFa, upregulation of maturation markers CD25, CD40, 
CD83, CD86, and HLA-DR was observed (Fig. 2.6A, thick black line). This 
upregulation corresponded with a functional change in allostimulatory potential 
characteristic of a mDC (Fig. 2.6B). Of note, the phenotype and priming capacity 
of cDCs derived from patients with chronic HCV was equivalent to that 
observed in normal individuals (Fig. 2.6B). 
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T cells:DC 
Figure 2.6. Normal phenotype and function of myeloid D C s in chronic 
H C V patients. A. FACS phenotype of myeloid DCs (BDCA-1+) is shown for 
representative chronic H C V patient #1181. Analysis was performed 
following CD19 depletion and BDCA-1 positive selection (90% purity, data 
not shown). Thick black line, myeloid DCs + TNFa; thick gray line, myeloid 
DCs; thin black line, isotype control. B. Allostimulatory responses for 
myeloid DCs purified from 4 chronic H C V patients and 3 normal 
individuals were evaluated. BDCA-1+ purified cells alone or cells exposed 
to TNFa, were placed into co-culture with allogeneic T cells, and cultured 
for 5 days. Proliferation was monitored by thymidine incorporation and 
data was normalized to the average maximum stimulation by mature 
myeloid D C as described in the study design section. Open circle, myeloid 
DCs or filled circle, myeloid DCs + T N F a (HCV patients); open triangle, 
myeloid DCs or filled triangle, myeloid DCs + T N F a (Normal controls). 
Average proliferation responses across the patient populations are indicated 
by solid lines. 
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W e next addressed the function of the pDCs in chronic H C V patients. In 
humans, pDCs produce robust amounts of IFNa after engagement of TLR7, a 
receptor for ssRNA, or TLR9, a receptor for CpG motifs153. We stimulated the 
PBMCs with live influenza virus or CpG-2216 and measured IFNa production by 
ELISA (Fig. 2.7A). Notably, IFNa production was lower in patients with chronic 
HCV as compared to normal individuals when stimulated with 50 HAU of 
influenza (3.9 ng/ml vs. 12.3 ng/ml, p=0.07, respectively) or CpG-2216 
(4.9ng/ml vs. 26.1 ng/ml, p=0.04, respectively). However, when normalized to 
the respective percentage of pDCs in the PBMC sample, the difference in IFNa 
secretion was no longer statistically significant between chronic HCV patients 
and normals for influenza (1.3 pg/ml vs. 1.9 pg/ml, respectively) or CpG (2.0 
pg/ml vs. 2.9 pg/ml, respectively) (Fig. 2.7B). These findings suggest that while 
lower in number, the pDCs are unimpaired in their production of IFNa in 
response to TLR ligands. 
In order to verify IFNa production by pDCs and to evaluate the 
percentage of IFNa-i- pDCs, we assayed stimulated PBMCs for intracellular IFNa 
by flow cytometric analysis after 5 hr of stimulation with influenza or CpG-2216 
(Fig. 2.7C). Only the pDCs produced measurable IFNa under these conditions 
and by gating on this population, the percentage of IFNa producing pDCs could 
be assessed (Fig. 2.7D). The data indicate that despite the decreased percentage 
of pDCs in the circulating blood, the pDCs respond equally well to influenza 
virus and CpG motifs on a per cell basis (Fig. 2.7B, D). 
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Figure 2.7. p D C s from chronic H C V patients produce IFNa in response to 
T L R stimulation. A. IFNa production in the supernatant of P B M C s 
stimulated with 50 H A U of influenza or 5fxg/ml CpG-2216 was evaluated 
by ELISA. Median values are indicated by black lines and p-values were 
determined using a Mann-Whitney test. B. Data from the ELISA was 
normalized based on the respective percentage of pDCs present in the 
P B M C fraction, p-values were determined using an unpaired t test, Welch 
corrected. C. pDCs were identified in the P B M C population using lineage-
specific markers BDCA-4 A P C and BDCA-2 FITC (Gate Rl). Intracellular 
IFNa staining in unstimulated or stimulated (50 H A U influenza) conditions 
was measured by cytometric analysis and the percentage of IFNa+ pDCs is 
represented in a dot-plot. Patient #1166 represents a chronic H C V donor 
with normal p D C (BDCA-2+) numbers (0.62%). Patient #1138 represents a 
chronic H C V donor with low p D C (BDCA-2+) numbers (0.05%). D. The 
percentage of pDCs responding to influenza stimulation and producing 
IFNa in 6 chronic H C V and 4 normal donors is graphically represented. 
Black lines indicate average percentage of IFNa+ pDCs across the respective 
patient population tested. 
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No robust infection of DCs in vivo or in vitro 
Finally, we evaluated productive infection in these DC subsets as detected by 
non-structural protein expression. Although RNA and structural proteins may 
stick to circulating DCs via binding receptors such as DC-SIGN, non-structural 
protein expression indicates viral replication. Purified cDCs and pDCs were 
permeabilized and stained with anti-NS5A. In all cases, neither cDCs nor pDCs 
showed expression of NS5A as monitored by FACS analysis (Fig. 2.8A). 
Recently, infectious chimeric HCV J6/JFH was reported to infect and 
replicate in hepatoma cell lines in vitro16. In order to test if this virus could infect 
DCs, monocyte derived DCs were exposed to virus and analyzed after 3 days. 
Despite robust infection of Huh7.5 hepatoma cells, no infection of monocyte 
derived DCs was seen 3 days post-infection, as monitored by intracellular NS5A 
staining (Figure 2.8B). 
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Figure 2.8. N o robust replication of H C V in D C s ex vivo or in vitro. A. 
pDCs or BDCA-1+ myeloid DCs were purified from an H C V + donor and 
stained for NS5A expression. B. Monocyte derived DCs or Huh7.5 
hepatoma cells were exposed to J6/JFH chimeric virus. NS5A expression 
was monitored after 3 days. 
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2.6 Discussion 
Controversial results in monocyte-derived DCs 
In this study, we have characterized HCV patient DCs, demonstrating 
phenotypically normal and functionally active mDCs. This finding differs from 
previous reports159'161, which we suggest is due to differences in culturing 
conditions. It is possible that incomplete maturation resulted in a perceived 
functional defect in the study by Auffermann-Gretzinger et al., as suggested by 
the presence of contaminating CD83" cells in the FACS plots of normal 
individuals mDC cultures160. Specifically, we do not find evidence for a defect in 
TNFa mediated DC maturation as demonstrated by a clear shift in allo-
stimulatory capacity when iDC are effectively matured (Fig. 2.4A). T cell 
priming with mDCs (Fig. 2.4A, B) contrasts other studies where reported 
thymidine incorporation was 10-fold lower than typically observed159, again 
reflecting poor growth conditions for DCs and or T cells in allo-MLR cultures. In 
our study, using adequate conditions for DC maturation and T cell priming, 
monocyte-derived DCs from chronic HCV patients are found to be both 
phenotypically normal and functionally active. Although these findings are from 
in vitro derived DCs, the presence of robust influenza specific T cell responses 
suggests that in vivo, chronic HCV patients maintain the ability to support central 
memory T cells. It also offers additional evidence for functionally competent 
mDCs in chronic HCV patients, and illustrates that the observed defect in the 
HCV-specific T cell repertoire does not extend to other viral antigens (Fig. 2.4C). 
These data are consistent with the current understanding of immune function in 
and pathogenesis of HCV, which suggests that the immune defect is HCV-
specific. These results are also consistent with the growing belief that in vivo, 
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P B M C s are not typically infected by H C V (141 and data not shown). Moreover, 
they offer crucial support for DC-based immunotherapy strategies for HCV. 
Despite our description of functional monocyte-derived DCs in chronic 
HCV, this data does not rule out a possible in vivo DC (or DC subset) defect. For 
example, as mentioned in chapter 1, HCV may directly interact with DCs via DC-
SIGN94'95 to modulate DC function in an HCV-specific fashion. Initial reports 
evaluating circulating cDCs suggest that functional defects in DCs are associated 
with HCV infection, but no direct mechanism for the putative DC dysfunction 
has been demonstrated173174. Furthermore, these reports do not account for the 
HCV-specificity of the immune defect. In order to evaluate these results in 
circulating DCs, we designed and inititated a clinical trial, CRI-0505, which 
allowed for the procurement of large numbers of PBMCs for BDC analysis. 
Lower numbers of circulating DCs in chronic HCV patients 
Similar to several recent studies162174, our data support the finding of lower 
percentages of circulating cDC and pDCs in PBMCs from chronic HCV patients 
(Fig. 2.5). However, these findings do not necessarily seem specific for 
HCV—SVRs and patients with non-HCV liver disease show similarly lower 
numbers. Further, HIV patients are reported to have lower circulating numbers 
of pDCs, which may suggest a general characteristic of chronic infection175. 
Importantly, lower numbers may reflect relocalization of cDCs or pDCs to 
inflamed tissue or lymph node following activation155 or dowregulation of BDC 
specific markers used to identify these populations in blood. Several forms of 
liver disease may cause decrease in circulating levels of cDCs due to migration to 
inflamed liver 176. Analysis of both infected tissue as well as draining lymph 
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nodes for pDCs and IFNa+ cells may offer insight into this question; however, 
access to high quality tissue is often limited. 
Functional pDCs in chronic HCV infection 
Consistent with previous reports 162, our data suggest that PBMCs from chronic 
HCV patients produce less total IFNa when stimulated with pDC specific 
agonist to TLR9 (Fig. 2.7A). However, in contrast to the interpretation by others, 
we believe that this decrease reflects a decrease in absolute pDC numbers and 
not inhibition of TLR9 specific signaling. First, we show that influenza, acting as 
an agonist for TLR7 (and possibly TLR3), produces similar levels of IFNa (Fig. 
2.7A). Second, when we normalize the data for total IFNa production per pDC, 
no statistical difference is seen between healthy controls and chronic HCV 
infected donors, suggesting that lower numbers of pDCs in the bulk PBMC 
cultures accounts for decreased IFNa production (Fig. 2.7B). 
These findings suggest normal function of pDCs and functionally intact 
TLR7 and TLR9-signaling pathways. In order to evaluate this formally, IFNa 
production in pDCs was directly assayed using FACS-based ICCS (Fig. 2.7C, D). 
Even in patients with low numbers of DCs, the same percentage of cells respond 
to TLR7 and TLR9 agonists to produce IFNa. 
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Important implications for immunotherapy 
Strong CD8+ T cell response are associated with successful resolution of 
HCV infection and protection41. These findings provide a rationale for 
immunotherapy as well as vaccination strategies to augment HCV-specific CD8+ 
T cell response. Autologous DC immunotherapy has been used to induce CTLs 
against tumor antigens177. Despite the limited success of DC vaccines in tumor 
immunotherapy, infectious diseases may be more amenable to this type of 
treatment. Our findings along with similar results in the chimpanzee model178 
support the use of autologous monocyte derived or circulating cDCs loaded with 
HCV antigen for these trials. 
IFNa is the currently approved treatment for chronic HCV infection. 
Although it is effective in approximately 50% of patients (depending on the HCV 
genotype), treatment is associated with significant side effects including nausea, 
dizziness, and flu-like symptoms which may persists for the six month course of 
treatment. TLR7 (Anadys Pharmaceuticals/Novartis) and TLR9 (Coley 
Pharmaceutical Group/Pfizer) agonist therapy for chronic infection are currently 
in clinical trials with multiple aims. First and foremost, it is necessary to evaluate 
the efficacy of these therapies in achieving an antiviral effect (i.e. a reduction in 
viral load). Second, it is hypothesized that the specific and localized triggering of 
endogenous IFNa may provide more effective delivery as well as avoid many of 
the side effects associated with systemic IFNa treatment. Our data suggest that 
pDCs during chronic HCV are competent to respond to these types of agonists; 
however, the effects of lower absolute pDC numbers need to be evaluated. An 
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additional benefit of TLR7/9 agonist therapy may involve pDCs role in H C V -
specific T cell priming which will be addressed in chapter 4. 
HCV antigen presentation in the absence of direct infection 
Although the data regarding infection of PBMCs and DCs, in particular, is 
controversial141163, our results suggest that circulating DCs are not robustly 
infected (Fig. 2.8A). These findings are supported by the lack of robust infection 
of monocyte derived DCs in vitro by the recently described J6/JFH virus (Fig. 
2.8B). One explanation for this difference may be that our conclusions are mainly 
based on intracellular staining for NS5A while contrasting data is based on RT-
PCR data163. Importantly, DCs do interact with E2 via DC-SIGN95. Thus, PCR 
based assays for DC infection must differentiate between positive and negative 
strand to conclusively show infection. Alternatively, cells should be washed 
with EDTA before RNA is prepared to dissociate bound viral particles. 
Although CD81, a key component required for HCV infection121618179, is 
expressed on many cell types, the availability of particular cellular proteins 
required for HCV replication may account for cell tropism. For example, certain 
hepatocyte cell machinery may provide for efficient replication not available in 
DCs. These cellular factors required for efficient HCV replication are currently 
under investigation. Alternatively, the production of and response to antiviral 
cytokines such as IFNa may play an important role in cell tropism. 
In the absence of direct infection, DCs may still acquire antigen for 
presentation to T cells via cross-presentation. A recent study has shown that 
DCs can cross-present viral particles for stimulation of HCV-specific T cells 
against structural proteins epitopes carried in the viral particles180. In light of the 
62 
presence of CD8+ T cells reactive against N S protein epitopes41, cross-
presentation of infected hepatocytes may likely play a key role in generating 
CD8+ T cell immunity. Thus, a detailed understanding of the mechanisms 
regulating immunologic outcome of cross-presentation may offer insight into the 
HCV immune response. 
Finally, our data support the investigation of alternate roles for the DC in 
HCV pathogenesis as we must account for the HCV-selective defect in the T cell 
repertoire of chronic HCV patients. In the next two chapters, I consider two 
important factors associated with HCV infection that may influence the 
immunologic outcome of DC / CD8+ T cell engagement—namely, IFNa/p and 
CD4+ T cell 'help'. 
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Chapter 3: D C maturation alters intracellular signaling networks 
enabling differential effects of IFNq/P o n antigen cross-
presentation 
3.1 Summary 
Type I interferons (IFN), produced largely by plasmacytoid dendritic cells 
(pDCs), bridge innate and adaptive immune responses and modulate immune 
function in complex ways. Here, we show that pDC-derived IFNa/p induces 
opposing effects on the immunologic outcome of cross-presentation. Specifically, 
IFNa/p acts on immature conventional dendritic cells (DCs) during antigen 
capture to block IL-12 production and inhibit subsequent CD8+ T cell activation. 
In contrast, exposure of mature DCs to IFNa/p enhances T cell activation. 
Further investigation revealed a molecular switch in intracellular signaling 
pathways, which occurs during DC maturation and accounts for the opposing 
effects of IFNa/p on antigen cross-presentation. The alteration of signaling 
networks offers a novel mechanism by which DCs modulate the integration of 
signals from the surrounding environment and helps to explain the paradoxical 
effects of IFNa/p on adaptive immunity. 
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3. 2 Introduction 
HCV infection, in contrast to other viral liver infections including HBV, induces 
robust IFN response genes upon infection139. Although this interferon gene 
signature is not predictive of clinical outcome, HCV replication is sensitive to 
IFNa and pegylated-IFNa / ribavirin is a highly effective therapy for HCV101. 
The difficulty in understanding the complex actions of IFNa/p during HCV 
pathogenesis is reflective of the pleiotropic effects of IFNa/p140. Although most 
widely known for its antiviral activity, IFNa/p is also a potent 
immunomodulator. For example, exposure of natural killer (NK) cells and naive 
T cells to IFNa/p during viral infection inhibits their production of IFNy181; 
however, IFNa/p has also been shown to trigger NK cell cytotoxicity and 
stimulate proliferation of certain T cell subsets182183. These polarized physiologic 
and pharmacologic effects are mediated by the same heterodimeric IFNa 
receptor. 
This complexity extends to the effects of IFNa/p on conventional dendritic 
cells (DCs). Considered the 'sentinels' of the immune system, DCs are 
responsible for integrating immune responses. Tissue DCs, which exist in an 
immature state of differentiation, are responsible for capturing and processing 
antigen, as well as transmitting pro-inflammatory and immune regulatory 
signals to cells within draining lymph nodes52. DCs also possess a unique ability 
to cross-present exogenous antigen, offering a mechanism for priming CD8+ T 
cells specific for viruses that do not directly infect DCs. Recent data suggests that 
type I IFNs may serve as a 'danger' signal during this process, facilitating DC 
activation184 and licensing DCs to cross-prime185; however, IFNa/p has also been 
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shown to inhibit the production of IL-12 by DCs186, and may also inhibit DCs 
from stimulating TH1 cell differentiation187. 
pDCs are widely recognized for their role in sensing viral and bacterial 
components and producing significant amounts of IFNa/p 188. In humans, pDCs 
express TLR7 and TLR9, receptors for ssRNA126 and CpG189, respectively. Upon 
activation, pDCs migrate to lymph nodes and produce IFNa/p, thus influencing 
the afferent phase of T cell activation155156. During chronic inflammation and 
infection, pDCs may also traffic to affected tissues190191. Although activated 
pDCs may serve as a strong adjuvant for adaptive immune responses189, the 
immunologic significance of pDC-derived IFNa/p in distinct spatial locations has 
not been carefully evaluated. 
Here, we evaluated the effects of IFNa/p on the cross-presentation of 
antigen. Importantly, our consideration of the distinct compartmentalization of 
IFNa/p production, in peripheral tissue versus the lymph node, led to a 
surprising result. Immature DCs (iDCs) exposed to IFNa/p (referred to herein as 
TFN-early')—mimicking the micro-environment of a tissue DC—were impaired 
in their ability to activate CD8+ T cells via the cross-presentation pathway. In 
contrast, mature DCs (mDCs) exposed to IFNa/p (referred to herein as TFN-
late')—mimicking the micro-environment of DC : T engagement within the 
lymph node—demonstrated enhanced T cell activation. Investigation into the 
regulation of these opposing effects revealed a molecular switch in IFNa/p 
signaling networks that is a consequence of DC maturation. Our findings offer 
insight into how IFNa/p shapes the adaptive immune responses to cross-
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presented antigen and uncover a novel mechanism by which DCs modulate their 
response to cytokine signals from the surrounding environment. 
3.3 Materials and Methods 
Isolation and preparation of cells 
Peripheral blood mononuclear cells (PBMCs), DCs, and T cells were prepared as 
previously described168. PBMCs were isolated from whole blood by 
sedimentation over Ficoll-Hypaque (Amersham Pharmacia Biotech, NJ). iDCs 
were prepared from the T cell depleted fraction by culturing cells in the presence 
of 1000 U/mL GM-CSF (Berlex, Seattle, WA) and 500-1000 U/mL IL-4 (R&D 
Systems, Minneapolis, MN) for 6 days169170. To generate mature DCs, cultures 
were stimulated on day 6 with 50 ng/mL TNFa (Alexis Biochemicals) and 
O.lmM PGE2 (Sigma) or lOng/mL LPS (Sigma) for 36-48hrs171. At days 6-7, >95% 
of the cells were CD14CD83HLA-DR10 DCs. After maturation, on days 8-9, 
70-95% of the cells were of the mature CD14"CD83+HLA-DRhi phenotype. CD4+ 
and CD8+ T cells were purified to >99% purity by positive selection with the 
MACS column purification system (Miltenyi Biotech, Auburn, CA). pDCs were 
also purified by MACS with BDCA-4 microbeads. pDCs were stimulated with 
CpG (2216: 5'-GGGGGACGATCGTCGGGGGG-3') in 1% single donor plasma. 
After 24 hrs, cultures were harvested and supernatants purified by 
centrifugation. 
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Induction of apoptotic death 
The mouse lymphoma cell line EL4 (number TIB-39, ATCC, Rockville, MD) was 
used as a source of apoptotic cells because they can be efficiently infected with 
influenza virus and do not induce marked background T cell activation to mouse 
antigens. EL4 cells were infected with influenza and apoptosis was triggered 
using a 60UVB lamp calibrated to provide 2 mj/cm2/s. 
Endogenous and exogenous loading of DCs with antigen 
For endogenous loading, mDCs were infected with 0.002 HAU influenza 
A/PR8/1976 (Charles River, Spafas Conn) per cell. Virus was quenched and 
removed with 2 washes of media with 5% pooled AB human serum (Labquip, 
NY). For loading DCs with exogenous antigen, iDCs were co-cultured with 
influenza infected EL4s that had been exposed to UVB62. Co-cultures were 
incubated in the presence of TNFa / PGE2 to allow for phagocytosis of the 
apoptotic EL4 cells, antigen processing and DC maturation to occur. mDCs were 
then used for functional assays. 
Detection of antigen-specific T cells: ELISPOT assay for IFNy release 
Antigen loaded DCs were collected, counted and added to purified T cell 
populations in plates that had been coated with lO^g/ml of anti-IFNy mAb 
(clone Mab-1-D1K, Mabtech, Cincinnati, OH). In all experiments, 2 x IO5 T cells 
were added to 6.6 x IO3 DCs to give a 30:1 T cell:DC ratio. The cultures were 
incubated for 40-44 h at 37°C. Cells were washed out with mild detergent (0.5% 
Tween-20 in PBS) and the ELISPOT plate was incubated with ljxg/ml of a biotin-
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conjugated IFNy m A b (clone M a b 7BG-1, Mabtech) for 2 hrs at 37°C. ELISPOT 
plate was then washed with 0.1% Tween-20 in PBS and developed using the 
Vectastain Elite kit (Vector Laboratories, Burlingame, CA) and 3-amino-9-
ethylcarbazole (AEC) substrate. Colored spots indicate the cells that had 
released IFNy and data is reported as spot forming cells /106 CD8+ T cells. Data 
from triplicate wells were averaged and mean data is reported. Error bars 
represent one standard deviation. 
Analysis of STAT phosphorylation 
DCs were harvested, washed with PBS, resuspended in 10% FBS containing 
media and stimulated with indicated concentration of rIFNa, purified IFNa/p or 
IFNy (Sigma, St. Louis, MO) for 30 minutes at 37°C. For western blot analysis 
and immunoprecipitation, lysates were prepared in RIPA lysis buffer (150mM 
NaCl, 50mM Tris-Cl pH 8,1% NP40, 0.5% DOC, 0.03% SDS, 2mM EDTA) with 
ImM Vanadate (Sigma), ImM PMSF, and Complete anti-protease tablet (Roche). 
Total protein was determined using the Bradford assay (Biorad). 
Immunoprecipitation was performed with 400^g of total protein and 0.2[ig of 
anti-IFNARl (CD118) overnight at 4°C. Protein A and G beads were mixed 1:1 
and incubated 4°C for 1 hour followed by three RIPA washes. Beads were boiled 
at 95°C in 2x loading buffer and run on 8% SDS-PAGE. For IFNAR2 western 
blot, 20pig of total protein was loaded on to 8% SDS-PAGE. Proteins were 
transferred to PVDF membrane and blotted with indicated antibodies (Cell 
Signaling Technologies). Blots were probed first with phospho-specific STAT 
antibodies, stripped with low pH, and reprobed with total STAT antibodies to 
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ensure p-STAT is monitored in the context of total STAT. For intracellular FACS 
analysis, samples were fixed, permeabilized with Cytoperm/Cytofix (BD 
Pharmingen). Cells were stained with STAT1-PE, STAT3-PE, and STAT4-APC 
(Pharmingen) at 1:50 final dilution as indicated. 
Affymetrix Microarray U133A (see Appendix 2) 
Biotinylated cRNA fragments were prepared from monocyte derived DCs as per 
affymetrix protocol192.107 cells were washed in PBS and lysed using Qiashredder 
(Qiagen, Valencia, CA). Total RNA was isolated using RNeasy Mini Kit (Qiagen, 
Valencia, CA). cDNA and fragmented biotinylated labeled cRNA were 
subsequently prepared as per manufacturer's instructions (Affymetrix and Enzo 
Life Sciences) and 20 [xg of fragmented cRNA was loaded onto Affymetrix 
U133A. Data was analyzed using Microarray Suite 5.0 (Affymetrix, Santa Clara, 
CA), and compiled using a Filemaker Pro-based customized database (adapted 
from a database that was generously provided by Dr. Nir Hacohen, Harvard 
University). Absolute expression, p-call, and p-value as calculated by MAS 5.0 
software was exported to Excel spreadsheet and converted into a Filemaker Pro 
document. Data from multiple runs was linked via Affy ID number. 
IL-12 and IFNa ELISAs 
IL-12p70 levels were confirmed in triplicate using IL-12 ELISA (R&D systems). 
IFNa ELISA (PBL Biomedical, Piscataway, NJ) was performed in triplicate and 
data from two donors was averaged. 
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Analysis of IL-12 production in M C M V infected mice 
C57BL/6 were obtained from Charles River (France); STAT1-/- (129SVE) from 
Taconic; and STAT4-/- (Balb/c) from Jackson. IFNAR-/- mice on the C57BL/6 
background were provided by D. Braun, Institut Pasteur. RB6-8C5 (anti-GR-1) 
bioreactor supernatant was obtained from monoclonal antibody facility 
(MSKCC) and mice were depleted with 500 pig at 36 hrs and 12 hrs before 
infection. Mice were infected with 4 x IO5 PFU/mL of salivary gland prepared 
MCMV. 36 hours after infection, spleens were harvested, incubated 1:50 dilution 
of anti-FcyR (BD Pharmingen) to block non-specific antibody interaction in 
mouse FACS wash buffer. Cells were surface stained with CD8 FITC (1:150 
dilution, BD Pharmingen) and CDllc PE (1:150 dilution, BD Pharmingen), fixed 
and permeabilized with cytoperm/cytofix (BD Pharmingen), and stained with 
IL-12 APC (1:150, BD Pharmingen). 
3. 4 Results 
Maturation prevents IFNa/p mediated inhibition of cross-presenting DCs 
In order to explore the effects of TPNa/p on antigen cross-presentation, we 
employed an experimental system based on the activation of primary human 
memory CD8+ T cells (Fig. 3.1). DCs cross-presenting antigen were generated by 
co-culturing iDCs with apoptotic, influenza (flu)-infected MHC-mismatched cells 
in the presence of maturation stimuli62. Antigen-loaded mDCs were then 
cultured with purified CD8+ T cells and the activation of influenza specific IFNy-
producing cells was monitored using ELISPOT. Maximal CD8+ T cell activation 
by cross-presentation requires CD40L engagement, mimicking the effect of CD4+ 
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Figure 3.1. In vitro system for monitoring CD8+ T cell activation 
requires CD40 ligation. DCs loaded with endogenously processed 
antigen were prepared by direct infection with influenza (flu D C ) and 
compared to uninfected DCs (DC alone). DCs loaded with exogenous 
antigen were prepared by cross-presentation of influenza infected 
apoptotic cells (flu-apoptotic cells) and compared to uninfected apoptotic 
cells (apoptotic cells). D C groups were cultured with syngeneic purified 
CD8+ T cells. T cell activation was monitored by IFNy ELISPOT and 
displayed as spot forming cell (SFCs) / IO6 CD8+ T cells. Recombinant 
CD40L was added to cultures as indicated. 
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T cell / D C interactions62 (Fig. 3.1). In order to model IFNa/p production in 
peripheral tissue, leukocyte derived or recombinant IFNa was added to iDCs 
during antigen capture and maturation (Fig. 3.2A) and then washed out prior to 
DC : T engagement. Alternatively, to model the production of IFNa/p in the 
lymph node, IFNa/p was added to mDCs during T cell engagement (Fig. 3.2A). 
Surprisingly, the effect of IFNa/p on the regulation of T cell activation 
depended on the maturation state of the DC. IFNa/p inhibited CD8+ T cell 
activation when delivered to iDCs (Fig. 3.2B, IFN-DC), but no inhibition was 
observed when adding the IFNa/p directly into the mDC : T cell cultures (Fig. 
3.2C, mDC + IFN). In some experiments, high doses of IFNa (600-6000 IU/ml) 
resulted in significantly increased T cell responses (data not shown). One caveat 
in this comparison is that, in the latter culturing condition, IFNa/p may be 
directly affecting the T cell. 
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Figure 3.2. Maturation prevents IFNa mediated inhibition of cross-
presenting DCs. A. Schematic depicting experimental setup. IFNa/p was 
either added to iDCs during antigen capture and maturation (IFN-early) 
or during DC:T cell engagement (IFNa-late). B,C. (B)IFNy ELISPOT with 
DCs cross-presenting uninfected apoptotic cells (white bars) or DCs cross-
presenting influenza antigen-expressing apoptotic cells (black bars) 
exposed to 60 IU/mL IFNa/p during antigen capture (IFN-early: IFN-
DCs) or (C) during DC:T cell engagement (IFN-late: m D C + IFN) cultured 
with purified CD8+ T cells. Data are representative of ten experiments 
and similar results were obtained when using recombinant IFNa (data 
not shown). 
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The inhibitory effect of IFNa/p is selective for CD40-dependent cross-presentation 
In order to evaluate if the inhibitory effect of IFNa/p on iDCs is specific for cross-
presentation, we compared DCs cross-presenting antigen to those directly 
infected with influenza. iDCs were treated with increasing doses of IFNa/p (10-
60 IU/mL) during their maturation. These IFN-DCs were washed extensively 
and exposed to live influenza virus. Again, IFNy production by influenza-
specific CD8+ T cells was used as a measure of the DCs capacity to stimulate T 
cells. While the cross-presentation pathway was sensitive to IFNa/p (Fig. 3.3, 
black line), no inhibition of CD8+ T cell activation was observed when IFN-DCs 
were directly infected (Fig. 3.3, red line). Further, the IFN-mDCs loaded with 
exogenous antigen showed no defect in stimulating influenza-reactive CD4+ T 
cells (Fig. 3.3, blue line), thus providing an internal control that antigen had been 
captured and that the DCs were capable of engaging T cells. From these 
experiments, we conclude that IFNa/p has a selective effect on T cell activation 
by cross-presenting DCs. 
This selective effect may be due to decreased antigen capture, inefficient 
DC maturation, or the skewing of activation signals specific for T cell activation 
by cross-presentation (e.g. CD40 engagement). In order to directly evaluate 
antigen capture, apoptotic cells and iDCs were labeled with fluorescent lipophilic 
dyes as described193. Capture of the red-labeled apoptotic cells by the green-
labeled DCs was monitored by flow cytometry. After 5hr, -40% of the iDCs had 
captured an apoptotic cell body / bleb (Fig. 3.4A). Addition of IFNa/p to the co-
cultures did not inhibit antigen capture (Fig. 3.4A), nor did it alter the kinetics of 
uptake (data not shown). We next evaluated the effect of IFNa/p on phenotypic 
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Figure 3.3. Inhibition by IFNa/P is selective for cross-presenting DCs. 
DCs were directly infected with influenza virus (flu DC) or co-cultured 
with apoptotic influenza-expressing apoptotic cells (DCs x/p flu-AC). In 
each, the iDCs were exposed to a dose range of IFNa/p iDCs (cone. 0-600 
IU/ml). CD8+ T cell and CD4+ T cell activation were monitored by IFNy 
ELISPOT. Percent inhibition of T cell activation is displayed. Maximal 
stimulation (no IFNa/p) in the experiment shown is equivalent to 400 spot 
forming cells / million T cells. 
76 
u 
< 
CM 
X 
PL, 
DCs 
1000 
T = 0hr 
Media Media 
39.0% 
PKH67 (DCs) 
T = 5hr • 
E D T A IFN-early 
3.8% 39.7% 
PKH67 (DCs) 
Figure 3.4. IFNq/P does not alter phagocytosis, phenotypic or functional 
maturation of DCs. (Continued on following page) 
77 
B 
100 
I o 
^100 
u 
o t 
CD83 CD86 
A 
H L A - D R CD40 
isotype control 
— iDC 
— m D C 
— IFN-DC 
o 250 
| 200 
Plh 
U 1501 
.2 1001 
cu 
o 
50-
• m D C 
X IFN-DC 
30 90 270 810 2430 
# DCs / T cell 
Figure 3.4. IFNa/P does not alter phagocytosis, phenotypic or functional 
maturation of DCs. A. Phagocytosis of PKH26 (red dye)-labeled apoptotic 
cells (AC) by PKH67 (green dye)-labeled iDCs was monitored by flow 
cytometry. iDCs and apoptotic T cells were distinguished based on forward 
scatter (FSC) and side scatter (SSC) properties, as shown. Gating on iDCs 
using scatter and FL-1 criteria permitted monitoring of cells that engulfed a 
red-labeled dying cell, as based on their becoming double positive (lower 
FACS plots). Co-cultures were incubated in the presence of media, EDTA, 
or IFNa as indicated. Percent phagocytosis is indicated. B. FACS analysis of 
CD83, CD86, HLA-DR, and CD40 expression levels on iDCs, mDCs, or DCs 
matured in the presence of IFNa/p (IFN-DC). C. Allostimulatory potential 
of m D C s or DCs matured in the presence of IFNa/p (IFN-DC) was 
monitored by stimulation of T cell proliferation after 5 days of culture. 
Proliferation was monitored by incorporation of 3H-thymidine. Triplicate 
wells are averaged and +/- standard deviation is represented by error bars. 
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and functional maturation of the DCs. Importantly, the addition of IFNa/p did 
not affect TNFa-mediated maturation as monitored by expression of CD40, 
CD83, HLA-DR and CD86 (Fig. 3.4B). Moreover, the allostimulatory capacity of 
IFNa-mDC was equivalent to mDCs, as measured using a standard allogeneic 
mixed lymphocyte reaction (Fig. 3.4C). The finding that antigen capture and DC 
maturation are intact is consistent with the observation that CD4+ T cells may be 
activated by IFNa early-DCs (Fig. 3.3). These data also suggest that IFNa/p 
treatment of iDCs may be affecting the DCs ability to be 'licensed' by CD40, a 
feature unique to the cross-priming of exogenous antigen in our model system' 62 
Maturation alters IFNa/p regulation of CD40L-induced IL-12 
In order to evaluate the inhibitory effect of IFNa, we focused our attention on the 
effect of 'IFN-early' on CD40L-induced gene changes. In order to screen for these 
changes, we took advantage of the Affymetrix U133A microarray (see Appendix 
2). Briefly, RNA was prepared from the samples of interest: iDCs or mDCs 
matured in the presence or absence of IFNa/p and stimulated with or without 
CD40L. RNA probes were prepared as per the Affymetrix protocol and the 
microarray data was analyzed with MAS5.0 statistical software. Our array data 
set was queried for gene changes in which: mDCs + CD40L > 2x mDCs; AND 
mDCs + CD40L > 2x IFNa-mDCs + CD40L (n = 2) (see Appendix 2). With such a 
Boolean search, we exclude gene changes that are simply a result of IFNa-
treatment of the DCs. From the list generated, genes were excluded if they did 
not meet a 'p' call in mDCs or mDCs + CD40L in either or both of the 
experiments, as per the Affymetrix MAS5.0 statistical package. Data on iDCs, 
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m D C s , IFNa-mDCs, m D C s + CD40L and IFNa-mDCs + CD40L from the two 
individual donors were averaged, and means are graphically represented to 
reveal CD40L-induced transcription changes that distinguish treatment of mDCs 
(blue) versus IFNa-mDCs (red). This analysis yielded nine candidate genes that 
were inhibited by 'IFN-early' (Fig. 3.5). 
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Figure 3.5. IFNo/p early alters CD40L gene induction profile. Affymetrix 
data was queried for genes induced by CD40L that were blunted by 
exposure of iDCs to IFNa/p during maturation. The top nine differentially 
regulated genes are displayed graphically by relative expression in iDCs, 
m D C , or m D C s exposed to CD40L ( m D C + 40L). Blue line, untreated. Red 
line, IFNa/p treated. 
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In light of the important role that IL-12 plays in cross-priming75,76194, w e 
further explored the observation of differential IL-12p40 mRNA expression (Fig. 
3.6A). Using an ELISA, we confirmed that CD40L-induced production of 
bioactive IL-12p70 was inhibited by 'IFN-early' (Fig. 3.6B). In contrast, 'IFN-late' 
synergized with CD40L, as even higher levels of IL-12p70 were produced by 
mDCs under these conditions (Fig. 3.6B). 
To determine the importance of IL-12 inhibition in the functional block of 
CD8+ T cell activation, we evaluated the ability to overcome the IFN-early block 
by adding rIL-12 to the IFN-DCs cross-presenting antigen. IFNy ELISPOT results 
from three donors were normalized to the donor specific maximal T cell response 
and the percent maximal T cell response is shown (Fig. 3.7). Indeed, IL-12 
rescued the ability to stimulate antigen-specific CD8+ T cells via the cross-
presentation pathway. While other factors may be involved, the decrease in 
CD40L-induced IL-12 seems to be a critical component of the inhibitory effects of 
IFNa/p. These data also suggest that cross-presentation per se remains intact in 
IFN-DCs, and that the dominant mechanism of regulation is via inhibition of 
CD40-dependent licensing of DCs. Thus, differential responsiveness of iDCs and 
mDCs to IFNa/p regulates the production of cytokines that determine the 
immunologic outcome of cross-presentation. 
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Figure 3.6. IFNa/p-early, not late, inhibits CD40L-triggered IL-12. A. 
Affymetrix analysis shows relative expression of IL-12B subunit in iDC, 
m D C , and m D C + CD40L. Untreated, black line. IFNa/p treated iDC, gray 
line. B. Supernatants from DCs matured alone (mDC), in the presence of 
IFNa/p (IFN-DC), or DCs exposed to IFNa/p after maturation ( m D C + IFN) 
were treated with CD40L as indicated for 2 hours. IL-12p70 was measure by 
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Figure 3.7. Exogenous IL-12 rescues inhibition by IFNa. T cell 
activation by DCs cross-presenting apoptotic cells (DC x/p AC), DCs 
cross-presenting apoptotic cells loaded with influenza antigen (DC 
x/p flu-AC) or DCs matured in the presence of IFNa/p cross-
presenting influenza antigen (IFN D C x/p flu-AC) was monitored by 
IFNy ELISPOT. In addition to CD40L alone (media), recombinant 
human IL-12 (rIL-12p70) was added to the DC:T cell cultures. Data 
from three donors were normalized to the donor-specific maximal T 
cell response and the percent maximal T cell response in the presence 
or absence of IFNa/p and IL-12p70 is shown. 
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D C maturation alters IFNa/p signaling by switching STAT utilization 
In light of the correlation of distinct DC maturation states with the paradoxical 
effects of IFNa/p, we considered the possibility that intrinsic differences between 
iDC and mDC IFNa/p responsiveness could account for the opposing effect on T 
cell activation. Three possibilities were evaluated to directly test this hypothesis: 
(i) differences at the level of IFNa/p receptor (IFNAR) expression; (ii) utilization 
of distinct signaling molecules; and (iii) altered CD40-mediated transcriptional 
events, resulting from differences in IFNa/p signaling. 
First, expression of IFNAR on iDCs and mDCs was evaluated by FACS. 
Surface expression of both subunits, IFNAR1 and IFNAR2, were equivalent in 
iDCs and mDCs (Fig. 3.8A). Immunoblot analysis of IFNAR1 and IFNAR2 
confirmed that there are equivalent levels of both subunits in iDCs and mDCs 
(Fig. 3.8B). Based on these data, we conclude that differential receptor 
expression does not account for the distinct effects of IFNa/p on iDCs and mDCs. 
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Figure 3.8. Maturation does not alter IFNAR surface expression. A. 
iDC and m D C were stained with anti-CD83-Cy5 and m A b s specific 
for IFNAR1 (AA3, Biogen) or IFNAR2 (MMHAR-2, Calbiochem). 
Anti-mouse IgG PE (Jackson) was used to visualize anti-IFNAR 
binding. Dot plots representative of a single donor are shown. Three 
individuals were evaluated and revealed similar results. MFI for x-
axis is indicated. B. Immunoblot for IFNAR1 and IFNAR2 
expression in iDC or m D C s by western and immunoprecipitation, 
respecitively. DCs were either unstimulated or treated with 
lOOIU/mL IFNa for 30 minutes. 
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W e next considered the possibility of differential signaling downstream of 
IFNAR. In order to screen for potential points of divergent regulation, we 
analyzed transcriptional profiles of iDCs and mDCs from four individuals using 
Affymetrix U133A microarrays. Analysis of genes known to be involved in 
IFNa/p-signaling revealed possible differences in IFN-response (Table 3.1). Our 
transcriptional analysis of DCs revealed a two-fold change in total Jakl and 
Tyk2, the kinases associated with IFNAR and responsible for STAT 
phosphorylation. In addition, transcriptional screening showed a 2-fold 
downregulation of total ST ATI upon maturation and 2-fold upregulation of 
STAT4. Consistent with the skewing of STAT expression, Affymetrix analysis 
shows numerous differences in IFN-induced genes between iDCs and mDCs 
exposed to IFNa/p (data not shown). 
In order to evaluate IFNa/p signaling in DCs, we first looked at kinase 
expression. As reviewed in chapter 1, IFNAR is constituitively associated with 
Jakl and Tyk2. Engagement of IFNAR by IFNa/p induces dimerization and 
oligomerization of the receptor, which allows for Jakl and Tyk2 
transphosphorylation. Consistent with the transcriptional data, Jakl protein 
expression is increased upon maturation (Fig. 3.9A). Although total changes in 
protein expression of Tyk2 are not apparent upon maturation, phosphorylation 
of Tyk2 in mature DCs is significantly decreased compared to iDCs in response 
to IFNa/p stimulation (Fig. 3.9A). 
We next investigated the effect of this differential kinase expression and 
activation on STAT activation as monitored by phosphorylation of STAT 
proteins by Western blot. Classically, ST ATI and STAT2 are phosphorylated in 
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T a b l e 3.1. Transcriptional profiles of I F N o / P associated g e n e s 
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mDCavg¥ 
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1.0 
2.7 
2.0 
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0.7 
0.9 
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¥ R N A from iDCs and mDCs was anlayzed by Affymetrix microarray U133A. Affymetrix data was 
compiled from four individual donors. Average relative m R N A expression for iDCs (iDC avg) and 
m D C s (mDC avg) are indicated with the range indicated in parentheses. 
* + Determination of the absence or presence (A/P) of a gene transcript as well as p-values were calculated 
using Affymetrix statistical package, MAS5.0 
§ Fold change of average expression levels are expressed as a ratio of m D C avg / iDC avg. 
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response to IFNa/p, forming a heterotrimer with IRF-9, which binds to interferon 
sequence response element (ISRE) containing genes118. In certain cell types, 
STAT4 may be phosphorylated in response to IFNa/p, leading to transcription of 
distinct sets of genes119. Exposure of iDCs to IFNa/p, results in phosphorylation 
of STAT1 and STAT2 (Fig. 3.9B). In contrast, despite the presence of total STAT1 
and IFNa/p-induced STAT2 phosphorylation, mDCs showed reduced levels of 
ST ATI phosphorylation. Notably, total STAT4 is significantly upregulated 
during maturation and exposure to IFNa/p resulted in its phosphorylation (Fig. 
3.9B). 
Intracellular FACS analysis confirmed, on a per cell basis, that differential 
IFNa/p-induced STAT-phosphorylation was dependent on the state of DC 
maturation. Using CD83 as a marker, analysis of STAT1 versus STAT4 
phosphorylation was evaluated in both iDCs and mDCs. Consistent with 
Western blot analysis, iDCs phosphorylate ST ATI and not STAT4 in response to 
IFNa/p (Fig. 3.9C), while mDCs phosphorylate STAT4 and show a significantly 
reduced phosphorylation of ST ATI. The qualitative shift in IFNa/p signaling is 
also reflected in the activation of STAT3. mDCs demonstrate increased STAT3 
expression (Table 3.2), however, maturation results in a blunting of STAT3 
phosphorylation in response to IFNa/p (Fig. 3.9D). Together, these results 
suggest that DC maturation alters IFNa/p signaling through the modulation of 
STAT utilization. 
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Figure 3.9. Dendritic cell maturation alters IFNa/P signaling 
network. A,B. iDC and m D C s were exposed to 60 IU/ml IFNa/p for 
30 minutes. 20jig of protein from the total cell lysates were run on an 
8% SDS-PAGE, transferred to PVDF membranes, and blotted with 
indicated antibodies. In selected experiments, blots were stripped 
and probed for p-actin as a control for loading the gel (data not 
shown). C,D. iDCs and m D C s were stimulated with media alone or 
indicated concentrations of IFNa/p for 30 minutes. Cells were stained 
with anti-CD83-FITC to identify CD83" iDCs and CD83+ mDCs. Cells 
were fixed and permeabilized as described in Materials and methods 
and stained for p-STATl-PE or p-STAT3-PE and p-STAT4-APC. 
Percentage of events in each quadrant is indicated on the respective 
plot. Data is representative of three independent experiments. 
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Importantly, this finding is not dependent on maturation conditions, as 
DCs matured with lOng/mL of LPS also showed impaired ST ATI 
phosphorylation (Fig. 3.10A). Furthermore, the inhibition of STAT1 signaling is 
also observed after TNFa-mediated maturation of BDCA-1+ circulating DCs (Fig. 
3.10 A). In order to test if the inhibition of ST ATI phosphorylation in mDCs is 
intrinsically impaired, we evaluated the ability of IFNy to trigger ST ATI 
activation. Notably, IFNy-treatment of mDCs resulted in efficient 
phosphorylation of ST ATI, indicating that inhibition of pSTATl is in fact specific 
to IFNa/p signaling (Fig. 3.10B). 
ST ATI required for IFNa/p inhibition of IL-12 
In order to evaluate the role of the STAT signaling switch in this dual 
regulation of IL-12 production, we took advantage of the fact that, similar to 
IFNa/p in our in vitro system, IFNa/p during MCMV infection significantly 
inhibits IL-12 production by CDllc+ DCs 195. We confirmed these results 
showing significant increase in CDllc+/CD8- IL-12 production in both 
IFNAR-/- and pDC depleted mice (Fig. 3.11A). In order to evaluate that STAT-
dependence of this effect, ST ATI and STAT4 KO mice, with 129SVE and Balb/c 
controls, respectively, were infected with MCMV Smith strain i.p. Analysis of IL-
12 production by CDllc high DCs in the spleen 36 hours post-infection by FACS 
revealed that STAT1, but not STAT4 plays a crucial role in inhibiting the 
production of IL-12 by CDllc high DCs (Fig. 3.11B). These results suggest that 
the inhibitory effect of IFNa/p on IL-12 production by DCs is mediated by STAT1 
and not STAT4. 
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Figure 3.10. Failure to phosphorylate ST A T I is IFNo/P-specific and 
characteristic of m D C s . A. iDCs and m D C s were stimulated with media 
alone, 60 IU/ml IFNa/p, or 10 ng/ml IFNy for 30 minutes as indicated. 
Cells were fixed, permeabilized, and stained for p-STATl (Pharmingen). 
B. iDCs, DCs matured with TNFa / PGE2, or DCs matured with LPS 
were stimulated with media alone or IFNa/p as indicated. Geometric 
mean fluorescence intensity (MFI) of p-STATl was calculated using 
Flo Jo statistical analysis. p-STATl activation index is represented as a 
ratio of MFI IFN-stimulated / MFI media alone. 
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production by DCs. A. Mice were untreated or infected with M C M V . 
At 36 hours post-infection, spleens were harvested and stained with C D 8 
FITC, CDllc PE, and IL-12 as described in Materials and Methods. The 
percentage of CDllc+/CD8- DCs that stained positive for IL-12 is 
expressed as bar graph. B. STAT1-/- or STAT4-/- mice and their 
respective controls (129SVE and Balb/c) were infected with M C M V . 
Similarly, the percentage of CDllc+/CD8- DCs that stained positive for 
IL-12 is expressed as a bar graph. 
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p D C IFNa/p differentially regulates CD8+ T cell activation by cross-presenting D C s 
In order to explore the effects of pDC-derived IFNa/p on antigen cross-
presentation, supernatants from CpG-stimulated pDCs were added to iDCs 
during antigen capture and maturation (Fig. 3.12A, iDC + pDC IFNa/p), and 
then washed out prior to DC : T cell engagement. Alternatively, the pDC 
supernatant was added to mDCs during T cell engagement (Fig. 3.12A, mDCs + 
pDC IFNa/p). pDC-derived supernatants were prepared from BDCA-4 purified 
cells that had been stimulated with 20^g/mL CpG-2116 for 24 hours and the 
concentration of IFNa in the supernatant was quantified by ELISA (Fig. 3.12B). 
Similar to the effects of recombinant IFNa, the effect of pDC-derived cytokines 
on the regulation of T cell activation depended on the maturation state of the DC. 
iDCs exposed to pDC IFNa/p were inhibited in their ability to stimulate CD8+ T 
cells (Fig. 3.12C). In contrast, mDCs demonstrated enhanced CD8+ T cell 
activation in the presence of pDC IFNa/p (Fig. 3.12C). This increase in IFNy 
production was antigen specific, as pDC-derived IFNa/p alone did not directly 
activate T cells. As a negative control for this experiment, supernatants from 
unstimulated pDCs were employed (Fig. 3.12C). Exposure of iDC co-cultures to 
CpG did not inhibit CD8+ T cell activation (data not shown). 
95 
A £ > 
apoptotic 
cell 
Maturation 
iDC 
p D C IFNa/p 
IFNy 
p D C IFNa/p 
B 70 
60 
f 50 
I40 
^ 3 0 
§ 20 
10 
0 
c 1600 
1200 
00 
D 
U 800 
eo 400 
u 
en 
- CpG 
• D C x/p apoptotic cells 
jjjj D C x/p flu-apoptotic cells 
media p D C C p G p D C C p G 
p D C p D C 
added to iDC added to m D C 
Figure 3.12. pDC-derived IFNo/P has a dual effect on cross-presenting 
myeloid DCs. A. p D C IFNa/p was generated from BDCA-4 purified pDCs. 
As illustrated, p D C IFNa/p was added to iDCs during antigen capture and 
maturation, or to m D C s during CD40 cross-linking and CD8+ T cell 
engagement. B. Quantitation of IFNa concentration in p D C supernatants 
unstimulated (-) or stimulated with CpG. C. In all conditions, DCs cross-
presenting (abbrev. x/p) antigen were cultured with purified CD8+ T cells 
and CD40L. The activation of influenza-specific CD8+ T cells was 
monitored by IFNy ELISPOT and reported as spot forming cells (SFCs). 
DCs cross-presenting uninfected apoptotic cells (white bars) or DCs cross-
presenting influenza antigen-expressing apoptotic cells (black bars). 
Unstimulated (pDC) or CpG-stimulated p D C (CpG-pDC) supernatant was 
added to the DCs as indicated. The data shown here is representative of 
two experiments. ELISPOT counts from triplicate wells were averaged and 
mean data is reported. Error bars indicate standard error of the mean. 
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In light of the dual effects of IFNa/p, w e wondered which effect would be 
dominant. In order to address this experimentally, pDC-derived IFNa/p was 
added to ELISPOT cultures of DCs exposed to IFNa/p during antigen capture 
and maturation (Fig. 3.13). Notably, pDC-derived IFNa/p added during DC/T 
cell engagement overcame the inhibition of IFNy production induced by IFNa/p 
on iDCs. This increase in IFNy production was antigen specific, as pDC-derived 
IFNa alone did not directly activate T cells. 
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Figure 3.13. pDC-derived IFNa/P overcomes inhibitory effects of IFNa/P 
on iDCs. DCs cross-presenting influenza antigen (flu ag) exposed to 
IFNa/p during antigen capture (IFNa/p iDC) were cultured with purified 
CD8+ T cells and CD40L in an IFNy ELISPOT with p D C sup alone (-) or 
CpG-stimulated p D C (CpG pDC) as indicated. Pictures of duplicate wells 
are shown with corresponding bar graph indicating relative levels of IFNy 
production as a function of total spot area (IFNy production = spot number 
x average spot size). 
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3.5 Discussion 
Dual regulation of cross-priming by pDC IFNa/p 
While it is widely accepted that pDCs and type I IFNs offer an important link 
between innate and adaptive immune responses188, there exist contrasting data 
regarding their immunoregulatory effects108. With respect to DC biology, there is 
support for IFNa/p as a 'danger' signal, triggering DC maturation and enhancing 
CD8+ T cell cross-priming 1%184185. These findings, however, must be reconciled 
with evidence for IFNa/p as a negative regulator of IL-12 production and its 
promoting TH2 skewing by DCs187. Our study offers new insight into these 
paradoxical effects and provides a mechanism to account for how signaling via a 
single receptor may act on a DCs to trigger distinct immunologic outcomes. 
Here, we demonstrated that the maturation state of the DC is responsible 
for determining the immunoregulatory effect of type I IFNs. When mDCs were 
exposed to IFNa/p (Fig. 3.14B, 'IFN-late'), a pro-inflammatory response ensued, 
as suggested by enhanced DC-mediated CD8+ T cell activation and greater 
production of IL-12p70 (Figs. 3.2C, 3.6B and 3.12C). This observation is 
consistent with the role of IFNa/p in enhancing TLR mediated cytokine 
production197198 and the 'licensing' of DCs for cross-priming185. In contrast, we 
discovered that iDCs exposed to IFNa/p during antigen capture and maturation 
(Fig. 3.14A, 'IFN-early') are impaired in their ability to activate CD8+ T cells (Figs. 
3.2B). This inhibitory effect of 'IFN-early' is specific for CD40-dependent CD8+T 
cell activation (Figs. 3.3 and 3.4), implicating the modulation of a 'third signal' 
produced by the DCs76. 
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Figure 3.14. Spatial location of pDCs results in compartmentalization of 
type I IFNs, and differential effects on cross-presentation due to a D C 
maturation-induced switch in S T A T utilization. This schematic 
represents our working model for how type I IFNs may exert their 
paradoxical effect on cross-presentation though the compartmentalization 
of IFNa/p. A. IFN-EARLY: IFNa/p produced in the tissue by infected cells 
or TLR engagement of pDCs activates ST ATI dependent signaling in 
immature myeloid DCs, which results in low IL-12p70 production and an 
impairment of helper-dependent cross-priming. B. IFN-LATE: Altered 
signaling networks in m D C s prevents STATl-mediated signaling. Instead, 
IFNa/p produced in lymph organs results in STAT4 dependent signaling 
in mature DCs, which facilitates enhanced production of IL-12p70 upon 
CD40 engagement. IFNa/p may also act directly on CD8+ T cells. 
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D C maturation alters IFNa/p signaling 
How can IFNa/p achieve opposite effects on iDCs versus mDCs when a 
single receptor exists? We show that a molecular switch in signaling networks is 
coupled to DC maturation and regulates the differential effects of IFNa/p on 
antigen cross-presentation. Specifically, iDCs phosphorylate ST ATI and STAT2 
upon IFNa/p stimulation and seem to employ the canonical type I IFN signaling 
pathway, while mDCs phosphorylate STAT4 and STAT2 (Fig. 3.9). This switch is 
reflective of similar intracellular regulation in NK and T cells, which accounts for 
their paradoxical responses to IFNa/p 108'181199. 
The molecular switch in signaling pathways selectively targets an IFNa/p 
signaling network. This is supported by mDCs responding to IFNy by signaling 
via STAT1 (Fig. 3.10). Interestingly, mDCs also show impaired phosphorylation 
of STAT3 in response to IFNa/p stimulation (Fig. 3.9D). In light of the similarity 
between ST ATI and STAT3, our findings demonstrate that the switch extends to 
redundant pathways in order to offer a functional skewing of the IFNa/p 
signaling network. Notably, IFNAR signaling requires STAT2 for activation of 
both ST ATI117 and STAT4 20°, while IFNy receptor binds and directly activates 
ST ATI. These differences may account for the selective regulation of pSTATl 
downstream of IFNAR. 
The master regulator of this switch in IFNa/p signaling remains unknown. 
Although quantitative shifts in ST ATI inhibit STAT4 activation199, it is not clear if 
reciprocal increases in STAT4 are directly responsible for inhibiting ST ATI 
activation. Alternatively, regulation may occur at the JAK level. Increase in total 
Jakl and the Jakl:Tyk2 ratio may skew downstream signaling (Fig. 3.9). 
101 
Alternatively, Tyk2 may play a dominant role in ST ATI phosphorylation201. 
Interestingly, transcriptional changes in suppressor of cytokine signaling-2 
(SOCS-2) and protein tyrosine phosphatase Nl (PTPN1) show 10-fold and 5-fold 
increase upon maturation respectively (Fig. 3.15). Although SOCS-2 has not 
been defined to play a role in the STAT signaling pathway, family members 
SOCS-1 and SOCS-3 negatively regulate the JAK-STAT pathway by directly 
inhibiting JAK activity202. PTPN1 may also play a role in skewing signaling by 
promoting ST ATI dephosphorylation. Experiments are currently underway to 
evaluate these candidate genes using retrovirally transduced shRNAs. 
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Figure 3.15. Maturation alters IFNa/P signaling in DCs. This schematic 
represents our working model for how type I IFNs signal in DCs. In iDCs, 
phosphorylation of ST ATI and STAT2 allows formation of ISGF3 and 
transcription of ISRE-dependent genes. In mDCs, striking upregulation of 
STAT4 correlates with impaired response of STAT1 phosphorylation. 
Formation of STAT4 homodimers leads to transcription of GAS-dependent 
genes. Upregulation of suppressor of cytokine signaling-2 (SOCS2), 
protein tyrosine phosphatase Nl (PTPN1), and STAT4 as a result of 
maturation may contribute to the signaling regulation. Histograms 
indicate relative m R N A expression determined by affymetrix microarray. 
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Altered signaling regulates outcome ofCD40 engagement via IL-12 
CD4+ T cells, acting via CD40L : CD40 engagement, serve as a 'licensing' 
signal for mDCs72,62 by triggering IL-12 production, a critical component of what 
has been termed 'signal 3'76. The contrasting effects of IFNa/p on cross-
presentation resides at this point of regulation, with type I IFNs serving to 
overcome CD4+ T cell help in some systems185, but acting as a potent inhibitor of 
IL-12 in others187. We propose that the switch in STAT utilization may account 
for this alternate regulation. IFNa/p stimulation of iDCs activates ST ATI-
dependent gene transcription (Fig. 3.14), which blunts CD40-induced IL-12 
production (Fig. 3.6, and 3.11). The importance of this pathway is illustrated by 
the ability of IL-12 to overcome the inhibitory effects of IFNa/p (Fig. 3.7). One 
report suggests that pSTATl may be acting directly to inhibit TNFa-mediated IL-
12 production via inhibition of NF-kB activation203, however the precise 
mechanism by which ST ATI versus STAT4 regulates IL-12 in human DCs 
remains to be discovered. 
Using STAT1-/- and STAT4-/- mice, it was possible to show that IFNa/p 
mediated inhibition of IL-12 is dependent on ST ATI but not STAT4 signaling 
(Fig. 3.11). The inhibition of IL-12 by IFNa/p is arguably occurring in the spleen, 
but the DCs analyzed are mostly resident DCs of the spleen that exist in an 
immature state under steady state conditions81. In contrast, tissue DCs must 
undergo maturation before migration to the lymph node. As such, we 
hypothesize that inhibition of IL-12 production would not be seen in this 
population. However, the ST ATI to STAT4 switch in mouse DC maturation has 
not been fully analyzed. Similar to our human data, splenic DCs upregulate 
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STAT4 upon maturation204; however, direct ST ATI or STAT4 activation has not 
been evaluated. Although early work suggested that IFNa-dependent STAT4 
activation does not occur in mice due to a STAT2 minisatellite insertions200, more 
careful analysis revealed that the pathway for STAT4 activation is intact in 
mice199, but variable expression may depend on genetic background205. STAT2 
minisatellite insertion may still account for species specific STAT2-dependent 
IFNa/p signaling. 
Location, location, location: Physiologic implications of spatial compartmentalization of 
IFNa/p production 
Regarding the physiologic and pathologic relevance for our findings, we 
suggest that spatial compartmentalization of IFNa/p production may offer a 
resolution for its paradoxical immunoregulatory effects on conventional DCs. 
Immature and mature DCs reside in different physiologic locations, with the 
former residing within peripheral tissue and the latter homing to the T cell area 
of draining lymphoid organs52. In situations of chronic infection, type I IFNs in 
the tissue (produced by parenchymal cells, pDCs that have moved into sites of 
chronic inflammation191 or by immature myeloid DCs themselves206) may exert a 
counter-inflammatory effect on iDCs (Fig. 3.14A). Specifically, we suggest 
IFNa/p produced in the tissue during antigen capture, inhibits subsequent T cell 
activation by cross-presenting DCs. The restriction of this inhibition to cross-
presentation is likely due to the CD40-dependence in our model system and may 
be more broadly applicable to other IL12-dependent responses68. 
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During some viral infections, P A M P engagement of p D C TLRs induces 
migration to the lymph node and production of robust amounts of type I IFNs 
(Fig. 3.14B). In this situation, IFNa/p would act on mDCs that had migrated from 
the peripheral tissue with captured antigen. The exposure of mDCs to IFNa/p 
may act directly on the DCs to synergize with other inflammatory stimuli and 
enhance IL-12 production. Our model does not rule out an additional, direct 
effect of IFNa/p or other pDC-derived cytokines on CD8+ T cell activation. For 
example, recent data suggests that activation of STAT4 in antigen specific CD8+ T 
cells may potentiate IFNy production207'208. Notably, the exposure of mDCs to 
IFNa/p during DC : T cell engagement overcomes the inhibitory effect of IFNa/p 
(Fig. 3.13). Thus, even if the cross-presenting DC had captured antigen in the 
presence of IFNa/p, pDC IFNa/p in the lymph would enable that DC to prime a 
T cell response. 
Why would the host employ IFNa/p production as an innate immune 
response if it interfered with the generation of adaptive immunity? The counter-
inflammatory roles of IFNa/p may play an important role in tempering the 
immune response during acute periods of hyperactivity. For example, IFNa/p 
inhibits bystander T cell activation209 as well as high levels of IL-12186 preventing 
cytokine toxicity. The inhibition of CD8+ T cell activation by cross-presenting 
DCs may provide another level of regulation against non-specific activation 
during viral infection. Delivery of inflammatory cytokines to draining lymph 
nodes at the site of DC : T cell engagement by accessory cells such as pDCs, 
therefore, may play an important role in regulating activation. 
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Both pathogens and therapies may take advantage of the inhibitory effects 
of IFNa/p on cross-priming. HCV, for example, induces robust levels of IFNa/p 
production soon after infection139. Although it remains unclear whether DCs can 
be infected by HCV, the high levels of IFNa/p in the liver may play an important 
role in preventing effective CD8+ T cell response in chronically infected 
patients41. Interestingly, the bacterial pathogen L. monocytogenes may also use the 
host's IFNa/p response to prevent an effective immune response210. In addition 
to its role in infectious immunity, the inhibitory effect of IFNa/p on tissue DCs 
may account for the recent observation of an inverse correlation between length 
of remission and pDC infiltration in early stage breast cancer211. Finally, the 
results presented here may offer a more detailed mechanism for the therapeutic 
use of type I IFN in multiple sclerosis to decrease T cell activation212. 
In contrast, the therapeutic effects of IFNa for HCV are thought to 
enhance T cell immunity to aid in viral clearance; however, recent reports 
suggest that this may not in fact be the case101. Despite sustained virologic 
response (SVR), T cell immunity to HCV may decrease with pegylated-IFNa / 
ribavirin213. The decreased T cell reactivity may be beneficial in reducing the 
hepatic inflammation and fibrosis during recovery. Several scenarios may 
account for these findings including a simple decrease in antigen load during 
SVR or the inhibitory effects of IFNa on iDCs when delivered systemically. In 
contrast, the therapeutic activation of pDCs may enhance IFNa/p production in 
lymph nodes and it will be interesting to see if comparative studies addressing 
the effects of pDC-derived IFNa/p on HCV-specific T cell immunity produce 
similar results. 
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Despite the potency of IFNa/p inhibitory effect on cross-presenting DCs, 
immune responses to viral infections do occur. As mentioned above, the 
inhibitory effects on cross-presenting DCs are most pronounced for immunity 
that depends on CD40 licensing of DCs and the production of IL-12 as a signal 
for T cell activation. Although these signals serve as an important component of 
the immune response in many infections, the number of infections that 
absolutely depend on these signals may be quite limited. Moreover, IFNa/p 
production is not restricted to the tissue in many viral infections that induce it. 
PAMPs, which trigger IFNa/p production in the tissue, may also trigger pDCs to 
produce IFNa/p at the DC/T cell interface, thereby overcoming the inhibitory 
effects of tissue IFNa/p. Nonetheless, these findings offer a more detailed 
understanding of the role of IFNa/p in both pathogenesis and therapy for all 
infections. 
In all, these findings show that DC maturation alters signaling networks, 
enabling distinct effects of IFNa/p on the immunologic outcome of cross-
presentation. This plasticity illustrates a novel mechanism by which DCs 
modulate the integration of signals from the surrounding environment. These 
findings suggest a rationale for spatial compartmentalization of pDCs during 
viral pathogenesis and offer insight into more effective therapeutic delivery of 
IFNa. As such, we turn in the next chapter to in vivo models to evaluate pDC-
derived IFNa/p in CD8+ T cell immunity. 
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Chapter 4: pDC-derived IFNq/P skews D C / T cell engagement 
from tolerance to priming in lieu of C D 4 + T cell 'help' 
4.1 Summary 
CD8+ T cell immunity is an important determinant in the clinical outcome of 
HCV infection and depends on CD4+ T cell 'help'. IFNa has been shown to play 
a role in overcoming the CD4 requirement for T cell priming; however, the role 
for pDCs in providing a signal sufficient for T cell activation in the absence of 
CD4+ T cells has not been demonstrated. Using the minor histocompatibility 
male antigen (H-Y) model for CD4-dependent CD8+ T cell priming, we 
evaluated the ability of MCMV- or CpG-mediated pDC activation to substitute 
for the CD4 'help' requirement in CD8+ T cell priming. The results show that 
pDC activation can offer priming signals. The pDC priming signal requires 
IFNAR but is independent of IL-12 production. In contrast, viral stimulation of 
non-pDC IFNa/p does not serve as a priming signal for CD8+ T cells. The model 
of pDC 'help' could also be extended to CD4-dependent HCV NS31073.1081-specific 
CD8+ T cell responses in transgenic mice expressing human HLA-A2.1. These 
findings offer a mechanism for the role of pDC-derived IFNa/p in host 
immunity, provide a rationale for therapeutic intervention to boost CD8+ T cell 
responses, and may offer insight into how some viruses evade 
immunostimulatory actions of IFNa/p. 
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4.2 Introduction 
In light of the fact that we find no overt defect in DC function in chronic HCV 
donors, we hypothesized that other signals may act on DCs to regulate HCV 
specific CD8+ T cell priming. As discussed in chapter 1, several lines of evidence 
suggest that CD4+ T cells play an important role in generating robust HCV 
specific CD8+ T cell responses41. However, the absence of a small animal model 
and the paucity of T cell reagents have precluded detailed evaluation of the 
immunologic outcome of 'help'-less CD8+ T cells in an HCV specific model. 
As detailed in the introduction, CD4+ T cells can directly support CD8+ T 
cell activation (via IL-2 production or CD40 engagement214) or indirectly via DC 
activation. This model for CD4 'help' affords a sense of specificity for CD8+ T 
cell priming and prevents autoimmunity in the absence of a specific CD4+ T cell 
response215. The flip side of this model, the absence of CD4 'help', affords a 
model for peripheral tolerance by which DC / T cell engagement leads to 
division, death, and consequent tolerance (see Fig. 1.5). Although the regulation 
of CD8+ T cell activation versus tolerance by CD4+ T cells offers a mechanism for 
antigen specific regulation, this model simply transfers the point of regulation to 
priming or tolerance of CD4+ T cells. In contrast, the "danger model" suggests 
that regulation of activation versus tolerance is controlled by inflammatory 
danger signals66. 
In light of our observation concerning spatial compartmentalization of 
IFNa/p on DC immunological skewing, we hypothesized that lymph node 
IFNa/p may act to enhance T cell immunity (Fig. 4.1). pDC activation by TLR9 
agonists result in pDC accumulation and IFNa/p production in lymph nodes and 
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spleen216. The importance of this spatial localization in viral immunity is not 
clear. Some reports suggests that pDCs may prime T cells in vivo217; however, 
their movement from blood to lymph node does not make them well suited for 
trafficking tissue antigens. Furthermore, the reason for IFNa/p production in the 
lymph node when viral infection occurs in the periphery is not clear. Recent data 
shows that IFNa/p itself may act as a key 'danger' signal by activating DCs as 
well as serving as a third signal for T cell activation185,207. Not all IFNa/p, 
however, is produced by pDCs 195'206. All cells have the capacity to produce type I 
IFNs and some (e.g. conventional DCs) will produce equally large amounts if 
triggered appropriately. The immunological effects of IFNa/p production by 
different cell types or by the same cell type in different locations is not clear. 
The role for activated pDCs in substitituting for CD4+ T cell 'help' has not 
been evaluated. In order to address this question, I took advantage of two in vivo 
systems. The first system is based on the minor histocamptibility (H) antigens 
that are associated with the Y chromosome (i.e. H-Y antigens)218. In C57BL/6 
mice, an immunodominant Derestricted Uty epitope has been well defined. This 
model is particularly fitting because the priming of Uty-specific CD8+ T cells is 
CD4-dependent215 and transgenic T cells are available219. The second model is 
one that I developed for HCV specific priming in transgenic mice expressing the 
human HLA-A2.1 molecule. In both models, I have focused on the endogenous 
T cell repertoire against these antigens. The findings show that activated pDCs 
can offer priming signals for CD8+ T cell activation and suggest important 
therapeutic implications for pDCs. 
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Figure 4.1. Immunological significance of p D C IFNo/P production 
in the lymph node. Following activation, p D C upregulated CCR7 
and migrate across the H E V to T cell zones of the lymph node. p D C 
can prime CTLs in vivo but they can not cross-present antigen. The 
antiproliferative effects of IFNa/p may play a role in preventing 
bystander activation in the bulk T cell population. The interaction at 
the D C / T cell interface is not well defined. 
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4.3 Materials and Methods 
Mice 
Wild-type and MHCII-/- C57BL/6 mice were obtained from Jackson, Europe. 
TCR transgenic mice (Matahari) with CD8+ T cell reactivity for 
immunodominant Uty epitope were provided by Olivier Lantz (Institut Curie, 
Paris). HLA-A2.1 HHD transgenic mice were provided by Francois Lemonnier 
(Institut Pasteur, Paris). IFNAR-/- mice backcrossed onto the C57BL/6 
background were provided by Deborah Braun. Disruption of IFNAR was 
confirmed by PCR (Forward primer: aag atg tgc tgt tec ctt cct ctg etc tga; Reverse: 
att art aaa aga aaa gac gag gcg aag tgg; 35 cycles; Annealing temperature: 55°C) 
and gel electrophoresis of the neomycin insert. Functional confirmation was also 
observed by day 5 lethality following i.p. infection with MCMV. IL-12B-/- mice 
were obtained from Jackson, USA. 
Media 
For all mouse cultures and BMDCs, 10% FBS in RPMI-1640 was used 
supplemented with lOmM HEPES, lOOmM non-essential amino acids, 66jiM p-
mercaptoethanol, ImM sodium pyruvate, and 2mg/mL of gentamicin (R-10). 
HCV cell lines were carried in 10% FBS in DMEM with 20fxg/mL puromycin and 
tetracycline (complete media) to suppress expression of HCV. Expression of 
HCV was induced in complete media without tetracycline. 
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Peptides 
For monitoring HY-specific CD8+ T cell responses, immunodominant Db-
restricted Uty246.254 peptide (WMHHNMDLI) was used. For MCMV T cell 
responses, immunodominant Derestricted M45 epitope (HGIRSNAFI) was used. 
For influenza ANSI endogenous CD8+ T cell responses, Derestricted NP366.374 
(NMEAMDSNT ) and Db-restricted PA^.^ (SCLENFRAYV) were used. All 
peptides were synthesized by Genemed synthesis. For monitoring HLA-A2.1-
restricted HCV-specific T cell responses, the following peptides were used: 
Core^ (YLLPRRGPRL), Core132.140 (DLMGYIPLV), NS31073.1081 (CVNGVCWTV), 
NS31406.1415B (KLTGLGLNAV), NS31406.1415A (KLVALGINAV). 
Antibodies 
PDCA-1 PE, CDllc (HL3) APC, Vp8.3 PE, and CD8 FITC are from BD 
Pharmingen. GK1.5 hybridoma supernatant was prepared in low serum media 
(containing <1% FBS). Briefly, hybridoma was grown to confluency until 60-70% 
death. Cultures were harvested and supernatant prepared by filtration. RB6-8C5 
(anti-GR-1) for in vivo depletion of pDCs cells was obtained from the monoclonal 
antibodies facility at MSKCC as bioreactor supernatant. 
Cell lines 
A human osteosarcomcell line with tetracycline-dependent full length HCV 
expression (HOS 57.3) was generated by Benno Wolk in the laboratory of Darius 
Moradpour (Basel, Switzerland). In order to induce HCV expression, cells were 
washed well with PBS (4-5 times) to remove residual tetracycline and plated at 
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20-30% confluency in complete media without tetracycline. Greater than 8 0 % of 
cells expressed NS5A by FACS by 36hrs. 3T12 is a mouse fibroblast cell line 
obtained from Peggy MacDonald (Rice lab, RU). 3T12 cells were grown in 
DMEM with 10% FBS with lOmM HEPES, lOOmM non-essential amino acids, 
and 100 units/mL penicillin and streptomycin. 
Bone Marrow Derived DCs 
Femurs and tibias were collected from C57BL/6 mice and bone marrow was 
harvested by flushing with PBS. Bone marrow cells were collected by 
centrifugation and lysed with 2.5mL 1.66% ammonium chloride for 5 minutes at 
37°C. Cells were washed, filtered and resuspended at 106/mL in R-10 media 
with 1:30 dilution of J558 hybridoma supernatant (mouse GM-CSF). 3mLs were 
aliquoted per well into a 6-well dish and incubated at 37°C. On day 2, day 4, and 
day 6, media was removed and replaced with fresh R-10 with J558. For 
maturation, cells were harvested by blowing gently on the plate with a 5mL 
pipette to collect loosely adherent DC clusters. Cells were centrifuged and 
resuspended at 0.5 x 106/mL in R-10 media with 1:30 dilution of J558 hybridoma 
and 12.5ng/mL of mouse TNFa (R and D systems). 2mL were added per well 
and cells were allowed to mature for 36 hours. DC phenotype and maturation 
was assessed by FACS phenotype using CDllc, CD80/86,1-Ab, and B220. 
In vivo depletions and immunizations 
GK1.5 hybridoma supernatant was used to deplete CD4+ cells and RB6-8C5 
(Monoclonal Antibody Facility, MSKCC) bioreactor supernatant was used to 
deplete GR-1+ pDCs. Mice were injected with 500[Ag i.p. at 36 hrs and 12 hrs 
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before immunization. Depletion of CD4+ T cell and pDCs was confirmed by 
FACS from both peripheral blood and spleen samples. 
For H-Y priming, mice were immunized with male splenocytes as 
indicated. Spleens were harvested and mashed in ice cold PBS. Splenic debris 
was removed, cells were spun, and red blood cells were lysed with 1.66% 
ammonium chloride for 5 minutes at 37°C. Lysis was quenched with 20 volumes 
of PBS and cells were pelleted. Cells were filtered and washed again. 
Splenocytes were resuspended at 25 x IO6/ mL and 200[xL was injected i.d. on the 
belly just medial to the inguinal lymph nodes. 
For peptide immunization, lOmg/mL of crude peptide dissolved in 10% 
DMSO was mixed 1:1 with titermax Gold (Sigma Aldrich). Mixture was 
vortexed for 45 minutes at room temperature to form an emulsion. 30|oL was 
injected into the footpad. 
For full length HCV cell line immunization, HOS57.3 were induced to 
express HCV proteins as described. After 36 hrs of induction, cells were 
harvested and washed well with PBS. Cells were resuspended at 20 x 106/mL 
and 250jaL injected i.p. 
Preparation of MCMV Smith strain from salivary gland 
1.5 x IO5 PFU tissue culture prepared MCMV was injected into 15 BALB/c. In 
susceptible mice, MCMV is cleared from tissues within a week but persists in the 
salivary glands for >3 weeks at high titers. Salivary glands were harvested at 17 
days post infection and homogenized with a dounce homogenizer at 10% (w/v) 
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in D M E M with 10% FBS, 10% D M S O . Aliquots were frozen at -80°C for long 
term storage. 
MCMV plaque assay 
Mouse fibroblast cell 3T12 were plated as 70% confluence in 6-well dishes and 
allowed to adhere for 5-6 hours at 37°C in DMEM with 10% FBS. Media was 
removed from 6-well dishes and 200|xl of serial 10-fold dilutions were added for 
1 hr with shaking. During incubation 1% (2x) NOBLE agar (DIFCO) was 
prepared in water. Agar was autoclaved and allowed to cool in 56°C water bath. 
Just before overlaying, 2x cMEM (2x MEM, 10% FBS, lOOunits /ml penicillin / 
streptomycin) was mixed with 1% NOBLE agar solution. Agar was allowed to 
cool to 37°C and 3mL was added to 6-well dish just before congeling with 
swirling to evenly distribute. Plates were incubated upside at 37°C. An 
additional overlay of 2mL was added on day 3. On day 6, agar overlay was 
prepared with .0375% Neutral Red and 2mLs added for 16 hrs to allow for 
visualization. Plaques were counted with a light box and enumeration used to 
calculate PFU/mL. 
Triggering and monitoring IFNa/p production in mouse serum 
Various titrations of i.p. injection of both MCMV and influenza ANSI were done 
to evaluate necessary PFU for maximal IFNa/p production. Based on these 
results, 5 x IO3 PFU/mL of MCMV and 2 x IO6 PFU/mL of ANSI were used for 
stimulation of IFNa/p production. CpG motif was prepared as previously 
described 156. Briefly, 5 ng of CpG motif (5'- tcattggaaaacgttcttcggggcg -3') with 
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phosphorothioate backbone was mixed with 170(xL of PBS and 30fxL of D O T A P 
Transfection Reagent (Roche Diagnostics) and delivered i.v. Retro-orbital 
eyebleeds were done to collect blood samples at the indicated times. Blood was 
allowed to clot at room temperature for 30 minutes and placed on ice for 10 
minutes. Samples were spun at 13000 RPM 4°C in a micro-centrifuge for 10 
minutes and serum supernatants were saved. 
IFNy ELISPOT analysis of antigen specific T cell responses 
Spleens or lymph nodes were harvested 7 or 12 days post-immunization as 
indicated. CD8+ T cells were purified using MACS microbeads and plated with 
indicated target cells. Syngeneic splenocytes from naive cells were used as target 
cells for ELISPOTs. Cells were pulsed lOmM of the indicated peptide at room 
temperature for 1 hr. Purified CD8+ T cells were resuspended at 4 x 106/mL and 
50|xL was added per well. Targets were resuspended at 106/mL and IOOjxL 
added per well (CD8+ T cell: Target ratio was 2:1). 
Cells were plated in 96-well Millipore plates previously coated with 
5[xg/mL of anti-IFNy mAb (Mabtech, Mab-1 AN18). Cultures were incubated for 
24-36 hrs at 37°C, washed with mild detergent, and incubated with lpig/mL 
biotin-conjugated anti-IFNy mAb (Mabtech, Mab R4-6A2). Spots were visualized 
using Vectastain Elite Kit (Vector Laboratories) and AEC substrate. Evaluation 
was performed in a blinded fashion by an independent service (Zellnet 
Consulting, Inc., NY) using an automated ELISPOT reader (Carl Zeiss, Inc., NY). 
Spots represent IFNy production by single cells and are reported as spot forming 
cells (SFCs)/106 cells. 
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In vivo proliferation 
Matahari spleens were harvested and red blood cells were lysed as described 
above. Splenocytes were resuspended in PBS and labeled with 5mM CFSE for 5 
minutes at 37°C. Cells were washed 3 times with PBS, resuspended in PBS at 
107/mL, and 100|jL was injected i.v. 6 hrs before immunization. 3 days after 
immunization, the draining inguinal lymph nodes and spleens were harvested. 
Matahari cells were identified by CD8, VP8.3, and CFSE staining described 
below. 
In vivo CTL 
Splenocytes were generated as above and resuspended at 107/mL in PBS with 
either 1 or 6mM CFSE for 10 minutes at 37°C. Cells were washed 2 times with 
PBS and incubated with or without lOmM of the indicated peptide for 1 hr at 
room temperature. Cells were washed twice with PBS and resuspended at 
108/mL. Cells were mixed 1:1 and injected i.v. into immunized animals. Spleens 
were harvested after 16 hrs, red blood cells lysed, and splenocytes analyzed for 
ratio of CFSE low to CFSE high population. Percent killing = 1 - (sample peak 
pulsed targets/sample peak unpulsed targets) / (control peak pulsed 
targets/control peak unpulsed targets). 
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FACS analysis of H C V expression, CFSE proliferation, tetramers, and p D C 
accumulation 
For HCV expression, cells were induced as above and resuspended at 2xl06/mL. 
Cells were washed with PBS and fixed/permeabilized with Cytoperm/Cytofix 
(BD Pharmingen) for 10-15 minutes. Cells were washed with permeabilization 
wash buffer (BD Pharmingen) and incubated with 1:200 dilution of mouse 
monoclonal against NS5A (9E10, generated by Tim Tellinghusien) or 1:100 NS3 
(Maine Biotechnology). A 1:400 dilution of goat anti-mouse PE secondary 
(Jackson Immunoresearch) was used to detect HCV expression. 
For CFSE proliferation and tetramer analysis, CD8 purified cells were 
incubated with lOfxg/mL of FcyR-block (BD Pharmingen) to block non-specific 
antibody interaction in mouse FACS wash buffer (PBS with 5% FBS and 5% goat 
serum). Cells were stained with anti-CD8 FITC (1:150 dilution, BD Pharmingen), 
antiVp8.3 PE (1:150 dilution, BD Pharmingen), NS31073.1081 HLA-A2.1 tetramer-PE 
(1:10 dilution, F. Lemaitre, Institut Pasteur, Paris), or Core35_44 HLA-A2.1 
tetramer-PE (1:10 dilution, F. Lemaitre), as indicated for 45 minutes at 4°C and 
analyzed using FACS analysis. 
Spleens were harvested at indicated times following stimulation or 
infection. Spleens were homogenized by mashing and debris was removed. 
Cells were collected by centrifugation and red blood cells were lysed with 1.66% 
ammonium chloride for 5 minutes at 37°C. Following lysis, cells were washed 
and incubated with lO^ig/mL of FcyR-block (BD Pharmingen) to block non-
specific antibody interaction in mouse FACS wash buffer. Cells were stained 
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with anti-CD45.2 FITC (1:150 dilution, B D Pharmingen), anti-CDllc A P C (1:150 
dilution, BD Pharmingen), and anti-PDCA-1 PE (1:150, BD Pharmingen). 
4.5 Results: H-Y model 
CD4+ T cell 'help' is required for in vivo priming of H-Y specific CD8+ T cells by 
endogenously loaded DCs 
In order to setup a model antigen system for CD4-dependent CD8+ T cell 
priming, we employed the male antigen (H-Y) system. Various routes of 
immunization with syngeneic male splenocytes were evaluated by assaying 
CD8+ T cell responsiveness to the immunodominant Uty epitope using IFNy 
ELISPOT. Intradermal (i.d.) immunization yielded the most reproducible 
priming and was the route of immunization employed in all of these studies. 
First, we verified previous results suggesting that CTL effector function 
required CD4+ T cell 'help' during priming215. In order to evaluate this in vivo, 
female WT or MHCII-/- C57BL/6 mice were immunized i.d. with 5 x IO6 
syngeneic male splenocytes. Spleens were harvested at 12 days and CD8+ T cells 
were purified with MACS magnetic beads. IFNy ELISPOT analysis using Uty 
pulsed splenocytes as targets showed WT but not MHCII-/- mice could generate 
Uty-specific CD8+ T cell IFNy-production (Fig. 4.2). Importantly, Uty-specific 
responses generated by immunization of male splenocytes vary significantly 
from mouse to mouse, but Uty-specific IFNy responses were never seen in 
MHCII-/- animals. Notably, MHCII-/- females were primed with MHCII-/-
male splenocytes to eliminate allo-reactivity. In order to confirm that this CD4-
dependence is not merely the result of differential expression of H-Y antigens in 
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Figure 4.2 Uty-specific CD8+ T cell IFNy production requires C D 4 
help during priming. Host C57BL/6 females were primed with male 
splenocytes from indicated C57BL/6 mice. The table shows spot 
forming cells (SFCs)/106 CD8+ T cells measured by IFNy ELISPOT 12 
day post-immunization. Each circle represents an individual mouse. 
C D 4 depletion indicates GK1.5 depletion as described in Materials 
and Methods. 
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MHCII-/- male mice, female mice depleted of CD4+ T cells with GK1.5 (anti-
CD4) were similarly immunized with male splenocytes. IFNy ELISPOT shows 
that CD4 depletion also prevents priming of IFNy-producing Uty-specific CD8+ 
T cell responses (Fig. 4.2). 
In order to evaluate if IFNy ELISPOT was representative of CTL function, 
specific killing in vivo was evaluated using Uty pulsed and unpulsed splenocytes 
that were differentially labeled with CFSE and injected 12 days following 
immunization (Fig. 4.3A). Similar to ELISPOT results, i.d. immunization with 
syngeneic male splenocytes induces robust Uty specific CTL activity (Fig. 4.3B, 
C). Priming of MHCII-/- females abgrogates in vivo killing suggesting that CD4 
'help' is required for CTL function. CD4 depletion also abrogates in vivo CTL 
function confirming the CD4-dependence of CTL priming. 
Further characterization of this system was done to evaluate the nature of 
the antigen presenting cell involved in Uty-specific T cell priming by male 
splenocytes. In order to test the contribution of endogenously loaded male DCs 
in Uty-specific priming during i.d. male spenocyte immunization, splenocytes 
were compared to CDllc-enriched or depleted splenocytes. CDllc+ enrichment 
enhanced Uty-specific CD8+ T cell IFNy production 12 days post-immunization 
while CDllc-depletion virtually abrogated the response(Fig. 4.4). Consistent 
with other reports218, this suggest that direct presentation is the dominant 
mechanism for Uty-specific priming. 
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Figure 4.3. In vivo CTL requires CD4+ T cell 'help'. Continued on 
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Figure 4.3. In vivo CTL requires CD4+ T cell 'help'. A. Schematic for 
in vivo CTL as described in Materials and Methods. Briefly, mice 
were immunized with male splenocytes. After 12 days, target 
splenocytes were pulsed with two different levels of CFSE and 
pulsed or unpulsed with peptide. Pulsed and labeled splenocytes 
were injected i.v. and spleens were harvested after 16 hrs. Specific 
killing was assessed by disapperance of target population as 
monitored by FACS. B. FACS plots showing gated CFSE populations 
16 hours after transfer to indicated mice. Numbers indicated percent 
of total CFSE positive cells. C. Percent killing in indicated mice was 
calculated as described in Materials and Methods in the indicated 
mice and is displayed as a dot plot. Each dot represent an individual 
mouse. 
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Figure 4.4. CDllc+ D C s required for efficient Uty-specific priming 
by male splenocytes. C57BL/6 W T female mice were either not 
immunized or immunized with total splenocytes, CDllc+ cell 
purified by two rounds of positive selection (CDllc+), or CDllc 
depleted cells remaining after CDllc+ purification (CDllc-) from 
syngeneic males. Spleens were harvested after 12 days and the T cell 
response monitored by IFNy ELISPOT. Irradiated mouse thymoma 
cell line (EL4) was pulsed with Uty peptide and used as targets for T 
cells. 
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The absence ofCD4+ T cell 'help' leads to antigen specific CD8+ T cell tolerance 
In light of the role of CD4+ T cell 'help' for CTL function, I wanted to 
address the question of what happens to antigen specific CD8+ T cells in the 
absence of CD4 'help' signals. The majority of assays designed to monitor CD8+ 
T cell function focus solely on the absence or presence of a response. These 
assays do not evaluate what happens to the CD8+ T cells when no response is 
present. Thus, in this system, I asked if the lack of response in the absence of 
CD4+ T cells was simply the result of ignorance or the absence of a priming 
signal. 
To address this question, I used TCR transgenic Uty-specific CD8+ 
(Matahari) T cells to monitor division in the presence or absence of CD4+ T cells. 
Matahari cells were CFSE labeled and adoptively transferred i.v. 6 hrs before 
immunization (Fig. 4.5A). In addition to the CFSE label, Matahari T cells can be 
identified by antibodies to TCR VP8.3. Lymph nodes and spleens were 
harvested 3 days post-immunization and division of CD8+/VP8.3+ CFSE labeled 
cells was analyzed by flow cytometry. In the presence of CD4+ T cell, CFSE 
division and expansion of Matahari cells was seen at day 3 in inguinal lymph 
nodes (Fig. 4.5B). Expansion was restricted to the draining lymph node and not 
seen in the spleen as primed T cells do not begin to circulate until day 4 post-
immunization78. Similarly, in MHCII-/- animals, CFSE division and expansion 
of Matahari was apparent after 3 days suggesting that antigen presentation and T 
cell engagement was intact in the absence of CD4+ T cells; however, the number 
of divisions lagged slightly behind wild type hosts and expansion was not as 
robust. Although we did not directly evaluate death in the 'unhelped' dividing 
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Figure 4.5. CD8+ T cells divide in response to immunization in the 
absence of CD4+ T cells. A. A schematic representation describing 
the use of CFSE staining to monitor cell division TCR transgenic 
Matahari cells are CFSE labeled and injected into a female mouse 6-
12 hrs before immunization. 3 days after immunization proliferation 
of cells is monitored by CFSE dilution and increase in cell numbers. 
B. CFSE labeled Matahari cells were transferred to W T or MHCII-/-
female mice and either not immunized or immunized with male 
splenocytes as indicated. Lymph nodes were harvested at day 3 
post-immunization and Matahari cells were idenitified by CD8, 
VP8.3, and CFSE staining. Histograms illustrate dilution of CFSE in 
each case. 
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CD8+ T cells, animals primed in the absence of CD4+ T cells were functionally 
non-responsive following re-challenge. These results suggest, therefore, that the 
lack of CTL effector function when primed in the absence of CD4+ T cells is not 
the result of ignorance, but rather the lack of specific priming signals. With this 
system in place, I setup to evaluate my hypothesis that lymph node IFNa/p 
produced by pDCs may act as a priming signal. 
CpG and MCMV induce pDC IFNa production and migration to spleen 
In order to establish a system for pDC-induced IFNa/p secretion, serum 
IFNa was measured following i.v. delivery CpG or i.p. delivery of MCMV. 
Intravenous injection of CpG rapidly induces high level of IFNa in serum within 
6 hrs of treatment (Fig. 4.6A). IFNa production is transient and disappears by 24 
hrs. In contrast, IFNa serum levels do not peak until 36 hrs after i.p. infection 
with MCMV (Fig. 4.6B) with maximal production seen with IO4 PFU/injection 
(Fig. 4.6C). The difference in time course is likely due to the replication time 
required to amplify the viral DNA which stimulates pDCs125. 
Despite the difference in time course, IFNa induction in both settings is 
dependent on pDCs156195,220. In order to evaluate this in our system, serum IFNa 
for both CpG and MCMV stimulated animals was evaluated in pDC depleted 
mice. As reported previously, pDC depletion abrogates the IFNa response to 
both stimuli (Fig. 4.6D). In order to determine the requirement for the IFNa-
dependent priming loop discussed in chapter 1, IFNa production was also 
monitored in IFNAR-/- mice challenged with CpG and MCMV. Interestingly, 
although CpG induced IFNa production requires IFNAR, MCMV triggers robust 
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Figure 4.6. Kinetics of p D C IFNa production following 
stimulation with C p G or M C M V . A. Serum IFNa is shown at 
indicated hour (HR) following i.v. delivery of 5fxg of C p G / D O T AP. 
B. Serum IFNa is shown at indicated hour following i.p. delivery of 
IO3 PFU of M C M V . C. Serum IFNa is shown 36 hours following 
intraperitoneal delivery of indicated PFU of M C M V . D. Serum IFNa 
is shown at indicated time following C p G or 5 x IO3 PFU of M C M V in 
either W T , p D C depleted (dep), or IFNAR-/- C57BL/6 mice. 
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IFNa even in the absence of IFNAR. Although the IFNAR-/- mice are on the 
MCMV-resistant C57BL/6 background221, challenge with 3 x IO5 PFU of MCMV 
i.p. was lethal in 5 out of 5 mice (data not shown) and subsequently could not be 
used for evaluation of adaptive immunity. Evaluation of splenocytes 
following stimulation confirmed accumulation of pDCs in the spleen. Using a 
pDC-specific marker, PDCA-1, and CDllc to identify pDCs, five to six-fold 
expansion of pDCs was seen by FACS at 6 hrs following CpG injection (Fig. 
4.7A). CpG stimulation did not alter the percentage of CDllc111811 cells in the 
spleen. Similarly, as reported previously222, MCMV infection dramatically 
increases the percent of PDCA-1+ CD11C+ cells in the spleen at 36 hrs (Fig. 4.7B). 
FACS staining confirmed that RB6-8C5 treatment depleted splenic PDCA-1+ 
pDCs. RB6-8C5 depletion does not affect CDllc1^ DCs (data not shown). 
pDC activation by MCMV can offer priming signals for Uty-specific CD8+ T cells 
Due to the accumulation of pDCs in the lymph nodes during DC / T cell 
engagement and the possible role of IFNa in substituting for CD4+ T cell signals, 
we next tested if pDC activation using a viral stimulus could provide priming 
signals in the absence of CD4s. Using the H-Y system described above, we 
evaluated the ability of MCMV infection to facilitate the priming of Uty-specific 
CD8+ T cells in MHCII-/- mice. Briefly, MHCII-/- females were immunized 
with male splenocytes 36 hrs after MCMV infection to maximize pDC activation 
and accumulation in spleen and lymph nodes (Fig. 4.8A). After 12 days, Uty-
specific CD8+ T cell responses were monitored by IFNy ELISPOT. Infection with 
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Figure 4.8. MCMV-triggered pDCs prime CD8+ T cells in the 
absence of CD4+ T cell 'help'. A. Schematic representing 
immunization schedule for M C M V triggered p D C activation at the 
time of immunization. pDCs are depleted with anti-GR-l+ antibody 
RB6-8C5 before infection with M C M V . B. IFNy ELISPOT results of 
indicated host females immunized or not with male splenocytes from 
syngeneic animals in the presence of M C M V infection with or 
without p D C depletion (dep). C. IFNy ELISPOT for Db restricted 
M C M V M 4 5 epitope in W T or MHCII-/- host infected with M C M V 
or depleted of pDCs analyzed in part B. 
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M C M V enabled the generation of Uty-specific CD8+ T cells in MHCII-/- animals 
(Fig. 4.8B). Although the absolute number of spot forming cells was less than 
wild type animals immunized with male splenocytes, the CD8+ T cell responsein 
MCMV treated MHCII-/- was antigen specific and significantly above 
background. In order to evaluate if this effect was dependent on pDC activation, 
pDCs were depeleted prior to MCMV infection using RB6-8C5 (anti-GR-1). As 
depicted in the figure, pDC depletion prevented the generation of Uty-specific 
CD8+ T cells in response to MCMV infection. Infection with MCMV alone in the 
absence of male splenocyte immunization did not induce any Uty-specific cross-
reactivity. 
In contrast to a recent report describing the importance of pDCs in HSV-
specific CTL priming223, pDC depletion during MCMV infection did not effect 
CD8+ T cell IFNy production to the immunodominant M45 epitope as monitored 
by ELISPOT (Fig. 4.8). M45 reactivity was dependent on MHCII, however, a 
strong response was still present in the absence of CD4+ T cells and pDC 
depletion did not abrograte this response. 
CpG stimulation also offers priming signals for Uty-specific CD8s 
In order to confirm that priming signals offered by MCMV-stimulated 
pDCs were not unique to MCMV, the ability of CpG stimulated pDCs to 
substitute for CD4+ T cells was also evaluated. Due to the difference in time 
course of IFNa/p production, CpG was delivered at the same time as 
immunization with male splenocytes and Uty-specific immune responses were 
monitored after 12 days. Similar to the results with MCMV, CpG stimulation in 
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136 
CD4-depleted females immunized with male splenocytes primed Uty-specific 
CD8+ T cells as monitored by IFNy ELISPOT (Fig. 4.9). 
Importantly, some reports suggest that mouse pDCs may have low level 
of CD4 expression; therefore, we evaluated the effect of CD4 depletion on pDC 
numbers and IFNa production following stimulation. CD4 depletion did 
slightly decrease the absolute numbers of PDCA-1 + cells in spleen and total 
IFNa levels in the serum (Fig. 4.10A,B), but it did not abrogate the response to 
CpG as IFNa production was still significant and pDC migration to the spleen 
remained intact (Fig. 4.10B,C). Moreover, the slight decrease in pDC numbers 
and IFNa levels was seen in MHCII-/- as well as CD4 depleted mice (Fig. 4.10A) 
suggesting that these findings may be secondary to changes induced by lack of 
CD4s (i.e. lymph node architecture changes). Despite these differences, the 
functional ability of CpG to provide 'help' following CD4 depletion remains 
intact. 
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Figure 4.10. Effects of C D 4 depletion on p D C number and 
function. A. Spleens from the indicated mice were harvested and the 
percent of p D C per CDllc+ cell (%pDC/CDllc+) assayed by FACS 
analysis. B. IFNa ELISA was used to quantitate the amount of IFNa 
in the serum 6 hrs after C p G administration in the indicated hosts. C. 
Spleens from the indicated hosts were harvested 6 hrs after C p G 
stimulation and the percent of pDCs was assessed by B220 and p D C 
specific marker PDCA-1. 
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pDC-dependent CD8+ T cell priming requires IFNAR but not IL-12 
In mice, pDCs can secrete IL-12 in addition to IFNa216. Given the potent 
role of IL-12 acting as a third signal for CD8+ T cell priming, we wanted to 
evaluate the respective roles for IL-12 and IFNa in the ability of pDCs to 
substitute for CD4+ T cell priming cells. CD4-depleted IFNAR-/- or IL-12B-/-
(p40 subunit of IL-12 and IL-23) mice were immunized with male splenocytes 
with or without CpG. IFNy ELISPOT showed that immunization of IFNAR-/-
females with WT male splenocytes was capable of priming Uty-specific T cell 
responses in a CD4-dependent fashion(Fig. 4.11); however, CpG stimulated 
pDCs were not able to prime in the absence of CD4 'help' suggesting that IFNAR 
is required for CpG to act as an adjuvant. 
In contrast to IFNAR, IL-12B was not required for CpG to trigger priming 
signals in the absence of CD4+ T cells. Immunization of female IL-12B-/- mice 
with male IL-12B-/- splenocytes primed Uty-specific T cells response in a CD4-
dependent fashion similar to other experiments, but CpG stimulation enabled 
Uty-specific priming, suggesting that IL-12 production by pDCs is not a critical 
component of this priming signal(Fig. 4.11). Notably, however, the ability of 
IL12B-/- male splenocytes to prime IL-12B-/- females suggests also that IL-12/23 
is not a crucial component of helper-dependent Uty-specific priming. 
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Figure 4.11. The ability of C p G stimulation to offer 'help' signals 
requires IFNAR but not IL-12. IFNAR-/- or IL-12-/- female mice 
with or without CD4 depletion as indicated were primed with 
syngeneic male splenocytes with or without i.v. CpG. The results of 
Uty-specific responses monitored by IFNy ELISPOT 12 days post-
immunization are shown. Bars represent averages of three mice. 
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IFNa production by influenza ANSI does not enable CD8+ T cell priming 
In efforts to examine the effects of non-pDC derived IFNa on CD4-
dependent immunity, we examined induction of IFNa following influenza ANSI 
infection. The NS1 protein of influenza binds dsRNA and prevents IFNa 
production in mice infected with wild type influenza; however, infection with 
influenza ANSI triggers IFNa production224. The kinetics of IFNa production is 
faster than MCMV and peaks around 12 hrs post-infection, consistent with the 
faster replication time of influenza (Fig. 4.12A). In contrast to MCMV, pDC 
depletion did not significantly inhibit IFNa production suggesting that a non-
pDC is responsible for the IFNa production (Fig. 4.12B). The IFNa production, 
however, was dependent on IFNAR. 
In light of the different cell type responsible for IFNa production, we 
evaluated if infection with influenza ANSI is capable of providing priming 
signals for CD8+ T cells. Similar to the experimental setup for the MCMV 
experiment, MHCII-/- female mice were infected with influenza ANSI 12 hrs 
before immunization with male splenocytes. IFNy ELISPOT shows that, in 
contrast to MCMV, influenza ANSI does not enable priming of Uty-specific 
CD8+ T cells (Fig. 4.12C). Responses against endogenous MCMV (M45) or 
influenza (PA) epitopes were monitored to provide an internal control for 
exposure to virus. Despite the differential adjuvant effects on Uty-specific 
priming, both MCMV and influenza ANSI generated antigen specific T cell 
responses against their respective endogenous epitopes. These data suggest that 
IFNa production by a pDC is an important component of this priming signal. 
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Figure 4.12. Non-pDC triggered IFNa by Influenza A N S I does not provide 
'help' signals for CTL priming. A. Levels of IFNa in serum at indicated time 
following IP challenge with influenza ANSI were monitored by IFNa ELISA. 
Each circle represents an individual mouse. B. Levels of IFNa in serum at 12 
hours post-infection were monitored for W T influenza (Flu) or influenza 
ANSI (ANSI) in W T , p D C depleted (dep), IFNAR-/- mice. C. MHCII-/-
females with or without p D C depletion (dep) were primed with male 
splenocytes with or without M C M V or influenza ANSI (ANSI) infection. 
IFNy ELISPOT for Uty, P A (influenza polymerase epitope), or M 4 5 ( M C M V 
epitope)-specific responses was performed 12 days after priming. 
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4.6 Results: H C V H H D transgenic mouse model 
In all, these results suggest that pDC IFNa may be sufficient to provide 
priming signals for CD8+ T cells in the absence of CD4s. The potential to trigger 
endogenous antiviral cytokines in a manner that also enhances CD8+ T cell 
immunity has important therapeutic implications for HCV in particular. 
Although a small animal model for HCV in which these types of manipulations 
can be performed has not yet been developed, HHD transgenic mice were 
primed with cell associated HCV antigen to evaluate the role for pDCs in HLA-
A2.1-restricted HCV-specific T cell responses. 
Immunization of HHD transgenic mice with apoptotic cells expressing full length HCV 
antigen primes NS31073.1081-specific CD8+ T cells in a CD4-dependent manner 
Although a few animal models exist to study HCV reactive T cell 
responses225, immunity in the context of full length HCV has not been assessed. 
Here, I setup to monitor HCV specific immunity in HHD transgenic mice 
expressing monochains of human p2-microglobulin linked to the N-terminus of 
the HLA-A2.1 chimeric heavy chain containing the ala2 domains of HLA-A2.1 
and a3 cytoplasmic domains of H-2Db (provided by F. Lemonnier). These 
transgenic mice were constructed in an H-2Ke/-De/- background and therefore 
express no H-2 class la molecules. The expression of HLA-A2.1 allows for a 
normally diversified TCR repertoire and the absence of MHCIa molecules 
enables a better CTL response to HLA-A2.1 restricted epitopes226. Several HLA-
A2.1-restricted epitopes for HCV are known, but the relative importance of each 
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for antigen processing227, immunity49, cross-reactivity228, or disease progression229 
is not well understood. 
In order to evaluate HCV specific T cell priming in vivo, a xenogeneic 
osteosarcoma cell line expressing full length HCV under a tetracycline inducible 
promoter (provided by B. Wolk and D. Moradpour) was employed to immunize 
HHD transgenic mice. HCV specific immunity was evaluated using 4 well 
characterized HLA-A2.1 epitopes: Core35.43, Core132.140, NS31073.1081, and NS31406.1414. 
In order to evaluate the presence of HCV reactive T cells in the endogenous 
repertoire, HHD transgenic mice were primed with a 1:1 mixture of Titermax 
(Sigma) and the respective peptide (Fig. 4.13A). Similar to other studies, our 
results showed antigen specific CD8+ T cell responses in the spleen and draining 
lymph nodes to all of the indicated epitopes after 7 days. In contrast to peptide 
priming, immunization with 5 x IO6 irradiated cells expressing full length HCV 
primed NS31073.1081 reactive T cells most efficiently(Fig. 4.13B). 
We considered the possibility that subcellular localization of cell 
associated HCV played a role in epitope usage. Expression of HCV in cell 
culture results in the formation of a "membranous web" that is tethered to the 
endoplasmic reticulum (ER)230. In order to evaluate if this membranous web and 
ER tethering were important for epitope selectivity, we employed a cell line 
expressing NS3-4A, which associates with ER, or NS3 alone, which is diffusely 
spread around the cytoplasm (Fig. 4.14A)230. Expression of equivalent levels of 
NS3 protein in both cell lines was confirmed by FACS analysis. IFNy ELISPOT 
two weeks post-immunization revealed equivalent NS31073.1081 responses 
suggesting that cellular localization was not crucial for epitope selectivity (Fig. 
4.14B). 
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Figure 4.13. Immunization of H H D transgenic mice with full length cell 
associated H C V results in NS31073.1081 dominant CD8+ T cell responses. A. 
Lymph nodes of H H D mice immunized with peptide and titermax were 
harvested after 7 days and antigen specific CD8+ T cell activity assessed by 
IFNy ELISPOT with DCs pulsed with relevant peptides versus DCs pulsed 
with irrelevant peptides as targets. B. Spleens from H H D mice immunized 
with cell associated H C V or cells not expressing H C V were harvested after 12 
days and antigen specific CD8+ T cell activity was assessed by IFNy ELISPOT 
with DCs pulsed with the indicated peptides as targets. 
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Figure 4.14. Alteration of subcellular localization of cell associated H C V 
does not change NS31073.1081 immunogenicity. A. A schematic showing the 
region of H C V expressed by the indicated cell lines and the consequent 
subcellular localization of NS3 in these cells (adapted from Woelk, B et.al J 
Virol 2000). B. T cell immunity to NS31073.1081 was monitored in H H D 
transgenic mice immunized with NS3-4A, NS3, or non H C V expressing cell 
lines after 12 days by IFNy ELISPOT. 
146 
CD4+ T cells regulate priming versus tolerance of HCV-specific CD8s 
In order to evaluate the role for CD4+ T cells in regulating the 
immunologic outcome of HCV-specific CD8+ T cell responses to NS31073.1081 CD4-
depleted HHD mice were immunized with cell associated HCV antigen. Similar 
to our findings for endogenous presentation in the H-Y system, CD4-depletion 
reduced NS31073.1081 specific T cells responses as monitored by IFNy ELISPOT 
(Fig.4.15). Tetramer analysis was also done to confirm these results. Using CD3 
and CD8 antibodies to gate on the CD8+ T cell population, the percentage of 
tetramer positive cells in the the CD8+ T cell population was calculated. 
Consistent with the ELISPOT results, NS31073.1081 antigen specific T cells expanded 
when immunized in the presence, but not in the absence of CD4+ T cells. 
Next, we evaluated the immunologic significance of the lack of CD8+ T 
cell response in the absence of CD4+ T cells. In other words, is the lack of 
response a result of ignorance or antigen specific tolerance? In order to do this in 
the HCV system, we boosted immunized mice to evaluate the functional state of 
the CD8+ HCV-specific T cells. IFNy ELISPOT seven days after boost shows an 
increase number of CD8+ NS31073.1081 reactive cells in mice primed and boosted 
compared to boost alone or primed with a non-HCV control cell line (Fig. 4.16). 
In contrast, CD4 depletion during priming resulted in a decrease in IFNy 
producing NS31073.1081 reactive CD8+ T cells after boost. Mice immunized with 
peptide alone were used as a positive control for tolerance induction76. These 
results were also confirmed using HLA-A2.1 tetramers for NS31073.1081 (Fig. 4.16). 
Consistent with the ELISPOT results, an increase in NS31073.1081 tetramer positive 
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Figure 4.15. NS31073.1081 priming by cell associated antigen requires CD4+ T 
cells. NS31073.1081 specific T cell responses were monitored in H H D transgenic 
mice with or without C D 4 depletion (dep) by IFNy ELISPOT at 12 days after 
immunization with cell associated antigen. Each circle represents an 
individual mouse. NS31073.1081 specific T cell responses in corresponding 
samples were also evaluated with tetramer reagents by FACS. CD8+/CD3+ 
T cells were gated and used to identify the percentage of NS310734081 specific 
T cells indicated on the plots. 
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Figure 4.16. CD4+ T cell 'help' regulates priming versus tolerance of 
NS3 1073-1081 CD8+ T cell responses. H H D transgenic mice with or without 
C D 4 depletion (dep) were primed and boosted after two weeks with H C V 
expressing cell lines (HCV) or non-HCV cell line controls (non-HCV). T cell 
immunity to NS31073.1081 was monitored 7 days after boost by IFNy ELISPOT 
and tetramer staining. Bars represent averages of three mice. 
149 
CD8+ T cells were seen in animals primed and boosted compared to boost alone 
or primed with non-HCV control cell line. CD4 depletion during priming 
inhibits the expansion of NS31073.1081 tetramer positive cells comparable to 
immunization with peptide alone. Core^.^ specific tetramer staining is shown to 
illustrate the dominance of the NS31073.1081 response. 
CpG overcomes the requirement for CD4 'help' in NS31073.mi T cell priming 
Finally, we evaluated if CpG could overcome the requirement for CD4 
'help' for NS31073.1081-specific CD8+ T cell priming. Briefly, mice were either 
untreated or CD4 depleted and immunized with either HCV expressing cell lines 
alone or with CpG. Analysis of NS31073.1081-specific CD8+ T cell responses after 2 
weeks by IFNy ELISPOT shows that CpG stimulation enables HCV-specific T cell 
priming in the absence of CD4 'help' (Fig. 4.17). 
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Figure 4.17. C p G can substitute for the absence of CD4+ T cells in priming 
NS3 1073-1081 •specific CD8+ T cells. H H D transgenic mice with or without 
C D 4 depletion (dep) were immunized with HCV-expressing cell lines (HCV) 
with or without i.v. CpG. NS31073.1081 T cell immunity was evaluated after 12 
days by IFNy ELISPOT. Circles represent individual mice. 
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4.7 Discussion 
pDC IFNa/p substitutes for CD4+ T cell 'help' in CD8+ T cell priming 
Despite the potent clinical efficacy of IFNa in the treatment of HCV, the effects 
on HCV specific immunity have been contradictory213,231. IFNa can serve as a 
'danger' signal in certain system to activate DCs184 or provide help directly to 
CD8+ T cells207. In some systems, IFNa may even act directly on DCs to 
overcome CD4+ T cell requirements for CTL priming185. However, the 
experiments discussed in the last chapters suggest that spatial 
compartmentalization of IFNa may be an important component in achieving this 
immunological effect. Although pDCs are recognized as the main producers of 
IFNa/p, their role in providing these signals at the DC / T cell interface is not 
well defined. Here, using viral and non-viral triggers for pDC- and non-pDC-
derived IFNa, we evaluated the ability of pDC IFNa in providing priming 
signals for CTLs in the absence of CD4 'help'. 
Our results show that both MCMV and CpG can overcome the need for 
CD4 'help' in generating Uty-specific IFNy producing CD8+ T cells (Fig. 4.8 and 
4.9). Although MCMV and CpG trigger IFNa production with different kinetics 
(Fig. 4.6), IFNa production by both stimuli requires pDCs. pDC depletion of 
female mice before immunization abrogates the adjuvant effects of MCMV 
suggesting that host pDCs are required for this effect (Fig. 4.8). Since donor DCs 
are the main stimulators of CD8+ T cell immunity (Fig. 4.4) and pDCs are not 
efficient at cross-presenting antigen232, our data suggest that host pDCs 
collaborate with immunizing male DCs to prime host CD8+ T cells (Fig. 4.18). 
Although this model lacks the antigen specificity afforded by CD4 engagement 
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of MHCILpeptide complexes, activated pDCs accumulate in the spleen 
following activation (Fig. 4.7A). This migration may put them in prime location 
to interact at the conventional DC / T cell interface, influencing priming and 
tolerance. 
The pDC-dependent CD8+ T cell priming requires IFNAR in the host (Fig. 
4.11). This may suggest that IFNa is acting directly on the CD8+ T cell to 
provide a third signal, similar to in vitro studies207; however, IFNAR is also 
required for IFNa production in response to CpG stimulation (Fig. 4.6D) and 
therefore effectively blocks potential effects on the immunizing WT DC as well. 
Preliminary data suggests that IFNAR is also required on the immunizing male 
splenocytes for CpG-dependent priming indicating that IFNa/p may also play an 
important role on the DC at the DC / T cell interface (Fig. 4.18). Although mouse 
pDCs may be capable of producing IL-12, this pDC-dependent priming effect is 
independent of IL-12p40, which excludes a role for both IL-12 and IL-23 (Fig. 
4.11). Notably, Uty-specific priming in this system does not require IL-12 and, as 
such, these results cannot rule out a role for pDC produced IL-12 on CTL 
priming in systems that are more sensitive to IL-12. 
As such, there are two notable differences between the in vitro human and 
in vivo mouse systems. First, IFNa is sufficient to allow for priming in the 
absence of CD4+ T cell 'help' in the mouse whereas IFNa synergizes with CD40L 
or TNF signaling to enhance priming in the human. It is possible that this 
reflects species specific differences in IFNa signaling200. Alternatively, signals 
provided by non-CD4+ T cells in vivo may synergize with IFNa/p to account for 
its ability to promote priming. Second, while IL-12 is sufficient to rescue the 
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Figure 4.18. pDCs collaborate with D C s at the D C / T cell interface to 
provide IFNa/P-dependent 'helper' signals for CTL priming. pDCs enter 
secondary lymph organs and the spleen from the blood across high 
endothelial venules (HEV). pDCs may migrate into T cell zones and 
collaborate with conventional DCs (cDC) for T cell priming via IFNa. 
Notably, IFNa from the pDCs may act directly on the CD8+ T cells or on the 
DCs to activate STAT4 and promote T cell activation. 
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inhibitory effects of IFNa on iDCs and enhanced IL-12 correlates with the 
immune enhancing effects of IFNa on mDCs in human, pDC-dependent CD8+ T 
cell activation in the H-Y model does not require IL-12/23. This may suggest 
that the immune enhancing effects of IFNa/p signaling on DCs trigger redundant 
pathways (e.g production of IL-27). 
In light of the signaling switch in DCs, as well as antigen specific T cells208, 
discussed in the previous chapter, it will be interesting to assess the role of 
STAT1 and STAT4 in pDC-derived IFNa/p immune enhancing effects. Although 
strain backgrounds prevented us from readily addressing these questions, 
STAT4 may be a crucial regulator of the priming signals in both DCs and T cells 
downstream of IFNa/p signaling. 
pDC- versus non-pDC-derived IFNa in shaping CD8+ T cell immunity 
Non-pDC cell types can also make IFNa depending on the viral 
stimulus195. For example, conventional DCs can produce IFNa in response to 
influenza ANSI206. Recent studies have revealed that while TLR7/9 stimulation 
is crucial for IFNa production by pDCs, RIG-I regulates IFNa production in vivo 
by conventional DCs in an MyD88 and TRIF-independent manner233. Although 
influenza ANSI is also capable of stimulating pDCs via TLR7 in vitro, our results 
in vivo suggest that a non-pDC is predominately responsible for IFNa production 
(Fig. 4.12B). 
In order to evaluate the effects of these distinct IFNa-producing cell 
populations in regulating adaptive immunity, we directly evaluated the ability of 
MCMV triggered IFNa versus influenza ANSI triggered IFNa to offer priming 
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signals. Surprisingly, while M C M V triggered p D C IFNa supported Uty-specific 
T cell priming, influenza ANSI triggered IFNa did not overcome the requirement 
for CD4+ T cell 'help'(Fig. 4.12C). This result suggests that the type of cell 
responsible for producing IFNa may be important in determining its effect on 
immunity (Table 4.1). While pDCs migrate to the spleen following activation, the 
IFNa producing cell during influenza ANSI infection may not reside at this 
crucial location for effecting T cell priming. Two chemotactic factors, CXCR3 
ligands and SDF-1 /CXCL12, play an important role in pDC migration to the T 
cell areas via high endothelial venules234 and it will be interesting to evaluate 
their role in pDC-dependent CD8+ T cell priming. 
These findings highlight two important points. First, viruses such as HCV 
may trigger IFNa production in a manner that does not effectively augment the 
immune response against it. Second, with respect to therapeutic delivery of 
IFNa, specific pDC agonists (e.g. TLR7 or TLR9 agonists) may more effectively 
target IFNa production for promoting antiviral immunity. 
156 
Table 4.1. Characteristics of IFNa production and effects by M C M V , CpG, 
and influenza A N S I 
p D C r e s p o n s i b l e 
f o r s e r u m I F N a 
I F N A R r e q u i r e d 
f o r s e r u m I F N a 
p D C r e q u i r e d f o r 
i n n a t e i m m u n i t y 
p D C r e q u i r e d f o r 
a d a p t i v e 
i m m u n i t y 
A c t s a s a d j u v a n t 
f o r p r i m i n g 
O v e r c o m e C D 4 
r e q u i r e m e n t f o r 
m o d e l a n t i g e n 
M C M V 
Y e s 
N o 
N o 
N o 
Y e s 
Y e s 
C p G 
Y e s 
Y e s 
N / A 
N / A 
Y e s 
Y e s 
F l u 
A N S I 
N o 
Y e s 
N o 
N o 
N o 
N o 
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H C V immunity in vivo 
Although our impetus for investigating CD4-dependent CD8+ T cell immunity 
rested on the role for CD4+ T cell 'help' in HCV-specific immunity, it is clear that 
the H-Y model system may not be representative of HCV immunity. Ultimately, 
a small animal model for HCV will be crucial for evaluating cellular 
requirements in efficient cell-mediated immunity. In lieu of an infectious small 
animal model, we were able to evaluate CD4-dependent HCV specific T cell 
responses in a human HLA-A2.1 specific system. A better understanding of HCV 
immunity in these mice will aid in the advancement of a mouse model for HCV. 
Interestingly, our work shows a dominant CD8+ T cell response to the 
NS31073.1081 epitope during immunization with full length, cell associated antigen 
(Fig. 4.13). This epitope cross-reacts with an influenza neuraminidase epitope 228 
which may account for the high rate of NS31073.1081-reactive T cells in HCV-naive 
individuals235. This epitope may also, however, play an important role in HCV 
pathogenesis as the strength of the NS31073.1081 response correlates with associated 
liver pathology during acute HCV infection229. Interestingly, one group reports 
a high rate of non-synonomous mutations at the C-terminal end of the NS31073.1081 
epitope in patients who progressed to chronic infection from a single source 
outbreak236. This mutation impairs NS31073.1081 carboxyterminal processing and 
thus antigen presentation. The selectivity for this epitope offers a target for the 
virus to avoid detection of priming with cell associated, full length HCV. 
Although this priming is likely due to cross-priming, the HCV cell line used 
expresses low levels of human HLA-A2.1 and cross-priming will need to be 
shown formally in a haplotype mismatched cell line. In any case, mutations in 
the carboxyterminal end of the NS31073.1081 epitope may block endogenous 
158 
presentation of this epitope by infected hepatocytes and consequently prevent 
detection by NS31073.1081-specific T cells237. Finally, this epitope is located directly 
downstream of the protease domain and the contributions of replication fitness, 
strength of cross-reactivity, and efficiency of antigen presentation in driving 
escape mutation have not been evaluated. Futher work will be required to see if 
this is true in vivo as well as in other HCV expression systems such as HCVcc. 
Activation versus tolerance in HCV-specific models 
In light of our in vivo findings of no overt DC defects during chronic HCV 
infection, we proposed that another level of regulation might determine the 
strength of CD8+ T cell immunity. Similar to our results in the H-Y system, 
CD4+ T cell 'help' is required for efficient CD8+ T cell priming to NS31073.10gl (Fig. 
4.15). Notably, the role for HCV-specific CD4+ T cells has not been directly 
evaluated. Specifically, it would be interesting to know if the efficacy of 
vaccination against HCV antigens by cross-presentation depends on the 
generation of strong MHCII epitopes227. 
Furthermore, our data suggests that in the absence of CD4+ T cells, 
functional tolerance of NS31073.1081 specific T cells ensues (Fig. 4.16). Currently, 
tolerance is not a heavily favored model in HCV infection because T cell 
responses can be seen in the liver of chronic patients many years following 
infection41; however, it is possible that not all chronic HCV situations result from 
a lack of effective CD8+ T cell immunity. Alternatively, although T cells may 
remain present in patients, the epitope specificity of those T cell responses may 
be crucial in determining clinical outcome229. This epitope selectivity may result 
from viral evolution41 or the effects of persistent antigen on T cell anergy238. 
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Finally, the role of C D 4 'help' in H C V immunity may offer insight into 
progression and treatment strategy for HCV/HIV co-infection4 ,48 
pDCs and CpG therapy for H C V immunity 
In light our finding that pDCs are functionally competent in patients with 
chronic HCV, the role of pDC IFNa serving in lieu of CD4+ T cell 'help' is 
extremely attractive. In order to verify this finding in another antigen system 
besides H-Y and, even better, an HCV specific system, we evaluated the ability of 
CpG triggered pDCs to overcome CD4 depletion in NS31073.1081 specific T cell 
priming. Similar to our findings in the HY system, CpG triggered pDCs enhance 
HCV-specific CD8+ T cell priming (Fig. 4.17). 
Notably, CpG motifs are currently in phase II trials for HCV and have 
shown good antiviral effect in vivo. Although the effects of IFNa on HCV-
specific immunity are unclear, it will be important to compare immunologic 
response in IFNa versus CpG treated HCV patients. Moreover, the ability of 
pDCs to substitute for CD4+ T cell 'help' may make CpG motifs and TLR7/9 
therapy suitable for co-infected HIV/HCV patients with compromised CD4+ T 
cell activity. 
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Chapter 5: D C s Coordinate H C V I m m u n i t y and Pathogenesis 
HCV infects nearly 3% of the world's population and over 1 million 
Americans. In some countries, the prevalence of HCV reactive antibodies is 15-
20%. Chronic HCV is a leading cause of cirrhosis and liver cancer. In addition to 
the morbidity and mortality of these diseases, the disease burden in the 4th and 
5th decades of life has significant socio-economic ramifications in some 
communities. Clearly, more effective therapies and even vaccination would 
substantially lower disease burden worldwide. But what are the crucial 
characteristics of effective HCV immunity? Here, I will integrate my findings 
into the larger literature of HCV immunity to gain insight into this central 
question. 
5.1 Re-examining the role for DCs and CD4+ T cell 'help' in generating 
effective CD8+ T cell immunity to HCV 
Several early studies provided evidence for the role of the CD8+ T cell 
response in HCV immunity. In humans, the presence of strong HCV specific 
CD8+ T cell immunity correlates with resolution40. Similarly, in chimpanzees, 
CD8+ T cell immunity, in contrast to humoral responses, correlates with 
protection against rechallenge34. This correlative data was directly tested by 
CD8+ depletion. As expected, depletion of CD8+ T cells before re-infection 
rendered the chimpanzees susceptible239. Although significant data support the 
role for CD8+ T cells in HCV immunity, robust CD8+ T cell responses may also 
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exist in chronic infection240 and the distinguishing characteristics of successful 
immunity are not clear. 
In order to evaluate the requirements for effective T cell priming during 
HCV infection, many labs have focused on conventional DCs as the educators of 
the CD8+ T cell responses. Early studies reported a generalized defect in 
monocyte derived DC maturation, suggesting that defective maturation 
prevented robust T cell priming159"161. This model, however, is inconsistent with 
immune competence of chronically infected HCV patients. Furthermore, no 
mechanism for the modulation of DC function (i.e. virus binding or infection) 
could be identified to account for this global defect of monocytes. In contrast, 
we241,242 and others243 have concluded that both monocyte derived and circulating 
BDCA-1 conventional DCs are phenotypically and functionally normal in 
chronically infected HCV individuals. 
These findings offer two significant developments for studies of HCV 
immunology. First, they suggest that another level of regulation exists to 
influence the immunologic outcome of HCV-specific T cell priming (Fig. 5.1). 
CD4+ T cell signals and differential cytokine production during HCV infection 
are important candidates for this alternate level of regulation. Importantly, our 
data are consistent with the possibility of HCV-induced modulation of DC 
cytokine secretion; however, a mechanism for this remains to be identified. 
Second, our findings lend credence to DC based immunotherapy for HCV. 
These therapies may prove useful for enhancement of HCV specific immunity. 
CD4+ T cell signals are a critical component of a successful CD8+ T cell 
response41. This was directly evaluated in chimpanzees by CD4 depletion 
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Epitope specificity of Effector Functions 
Figure 5.1 Functional D C s regulate CD8+ T cell immunity. In light of 
normal D C function in chronic H C V , w e evaluated several alternate 
mechanisms of regulating CD8+ T cell priming. Although DC-SIGN 
binds E2, direct infection of DCs has not been demonstrated. Cross-
presentation of both viral particles or cell associated antigen is a 
mechanism for generating H C V epitopes. Epitope selection may be 
regulated by primary sequence mutations. CD8+ T cell priming is 
dependent on C D 4 help and plays a critical role in generating effective 
immunity in vivo. Finally, the epitope specificity of CD8+ T cells is an 
important determinant of their efficacy. 
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prior to rechallenge47. The results showed that CD4+ T cell 'help' was necessary 
for preventing escape mutations and allowing for resolution of infection. 
Although these types of experiments cannot be done in humans, HCV /HIV co-
infection provides a surrogate model for CD4 depletion. A recent study of co-
infected patients showed that HCV CD8+ T cell responses correspond with 
absolute CD4+ T cell count48. Furthermore, data from two patients infected from 
a known source suggests that the diversity of the CD4+ T cell response correlates 
with CD8+ T cell responses and resolution of infection49. 
The status of HCV-specific CD8+ T cells in the absence of strong CD4+ T 
cell 'help' is less well understood. In several animal models, CD4+ T cells are 
required for the generation of effective CD8+ T cell memory68,244,245. Moreover, 
we have shown that immunization with cell associated full length HCV in the 
absence of CD4+ T cells induces HCV-specific non-responsiveness to re-
challenge (see Fig. 4.16). Despite these data, T cell tolerance in HCV immunity 
has not been widely favored due to the presence of CD8+ T cells in chronically 
infected patients41. However, mutations in viral RNA makes HCV a rapidly 
moving target and, although HCV responsive T cells can still be detected in 
chronic HCV, the epitopes efficiently presented by APCs may be significantly 
altered41. Moreover, the persistence of antigen during chronic infection may 
induce functional anergy in a subset of HCV-specific T cells238. These data 
suggest that while a crucial decision regarding T cell activation versus tolerance 
is made during intial exposure, the generation of effective immunity depends on 
the ability to prevent escape mutations and the adverse effects of persistent 
antigen. Importantly, therapeutic intervention usually occurs after viral escape 
and/or the effects of persistent antigen on selective antigen specific T cell 
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responses. Thus, with better tetramers and larger cohorts of H C V donors, it will 
be important to measure the relative importance of these processes on T cell 
immunity to HCV through the course of infection. These data may provide 
important insight into the important epitopes to target during immunotherapy 
for chronic infection. 
5. 2 Mechanism of antigen presentation in generating CD8+ T cell immunity 
Although hepatocytes are generally recognized to be infected during HCV 
infection, it is not clear if antigen presenting cells are directly infected141 (Fig. 5.1). 
Some studies suggest that DCs are infected in vivo2i6; however, these results are 
not reproducible between patients. Furthermore, these findings are not based 
on negative strand synthesis and therefore indicate the presence, but not 
necessarily the replication, of HCV. Several studies have shown that HCV E2 
glycoprotein binds to DCs via DC-SIGN94,95, providing a putative mechanism by 
which HCV RNA is merely bound to surface of DCs. Although one report 
suggests that DC-SIGN enables HCVpp infection247, the role for DC-SIGN in 
HCVcc infection has not been substantiated (see Fig. 2.8). In lieu of mediating 
direct infection, DC-SIGN binding may play an important role in virus 
trafficking. This mechanism of "hitching a ride" may account for HIV trafficking 
from mucosal surfaces to lymph nodes for T cell infection97. The importance of 
this interaction in trafficking HCV from sites of mucosal or intravenous infection 
to hepatocytes has not been defined. 
Although APCs can efficiently generate MHCII epitopes from exogenous 
antigen, MHCI epitopes for the stimulation of CD8+ T cells are classically 
generated from cytoplasmically processed antigen. The lack of direct infection of 
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DCs would prevent classical loading of M H C I ; however, it was recently shown 
that DCs can cross-present antigen from viral particles for stimulation of HCV-
specific T cell lines180. We have confirmed the ability of full length cell associated 
HCV antigen to be cross-presented for stimulation of NS protein T cell immunity 
in mice; however, presentation of HCV epitopes by uninfected DCs in humans or 
chimpanzees has not yet been shown. This strategy also has the potential to 
identify new HCV epitopes. Interestingly, cross-presentation of NS3 antigen in 
the context of cytopathic bovine viral diarrheal virus (BVDV) infection was 
found to generate robust NS3 T cell immunity, suggesting that cross-presentation 
may offer unique advantages for vaccination strategies227. 
In light of the alternate methods for antigen presentation, differential 
antigen processing may be important in epitope generation (Fig. 5.1). In general, 
peptide epitopes generated by proteasomes are loaded onto MHCI in the 
endoplasmic reticulum. However, different cells process antigen differently. In 
the influenza model, direct infection of DCs can generate strong immune 
responses to both nucleoprotein (NP) and polymerase (PA) epitopes; however, 
cross-presentation of influenza antigen results primarily in NP-specific 
priming248. This epitope selectivity may have important consequences for the 
efficacy of the adaptive immune response in mediating viral clearance. There is 
precedent to suggest that viruses may use epitope preferences to mislead the 
host. Although cross-presentation generates robust Derestricted M45 T cell 
responses during MCMV infection, immune evasion protein ml52/gp40 
specifically blocks epitope presentation and subsequent detection in infected 
tissue237. In vivo mouse data for presentation of full length, cell associated HCV 
antigen suggest that NS31073.1081 is the dominant CD8+ T cell epitope. 
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Interestingly, a high rate of non-synonomous mutation is seen at the C-terminal 
end of this epitope which blocks proteasome processing and presentation236. In 
light of the strong T cell immunity to NS31073.1081, mutation at the C-terminus of 
this epitope might disrupt T cell stimulation. Alternatively, mutations at this site 
may allow HCV to evade T cell immunity in the infected tissue, similar to 
MCMV evasion described above237. With the availability of infectious HCVcc, it 
will be important to determine MHCI epitopes generated by infected hepatocytes 
versus DCs from infected patients by mass spectroscopy249. In conjunction with 
concurrent tetramer data, these experiments will provide a more complete 
picture of distinct regulation points in effective CD8+ T cell immunity: antigen 
presentation by APCs, epitope specific T cell responses, and presentation of 
antigen by infected hepatocyte targets. 
5. 3 A role for DCs in the characteristic intrahepatic IFNo/P signature of HCV 
infection 
In contrast to other viral liver infections such as hepatitis B, HCV induces 
robust expression of IFNa response genes in the liver during acute infection250. 
IFNa is a potent antiviral cytokine that can act by both autocrine and paracrine 
signaling mechanisms to induce the expression of proteins which protect against 
viral infection: MxA, PKR, 2'-5' OAS, and ADAR (see Fig. 1.6). These antiviral 
activities likely account for the potent therapeutic effects of pegylated-IFNa for 
HCV101. 
Which cells are responsible for IFNa production during HCV infection? 
Theoretically, all cells are capable of inducing IFNa production in response to 
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viral infection. The strong data showing the infection of hepatocytes with H C V 
in vivo U1, therefore, suggest that infected hepatocytes may be the most likely 
producers of IFNa during acute infection. Several reports suggests that 
hepatocytes are competent to respond to dsRNA via RIG-I and TLR3 signaling 
pathways131,137. On the contrary, although IFNa response genes are significantly 
upregulated in liver tissue, IFNa transcripts themselves are not found in liver 
tissue. In response to this finding, it has been argued that IFNa transcripts are 
present in PBMCs of acutely infected patients143. In contrast to hepatocyte 
infection, HCV infection of PBMCs remains controversial. However, PBMCs 
express numerous pattern recognition receptors e.g. toll receptors (TLRs), which 
may make them uniquely suited to detect virus even in the absence of infection. 
In particular, the natural interferon producing cells in the blood, plasmacytoid 
DCs (pDCs), express TLR7 (receptor for ssRNA126) making them well suited to 
produce IFNa in response to the HCV RNA. However, a mechanism for HCV 
induction of IFNa has yet to be defined. In fact, infectious J6/JFH chimeric HCV 
virus fails to trigger IFNa production in pDCs in vitro (Fig. 5.2) suggesting that 
another PBMC cell type may be involved in the IFNa response to infection; 
however, the response of liver pDCs in vivo also needs to be assessed. 
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Figure 5.2 J6/JFH chimeric H C V does not induce IFNa production by 
human pDCs. BDCA-2 and BDCA-4 were used to identify and gate 
pDCs by FACS. Histograms show IFNa staining in p D C fraction 
following 6 hr stimulation as indicated. 
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Despite the lack of evidence for direct p D C activation by H C V , our 
work242 as well as that of others162,174 has revealed lower percentages of pDCs per 
PBMC in HCV-infected donors compared to healthy controls (see Fig. 2.6). It 
remains unclear if this reflects decreased pDC production, migration to 
extravascular sites such as lymph node or liver, or disappearance (albeit real or 
artifactual) due to death or down regulation of characteristic pDC markers. The 
latter occurs with phenotypic maturation of pDCs in response to viruses both in 
vivo251 and in vitro (Fig. 5.3A). Although downregulation of BDCA-2 during pDC 
maturation is coincident with migration, a transitional cell population may be 
apparent in the circulating blood. For example, a BDCA-2 low population was 
observed in PBMCs from 2 out of 22 HCV patients, but not in any healthy donors 
(Fig. 5.3B). This BDCA-2 low population expressed CD123 and HLA-DR but 
downregulated BDCA-4 (Fig. 5.3C). Consistent with a mature phenotype, this 
BDCA-2 low population expressed high levels of CD83 and increased CD40. 
This finding, however, was only present in select HCV+ patients and the 
defining clinical characteristics could not be identified. Furthermore, exposure to 
J6/JFH chimeric HCV in vitro does not induce phenotypic maturation or enhance 
survival. In vivo studies are required to evaluate the presence of pDCs in 
infected liver or draining lymph nodes. An important caveat of this data is that 
these findings are not necessarily HCV-specific (see Fig. 2.6) and may be 
indicative of chronic infection172. Notably, endogenous as well as therapeutic 
IFNa negatively regulates pDC number and IFNa production252; as such, it is 
important for studies evaluating pDCs in chronic infections to document IFNa 
serum levels as well as the time elapsed since termination of IFNa therapy. 
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Figure 5.3. BDCA-2 low population in chronic H C V upregulates 
maturation markers. (Continued on the following page) 
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Figure 5.3. BDCA-2 low population in chronic H C V upregulates 
maturation markers. A. BDCA-2 and BDCA-4 were used to identify 
pDCs in P B M C cultures by FACS. Numbers indicate p D C percentage 
per P B M C . Cells were exposed to influenza or not and analyzed at 
indicated times after exposure. B. Enumeration of BDCA-1, BDCA-2, 
and BDCA-2 low population as described in material methods. FACS 
plot shows data from H C V - donor 24263 and H C V + donor 24262. C. 
Surface expression of indicated markers on BDCA-2 low (gray line) 
compared to BDCA-2 high (black line) cell populations is represented by 
histogram. 
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Despite these reported abnormalities in cell numbers, pDCs from 
chronically infected HCV donors are functionally competent to make IFNa/p in 
response to TLR7/9 agonists. An initial report suggested that pDCs from HCV 
infected donors showed impaired IFNa production in response to TLR9 specific 
agonists; however, these results were based on IFNa levels from bulk PBMC 
cultures and did not account for the decreased percentage of circulating pDCs 
seen in chronic HCV infection162. More careful analysis accounting for the 
decreased numbers of pDCs as well as FACS-based assays to monitor 
intracellular IFNa production by pDCs revealed that the decrease in TLR9 
triggered IFNa is a result of decreased pDC numbers and not reflective of a 
functional defect in pDC IFNa production (see Fig. 2.7)242,243. These findings 
suggest that HCV does not specifically interfere with pDC production of IFNa, 
supporting a potentital role for TLR7/9 agonist therapy for HCV. 
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Conventional DCs can also produce significant amounts of IFNa206. Using 
influenza as a stimulus, we showed that iDCs produce IFNa equivalent to pDCs 
stimulated with CpG (Fig. 5.4A). 2-aminopurine inhibits this IFNa production 
suggesting the importance PKR or other kinase activity in this response (Fig. 
5.4B). Interestingly, DC maturation shuts down this IFNa production (Fig. 5.4B). 
We hypothesized that this finding reflects an intrinsic inability of mDCs to make 
IFNa due to their decreased need to detect pathogens (and consequent 
downregulation of TLRs (Fig. 5.4C)); however, infection with influenza ANSI 
revealed the capacity of mDCs to produce IFNa (Fig. 5.4D). This finding needs 
to be evaluated by intracellular cytokine staining to rule out the possibility of 
contaminating iDCs accounting for the interferon production. This finding 
suggests that viruses may actively inhibit IFNa production in mDCs. The ability 
of HCV to trigger conventional DC IFNa production in vivo or in vitro has not 
been evaluated. 
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Figure 5.4. Influenza NS1 protein antagonizes m D C IFNa production 
via non-TLR dependent mechanism. (Continued on the following page) 
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Figure 5.4. Influenza NS1 protein antagonizes m D C IFNa production 
via non-TLR dependent mechanism. A. pDCs or iDCs at 106/mL were 
stimulated with 3 m g / m L of C p G 2216 or 50 H A U influenza (Flu) in the 
presence of 2-aminopurine (2-AP) or acetic acid solvent (AA). IFNa in 
24 hour supernatants was quantified by ELISA. B> iDCs or m D C s at 
106/mL were stimulated with 50 H A U influenza (Flu) and cultured in 
media alone or media with maturation stimuli T N F a and PGE-2 (T+P) 
for the indicated amount of time. IFNa was quantified by ELISA. C. 
Surface staining of iDCs and m D C s for TLR3 and CD83. D. IFNa in iDC 
and m D C supernatants containing 106 cells/mL stimulated for 24 hours 
with media alone, 50 H A U influenza (Flu), or 50 H A U influenza ANSI 
(Flu ANSI) monitored by ELISA. 
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Despite the clinical efficacy of IFNa and the sensitivity of H C V to IFNa in 
vitro, it is surprising that induction of IFNa response genes does not correlate 
with resolution of acute HCV infection139. Notably, several mechanisms by 
which HCV proteins antagonize IFNa signaling and production in infected cells 
have been elucidated133,134 (Fig. 5.5). The NS3-4A protease plays a key role in 
disrupting IRF-3 phosphorylation135 by targeting the RIG-I adaptor, Cardif136,253 
and TLR3 associated TRIF adaptor protein137. These antagonistic functions may 
limit IFNa's anti-viral effect during acute infection. Another study has 
suggested that the dose of infection may be an important factor in determining 
the nature of the protective response37. In other words, innate immunity and 
IFNa may play a more important role in low dose exposures. Alternatively, 
HCV, as well as other pathogens, may take an active role in manipulating the 
host's IFNa/p response to evade adaptive immunity and promote viral 
persistence. 
177 
TLR9 
CpG DNA 
TLR7 
I — • IRF3 targets; IFNp 
Hepatocyte 
Figure 5.5. Regulation of IFNa production and induction of IFNa 
response genes during H C V infection. Despite the robust induction of 
IFNa response genes in liver tissue samples, H C V has numerous 
mechanisms to inhibit both effector function and production of IFNa. 
The nature of the IFNa producing cell during acute H C V infection 
remains unidentified as does the mechanism by which it detects H C V . 
As proposed in the figure, RIG-I and TLR3 mechanisms may trigger 
IFNa production directly by hepatocytes. Although a decrease 
circulating p D C numbers has been documented, it is not clear which 
P B M C cell type produces IFNa during acute infection. 
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5.4 IFNa/P's double-edged sword: strategies for immunoevasion and immunity 
The actions of IFNa/p on immune regulation are pleiotropic140. The 
counter-inflammatory effects of IFNa/p play important role in controlling non-
specific activation during times of hyper-activity. During viral infection, for 
example, IFNa/p suppresses bystander T cell activation209 as well as excessive 
production of IL-12 186 via ST ATI dependent signaling140,208. Moreover, we have 
shown that the inhibition of IL-12 production by ST ATI signaling in iDCs blocks 
CD8+ T cell activation by cross-presentation, thereby providing another level of 
regulation against non-specific activation during viral infection (Fig. 5.6). 
These counter-inflammatory actions provide crucial targets for invading 
pathogens. L. monocytogenes, for example, uses the IFNa/p response to promote 
lymphocyte apoptosis254 and inhibit IL-12 production210. As such, IFNAR-/- mice 
are significantly more resistant to high dose challenge. Viruses, such as HCV, 
may also take advantage of these counter-inflammatory targets. Although HCV 
has several mechanisms to inhibit IFNa/p signaling in infected cells, high levels 
of IFNa/p are present in hepatic tissue. Thus, in the absence of DC infection, 
IFNa/p will act on the DCs as they capture antigen in the liver. The importance 
of CD4+ T cell 'help' in generating strong HCV-specific CTLs may enable IFNa/p 
in the tissue to play an important role in preventing CD8+ T cell activation by 
cross-presenting DCs. Polymorphisms in IL12B promoters could contribute to 
the complexity of IFNa/p regulation of IL-12 production, resulting in wide 
variation in clinical outcomes255. 
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Figure 5.6. Spatial compartmentalization of IFNa reflects both therapeutic 
and viral strategies of modulating immunologic outcome. A. IFNa in 
peripheral tissue during an infection or inflammatory response can be 
produced by infected cells, pDCs, or cDCs. Activation of STAT1 dependent 
signaling in cDCs decreases consquent IL-12 production and T cell priming. 
This mechanism may play an important role in viral infections that trigger 
non-pDC-produced IFNa in tissue such as H C V , inflammatory situations 
with p D C infiltrates, or therapeutic Betaseron® for multiple sclerosis. B. In 
contrast, IFNa in lymph nodes may facilitate immunity. Activation and 
migration of pDCs or cDCs to the D C / T cell interface places them in prime 
location to affect the immunologic outcome. IFNa/p might act on the D C or 
the CD8+ T cell via STAT4-dependent signaling. 
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In addition to its counter-inflammatory effects, IFNa/p also plays an 
important role in enhancing immune responses. Although IFNa/p inhibits IFNy 
production by NK cells and naive T cells during viral infection181, it is required to 
trigger NK cell cytotoxicity and stimulate proliferation of certain T cell 
subsets182,183. Similarly in DCs, although our data show that the inhibition of IL-
12 by IFNa/p blocks T cell activation, other reports suggest that type I IFNs may 
serve as a 'danger' to facilitate DC activation184 and 'license' DCs to cross-
prime185. In some conditions, IFNa/p may even synergize with TLR ligands to 
enhance IL-12 production by DCs198. 
We have identified a signaling switch in DCs coincident with maturation 
that modulates the effect of this pleiotropic cytokine acting through a single 
IFNa/p receptor (Fig. 5.6). In contrast to IL-12 inhibition by STAT1 signaling in 
iDCs, exposure of mDCs to IFNa/p results in signaling via STAT4, enhanced 
production of IL-12p70, and subsequent T cell activation. This data provides 
evidence for a maturation-induced molecular switch in signaling pathways, 
which accounts for the opposing effects of type I IFNs on antigen cross-
presentation. This alteration in signaling networks offers a novel mechanism by 
which DCs modulate the integration of signals from the surrounding 
environment. This switch is reflective of similar intracellular regulation in both 
NK and T cells181,199. Recent data suggest that antigen specific CD8+ T cells 
regulate total STAT1 levels, thereby reducing their sensitivity to IFNa/P's anti-
proliferative effect208. In sum, the cell-specific regulation of signaling networks 
enables multiple, yet specific, effects of IFNa/p in coordinating immunity. 
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5.5 IFNa7P compartmentalization in disease and immunity 
The migration of pDCs to secondary lymph organs upon activation offers 
a clear mechanism for IFNa/P's immune enhancing effects. IFNa/p production 
during most viral infections is not restricted to the tissue and may also activate 
pDCs to produce IFNa. Our experiments suggest that pDC-derived IFNa at the 
DC / T cell interface can overcome the inhibitory effect of IFNa 'early' (see Fig. 
3.13). This finding supports the hypothesis that inflammatory cytokines in the 
periphery may not be sufficient and that TLR-dependent detection and 
movement of blood cells is crucial to orchestrating an effective CTL response. In 
contrast, a recent study suggests that inflammatory cytokines triggered by CpG 
are insufficient to allow for activation of transgenic CD4+ T cells256. These 
findings may reflect differences in activation of transgenic CD4+ T cells versus 
endogenous CD8+ T cells. Alternatively, the delivery of CpGs in the footpad 
may not be sufficient to trigger pDC migration and IFNa production in the 
lymph node at the DC / T cell interface. Another recent study suggests that 
pDCs are critical for generating herpes simplex virus (HSV)-specific CTLs in 
response to viral challenge223. This finding, however, may be specific for HSV, as 
pDC depletion does not affect the generation of M45 epitope-specific CD8+ T cell 
priming in response to MCMV infection(see Fig. 4.8). However, MCMV or CpG 
activated pDCs can substitute for CD4+ T cell 'help' in priming CD8+ T cells 
against H-Y model antigens. Thus, in the absence of robust CD4+ T cell 
responses (e.g. in HIV-AIDS), pDCs may play an important role in T cell 
priming. This pDC effect is independent of IL-12, but dependent on IFNAR 
suggesting that IFNa production is required at the DC / T cell interface. These 
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findings show that pDCs can offer priming signals to CD8+ T cells and provide a 
functional rationale for their migration to lymph nodes during viral infection. 
As previously mentioned, pDCs are not the only cells capable of making 
IFNa/p. Infected tissue as well as conventional DCs are able to produce IFNa/p. 
Naturally, the IFNa/p produced by infected tissue is restricted to the local area of 
infection. Although DCs may migrate to lymph nodes like pDCs, maturation is 
coincident with decreased IFNa/p production (Fig. 5.4). This may represent 
active interference by viral proteins to prevent the immune enhancing effects of 
IFNa/p production at the DC / T cell interface. With regard to vaccine 
development, viral vectors lacking viral proteins that disrupt IFNa production 
by mDCs (i.e. influenza ANSI) may enhance immunogenicity. 
Compartmentalization of IFNa/p production during viral infection may 
represent a distinct signature of the host-pathogen interaction. Herpesviruses, 
such as HSV and MCMV, are potent activators of pDC-derived IFNa/p188. The 
activation of pDCs by herpesviruses such as HSV and MCMV may be tightly 
linked to the importance of cross-priming for robust T cell immunity during 
infection257. In contrast, influenza ANSI triggers IFNa/p production by a non-
pDC and can generate an immune response via direct infection of APCs248. 
Notably, the production of IFNa/p during influenza ANSI infection does not 
substitute for CD4+ T cell 'help' during H-Y priming. LCMV also induces 
production of IFNa by a non-pDC195. Although LCMV-specific CD8+ T cell 
priming was classically defined as CD4-independent, recent data suggest that 
CD4+ T cells are important for secondary expansion68. It will be interesting to 
see if pDC IFNa/p affects secondary expansion in this model. 
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H C V may also induce spatial compartmentalization of IFNa/p. Despite 
the functional responsiveness to TLR9 agonists242 ex vivo, no direct evidence 
shows HCV activation of pDC-derived IFNa; nonetheless, IFNa/p response 
genes are induced in hepatic biopsy tissue139. This spatial compartmentalization 
during HCV pathogenesis may make HCV uniquely suited to take advantage of 
the inhibitory effects of IFNa/p on CD8+ T cell activation by cross-presenting 
DCs. 
5.6 pDC-based therapy for HCV 
Given the correlation between T cell immunity and clinical response, it 
was hypothesized that IFNa treatment would enhance HCV-specific T cell 
immunity. A recent report, however, suggests that this is not necessarily the 
case213. Despite the sustained virologic response (SVR), HCV-specific T cell 
immunity was not enhanced. Several possibilities may account for these 
findings. First, a simple decrease in antigen load may have led to a decrease in T 
cell response. Second, as described above, the inhibitory effects of IFNa on DCs 
may dominate during systemic delivery to decrease T cell activation. Third, 
treatment may selectivity enhance T cells with an antigen specificity not 
represented in the functional assays used. As such, it will be important to follow 
these T cells responses, especially CD8+ T cell response, after SVR to a variety of 
epitopes expressed by the particular virus that infected the patient. 
Targeted activation of pDCs for HCV therapy may offer a more effective 
strategy for enhancing the immune response. Our results evaluating HCV 
specific immune responses in mice suggest that pDC-derived IFNa/p enhances T 
184 
cell immunity. Although decreases in p D C number have been reported during 
chronic HCV infection by us242 and others162,174, these pDCs still produce 
significant amounts of IFNa/p upon stimulation. CpG trials by Coley 
Pharmaceutical Group report good anti-viral activity suggesting that the CpG 
motifs are effective in triggering IFNa in vivo. TLR7/9 agonist therapy may be 
an important therapeutic strategy to promote CD8+ T cell immunity in patients 
with compromised CD4+ T cell responses (i.e. HIV/HCV co-infected patients). 
In all, host-virus interactions play a key role in dictating the 
immunological outcome of HCV infection. Although we are still in the early 
stages of understanding these interactions in vivo, the role of IFNa/p in response 
to HCV infection offers a salient example of the complexity with which HCV 
modulates the immunologic outcome. Better tools for studying human 
immunology and the development of a small animal model for HCV will add 
tremendous insight into the mechanisms involved in the interaction of HCV with 
its host, as well as novel mechanisms of immune evasion required for viral 
persistence. A better understanding of the crucial aspects of this interaction will 
put us on more solid ground for designing therapeutic interventions to prevent 
and possibly cure HCV infection. 
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A p p e n d i x 1: Learning from our successes—Yellow fever interacts 
with D C s to generate robust C D 8 + T cell i m m u n i t y 
When looking to achieve a specific aim in almost all endeavors, it is helpful to 
know what worked in the past. Accordingly, HCV research in general and my 
thesis work in particular takes advantage of both natural resolvers and sustained 
virologic responders to gain insight into successful immunity, disease 
pathogenesis, and rational therapeutic design for HCV. Although we frequently 
learn many things from these situations, these successes are sometimes not 
widely studied. For example, the vaccine for yellow fever, developed in part 
here at Rockefeller University, is an extremely effective vaccine that has been in 
use for over 60 years to immunized over 400 million people; however, the 
mechanisms associated with the robust immunity it generates are poorly 
defined. During my thesis work, I had the opportunity to address some of these 
questions in collaboration with Giovanna Barba-Spaeth in the Rice lab. It is my 
hope that a better understanding of the effective components of the yellow fever 
vaccine will bring us closer to developing an HCV vaccine. 
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Al.l Abstract 
The yellow fever (YF) 17D vaccine is one of the most successful live attenuated 
vaccines available which confers life-long immunity to pathogenic YF, a 
flavivirus related to HCV. A single immunization of YF17D induces both YF 
specific T cell responses and neutralizing antibodies that can be detected for 
many years after vaccination. Surprisingly, the mechanism for this robust and 
long-lasting immunity has not been widely studied. Several recent reports have 
shown flavivirus interaction with dendritic cells (DCs); however, the mechanism 
of YF17D interaction with DCs and the significance of this interaction in 
generating T cell immunity have not been explored. Here, we show that YF17D 
can infect immature and mature human DCs. Viral entry is Ca2+-dependent, but 
independent of DC-SIGN as well as multiple integrins expressed on the DC 
surface. Similar to infection of cell lines in vitro, YF infection of iDCs is 
cytopathic. Although infection itself does not induce DC maturation in vitro, 
TNFa-induced maturation protects DCs from YF-induced cytopathogenicity. 
Furthermore, we show that DCs infected with YF17D or YF17D carrying a 
recombinant epitope can process and present antigens for CD8+ T cell 
stimulation. This work offers insight into the immunologic mechanisms 
associated with the highly effective YF17D vaccine that may guide effective 
vaccine design. 
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A1.2 Introduction 
"He gave to man control over that dreadful scourge, yellow fever." 
President Eliot, Harvard University 
Upon conferring master of arts to Dr. Walter Reed 
Yellow fever had tremendous public health impact on Central and Northern 
America from the 1600's until early 1900's infecting over 300,000 people with a 
mortality of over 40%. It was named "yellow" fever for the characteristic 
jaundice it produced in infected individuals. In his pioneering work presiding 
over the Yellow fever Board in Cuba in 1900, Major Walter Reed and his 
colleagues proved Carlos Juan Finlay's theory, that the mosquito, Aedes aegypti, 
was the vector for this transmissible agent258. The following year, Reed's 
colleague, Dr. James Caroll, showed that yellow fever agent was filterable259. YF 
is classified in the same family as HCV, Flaviviridae, based on sequence and 
physical similarities. 
In 1930's, Max Theiler's seminal work on YF grew out of his observations 
that propagation of the virus in mice produced an attenuated virus that was less 
infectious in rheseus macques. After his move to the Rockefeller Foundation 
(renamed Rockefeller University), Theiler along with Hugh Smith produced an 
attenuated virus in chicken embryos that conferred protection to pathogenic 
infection260. In 1951, Theiler was awarded the Nobel Prize for his discovery of a 
live attenuated yellow fever vaccine. 
The yellow fever vaccine strain 17D (YF17D) is a live attenuated vaccine 
that has been used for over 60 years in more than 400 million people for 
vaccination against yellow fever virus with a remarkable record of safety and 
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efficacy261. The vaccine strain YF17D was generated from the wild-type strain 
Asibi and differs from Asibi by only 32 amino acids, 12 of which are clustered in 
the envelope protein262. Viscerotropism of the parental Asibi is markedly 
reduced in YF17D but the basis of the attenuation remains unknown. 
Furthermore, the YF17D receptor and mechanism of entry are not known. 
YF17D vaccination generates both neutralizing antibodies and T cell 
responses that persist for many years 263,264. Given its safety and efficacy, YF17D 
has been engineered as vaccine vector for antigens of other flaviviruses such as 
dengue, Japanese encephalitis and West Nile viruses. Some of these chimeric 
viruses are in phase II clinical trials265. YF17D can also be engineered to deliver 
epitopes from unrelated pathogens and it is able to induce protective immunity 
against heterologous agents266,267. The antibody response most likely accounts for 
the effectiveness of the vaccine; however, a role for cell-mediated immunity in 
generating an effective immune response has also been suggested264. Only 
recently have YF-specific human CD8+ T cell response been assayed268, but the 
immunologic mechanisms associated with YF-specific CD8+ T cell priming are 
still unknown. 
As discussed in the introduction, DCs are potent antigen presenting cells 
that play a crucial role in regulating the adaptive immune response52. DCs may 
interact with pathogens in peripheral tissue via direct infection or via 
phagocytosis of either infected cells or viral particles. Upon exposure to 
inflammatory signals or certain pathogens, DCs undergo a programmed 
phenotypic maturation program coincident with CCR7 upregulation and 
migration to the lymph node for engagement and activation of T cells. In 
addition, DC maturation confers resistance to cytopathogenicity of some viral 
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infections, facilitating T cell priming m. DC-SIGN, a D C specific ICAM-3 
grabbing non-integrin that is present most robustly on immature dendritic cell 
(iDCs), mediates entry of dengue virus into DCs92,93 and binding of the HCV 
envelope protein269. 
In this chapter, I explore the interaction of YF17D with human DCs. We 
investigate the ability of YF17D to infect DCs, the requirements for viral entry, 
and the cytopathic effect of YF17D in DCs. Furthermore, we evaluate the 
immunologic determinants of DC infection by monitoring T cell responses to 
endogenous and model antigens from YF17D vectors. This work provides new 
insight into the immunologic mechanisms associated with the highly effective YF 
vaccine and may provide clues relevant to effective vaccine design. 
A1.3 Materials and Methods 
Isolation and Preparation of cells 
PBMCs, DCs, and T cells were prepared as previously described168. PBMCs were 
isolated from whole blood by sedimentation over Ficoll-Hypaque (Amersham 
Pharmacia Biotech, NJ). T cell enriched and T cell depleted fractions were 
prepared by adherence to plastic in 1% single donor plasma. iDCs were prepared 
from the T cell depleted fraction by culturing cells in the presence of 1000 U/ml 
GM-CSF (Berlex, Seattle, WA) and 500-1000 U/ml IL-4 (R&D Systems, 
Minneapolis, MN) for 6 days 170. To generate mature DCs, cultures were 
stimulated on day 6 with 50 ng/ml TNFa (Alexis Biochemicals) and lOmM PGE-
2 (Sigma) for 36-48 hr 171. Patient material was obtained as per protocol approved 
by the IRB The Rockefeller University Hospital (JKR-0397), and all patients gave 
written informed consent. 
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Preparation of virus stocks 
Yellow fever 17D (YF17D) viral stocks were derived from pACNR/FLYF 
plasmid containing the full length infectious YF17D genome under a SP6 
promoter270. In vitro-generated RNA transcripts were electroporated in SW13 
cells as previously described 271. Virus stocks were harvested at 48 hrs post-
transfection with typical yields of 107-108 PFU /ml as determined by plaque assay 
on SW13. Single use aliquots were stored frozen at -80°C until use. YF17D/M1 
was constructed by inserting the influenza HLA-A2.1 CTL epitope of matrix 
protein (GILGFVFTL)272 between yellow fever NS2B and NS3 proteins. Two 
specific oligonucleotides containing the Ml epitope sequence (forward 5'-
aggggagcgcgcagaagtggaattttaggattcgtgttcacgctcggtcaccggagaagt-3' and reverse 
5'-acttctccggtgaccgagcgtgaacacgaatcctaaaattccacttctgcgcgctcccct-3') and two 
YF17D-specific primers were used to generate two PCR fragments containing the 
influenza Ml epitope and a portion of the NS2B or NS3 gene, respectively. One 
of 50pil of each PCR reaction was mixed together and used as template for PCR 
with YF17D-specific primers lying in NS2B and in NS3. The final product was 
digested with BssHII and BstEII and cloned in YF17D2B/3 described 
elsewhere267. The recombinant virus was recovered 48 hrs post-transfection of 
SW13 cells with infectious RNA and tested for stability by PCR and sequence 
analysis of the region overlapping the insertion. UV-inactivation was carried out 
with a GS Gene-Linker UV chamber (Bio-Rad) using the sterilizing program. 
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,2+ 
Infection of Cells 
DCs were washed in RPMI and infected for 1 hr at 37°C using the indicated 
PFUs. UV-inactivated virus was used as a negative control. The infection was 
quenched with 5% pooled human serum and washed twice to remove excess 
virus. For EDTA/EGTA blocking, DCs were washed twice in PBS without Ca2 
and Mg2+ and lOmM EDTA or EGTA was added before infection. For antibody 
blocking, DCs were washed in RPMI and resuspended in 1% FBS/PBS. DCs 
were incubated with 10^g/mL of antibody (DC-SIGN (612) or avP3 (Chemicon)) 
or 100^g/mL RGD tripeptides (Sigma) for 15 minutes at room temperature prior 
to infection. Following 1 hr infection, DCs were resuspended in conditioned 
media with or without TNFa / PGE-2 maturation stimulus as indicated and 
incubated 24 hrs before monitoring for infection. 
Immunostaining for FACS Analysis 
Surface staining was done in serum containing media at 4°C. Anti-CD14, CD25, 
CD40, CD83, CD86, HLA-DR, and isotype control were obtained from BD 
Biosciences. Cytoperm / CytoFix Kit from BD Biosciences was used for fixation 
and permeabilization. MAb 1A5 is a mouse monoclonal antibody against the 
nonstructural protein NS1273 and C12 is a rabbit polyclonal antisera that 
recognize the nonstructural proteins NS4A and NS4B 274. Secondary antibodies 
used were from Jackson (PE) or molecular probes (APC). 
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Plaque Assay 
For plaque titration serial 10-fold dilutions were used to infect monolayers of 
SW13 for 1 hr at 37°C. After infection cells were overlayed with 0.6% agarose-
containing medium and plaques were allowed to develop at 37°C for 4 days. 
Plaques were fixed in 7% formaldehyde for 1 hr and stained with crystal violet 
(1.25%in20%EtOH)271. 
Detection of influenza-specific T cells by ELISPOT 
DCs and T cells were plated in 96-well Millipore plates coated with 5}xg/ml of 
anti-IFNy mAb (Mabtech, Mab-1-D1K). Cultures were incubated for 24-36 hrs at 
37°C, washed with mild detergent, and incubated with l[xg/ml biotin-conjugated 
anti-IFNy mAb (Mabtech, Mab 7BG-1). Spots were visualized using Vectastain 
Elite Kit (Vector Laboratories) and AEC substrate. Evaluation was performed in 
a blinded fashion by an independent service (Zellnet Consulting, Inc., NY) using 
an automated ELISPOT reader (Carl Zeiss, Inc., NY). Spots represent IFNy 
production by single cells and are reported as spot forming cells (SFCs)/106 cells. 
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A1.4 Results 
YF17D infects immature and mature DCs 
To test the hypothesis that the immune response induced by YF17D vaccination 
is generated by direct infection of DCs, we exposed both immature and mature 
human monocyte-derived DCs with characteristic surface phenotype to YF17D 
virus. FACS analysis for intracellular nonstructural protein NS1 showed robust 
expression in both immature DCs (iDCs) and mature DCs (mDCs) infected at 2 
or 20 PFU/cell (Fig. A1.1A). Detection of nonstructural viral proteins not present 
within the virion indicates productive infection. Infection was confirmed using 
an antibody to nonstructural proteins NS4AB (Fig. A1.1B). In addition, virus 
production in both the iDC and mDC cultures was monitored by plaque assay. 
Results showed a 3-log increase in infectious particles within 24 hrs that peaks 48 
hrs post-infection confirming productive infection (Fig. A1.1C). No significant 
difference in infectious particle production was seen between iDC and mDC 
cultures. To exclude antibody-mediated enhancement of YF17D DC infection, 
DCs were generated in plasma from non-immunized donors and in control 
experiments, blocking antibodies against the Fc-receptor (FcR) did not block 
YF17D infection (data not shown). These data demonstrate that YF17D can infect 
and productively replicate in human DCs, and infection occurs irrespective of 
their maturation state. 
Other cell types were not as susceptible to YF infection. High-level virus 
production was not seen in T cell, B cell or monocyte enriched PBMC (Fig. 
A1.1D). In addition, infection of B cell lines (MC116, RAMOS, and Raji) did not 
result in productive infection (data not shown). 
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Figure Al.l. Immature and mature D C s are productively infected 
by YF17D. A. Intracellular FACS analysis of NS1 expression in iDCs 
and m D C s infected with 2 or 20 PFU/cell 48 hrs post-infection. B. 
Intracellular staining of NS4 expression in iDC infected with 2 
PFU/cell. C. Virus production by iDC and m D C cultures measured 
by plaque assay on SW13. D. Virus production by T cell enriched 
and monocyte enriched P B M C fractions compared with iDCs. 
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In order to test if resident skin DCs exposed to YF during natural 
transmission by mosquito or subcutaneous vaccination are infected by YF, 
langerhan cells (LCs) and dermal DCs (DDCs) were generated from CD34+ 
hematopoetic progenitor cells and exposed to YF17D275. FACS analysis for 
NS4AB revealed that YF17D exhibited a significant preference for CD34+ derived 
DDCs compared to LCs (Fig. A1.2). 
DC infection is Ca2+ dependent 
The cellular receptor involved in YF17D infection is unknown. In order to assess 
a possible requirement for divalent cations, iDCs were pre-treated with lOmM 
EDTA and then exposed to YF17D for 1 hr to evaluate their role in infection. 
NS4AB expression at 24 hr was completely blocked by pre-treatment of DCs with 
EDTA (Fig. A1.3A) whereas EDTA pre-treated DCs were still competent for 
infection with influenza (Fig. A1.3B). EGTA treatment also blocked infection 
indicating a Ca2+-dependent mechanism (Fig. A1.3A). Consistent with this 
finding, addition of Ca2+, but not Mg2+, was able to overcome the EDTA block 
(Fig. A1.3A). 
In light of this result, we tested specific integrin blocking antibodies 
including pi7 p3, avp3, p5, avp5, avp5 as well as RGD peptides to evaluate the role of 
specific integrins in viral entry. Antibodies and peptides were used at 
concentrations reported to be sufficient for blocking West Nile virus98. None of 
the integrin blocking antibodies significantly inhibited infection as monitored by 
NS4AB expression 24 hrs post-infection (Fig. A1.3C and data not shown). The 
lack of inhibition by RGD peptides is consistent with previous reports suggesting 
YF17D infection is independent from the RGD motif ' 
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Figure A1.2. Dermal D C s but not LCs are infected by YF17D. 
Monocyte derived DCs, CD34+ derived D D C s and LCs were exposed 
to 2 PFU/cell YF17D and stained for FACS analysis after 48 hrs with 
maturation stimuli. Cells were gated based on side scatter (SSC) and 
forward scatter (FSC) as well as HLA-DR and CD83 positive staining. 
NS4A staining in this gated population is indicated by histogram on 
the right and the number above the gate indicates the percent of cells 
that stain positive for NS4. 
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Figure A1.3. YF17D Infection of D C s is Ca2+ dependent. A. YF17D 
infection of iDCs at 2 PFU/cell was monitored by intracellular FACS for 
YF NS4 24 hrs post-infection. DCs were treated as indicated with l O m M 
E D T A or l O m M EGTA. 6 m M Ca2+ or Mg2+ were added as indicated. 
Percentage of NS4 positive cells is indicated. B. Intracellular YF NS4 or 
surface influenza H A staining after 24 or 8 hrs, respectively. Infection 
was done with or without pre-treatment with E D T A as indicated. C. Bar 
graph represents percent of iDCs staining positive for YF17D NS4 24 hrs 
post-infection. Samples pre-incubated with lOfxg/ml of DC-SIGN or avP3 
blocking antibodies or lOO^g/mL of R G D peptides are indicated. 
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In addition, blocking antibodies against DC-SIGN93 did not inhibit YF17D 
infection (Fig. A1.3C). This finding is consistent with our data showing 
equivalent virus production in iDCs and mDCs which significantly differ in DC-
SIGN expression (high in iDC, low in mDC) (Fig. A1.1C) as well as a recent 
report showing the inability of DC-SIGN to permit infection in THP-1 cells92. 
Although YF17D infection of DCs is Ca2+ dependent, the receptor for YF17D 
remains elusive. 
YF17D infection does not alter DC maturation in vitro 
Several reports indicate that viral infection of DCs promotes or inhibits 
maturation84"86. In order to evaluate DC maturation as a result of YF17D 
infection, surface expression levels of CD83, CD86, and MHCII were assayed 36 
hrs post-infection. Interestingly, infection alone did not induce robust DC 
maturation. Although slight upregulation of CD86 and MHCII was observed 
(data not shown), conventional maturation markers such as CD83 were not 
expressed (Fig. A1.4A). However, in contrast to inhibition of maturation by 
several infectious pathogens 85,86, YF17D infection did not inhibit TNFa-mediated 
DC maturation (Fig. A1.4B). 
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Figure A1.4 YF17D infection does not induce or inhibit D C 
maturation. A. iDCs infected with 10 PFU /cell were analyzed for 
CD83 surface expression. CD83 expression of YF17D infected 
population (compared to mock infected) was analyzed 36 hrs post-
infection. B. iDCs were infected with 10 PFU/cell and exposed to 
T N F a / PGE-2 maturation cocktail. CD83 expression of YF-infected 
population (compared to mock infected) was analyzed after 36 hrs. 
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Maturation protects DCs from YF17D-induced apoptosis 
Since YF17D has been shown to be cytopathic in mammalian cells, we evaluated 
potential cytopathogenicity in human DCs using a FACS-based assay for 
monitoring apoptotic cell death. Similar to infection by several other viruses, 
YF17D induces cleavage of caspase-3 in iDCs and triggers cell death. In a 
representative individual, we show 37% (2 PFU/cell) and 54% (10 PFU/cell) 
caspatag™-positive iDCs at 48 hrs post-infection (Fig. A1.5A). These values were 
similar to the ones obtained in the SW13 cell line (29% at 2 PFU / cell and 69% at 
10 PFU / cell). Interestingly, when we exposed infected iDCs to inflammatory 
stimuli capable of inducing maturation, there was a significant reduction in the 
YF17D-induced cytopathogenicity—9% (2 PFU/cell) and 13% (10 PFU/ cell) of 
the total cells had activated caspase-3 48 hrs post-infection (Fig. A1.5A). 
In order to confirm that iDC cytopathogenicity was YF17D-specific and 
that caspatag™-negative mDCs were indeed YF17D-infected, we stained the 
infected iDCs for CD83, YF NS4AB, and activated caspase-3. In a data set 
representative of 3 similar experiments, gating on the YF-infected CD83" cells 
showed 21% caspase activation compared to 6% in the YF17D-negative 
population (Fig. A1.5B). In contrast, mature, YF17D-infected DCs (CD83+ / NS4+) 
showed only 3% caspase activation (Fig. A1.5B). Plaque assays performed on the 
supernatants from both cultures confirmed comparable levels of virus 
production (data not shown). Based on this data, we conclude that the resistance 
to YF17D-induced cytopathogenicity is dependent on DC maturation. 
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Figure A1.5. Maturation protects iDCs from Y F cytopathogenicity. 
A. Caspase activation is measured using Caspatag™-FITC in S W 1 3 , 
iDCs, or iDCs + T N F a , exposed to the indicated P F U of Y F 1 7 D virus 
at 48 hrs. Tables indicate the percent of cells that were caspatag™ 
positive. B. Y F 1 7 D infected iDCs or iDCs + T N F a were identified by 
intracellular staining with NS4. C D 8 3 staining w a s used to 
distinguish iDC vs. m D C . Caspase activation of the indicated cell 
populations are indicated by histogram and the percent Caspatag™ 
positive indicated. 
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Infection of DCs allows for processing and presentation of endogenous and model 
antigens 
In light of the direct infection of DCs and the resistance to YF17D-induced cell 
death upon maturation, we evaluated the ability of mDCs to process and present 
endogenous antigens produced by YF17D. mDCs generated from subjects 
vaccinated with YF17D were infected and used to stimulate autologous CD8+ 
and CD4+ T cells. IFNy ELISPOT results showed that infected DCs were able to 
process and present YF17D antigen for antigen specific CD8+ and CD4+ T cell 
stimulation (Fig. A1.6A). No T cell response was detected in non-immune 
donors. Influenza was used as a positive control to show T cell responses in both 
immune and non-immune donors. 
Due to the efficacy of the YF17D vaccine, many groups have proposed its 
use as a vaccine vector for generating CD8+ T cell immunity. We propose that 
these vectors may directly infect DCs allowing for processing and presentation of 
CD8+ T cell epitopes. We tested this hypothesis by constructing a YF17D vector 
carrying the immunodominant HLA-A2.1 Ml CTL epitope from influenza matrix 
protein. The Ml CTL epitope was inserted between NS2B and NS3 protein (Fig. 
A1.6B). This site has been shown previously to tolerate small insertion of foreign 
sequences266 mDCs from naive donors were infected with YF17D or chimeric 
YF17D-M1 virus at 2 PFU/cell as described above and used to stimulate 
autologous CD8+ T cells. IFNy ELISPOT results showed that YF17D-M1 infected 
DCs stimulate robust Ml-specific CD8+ T cell responses similar to Ml-peptide 
pulsed or influenza-infected DCs (Fig. A1.6C) while DCs infected with YF17D 
alone did not stimulate IFNy secretion in the non-immune donor. Importantly, 
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site of the M l eptiope at 2B-3 junction. C. DCs infected with 
influenza, YF17D, YF17D-M1, or pulsed with 10fxM M l peptide were 
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was measured by IFNy ELISPOT, as mentioned above. 
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this is the first demonstration of a YF17D 2B/3 chimeric virus presenting an 
HLA-A2.1 CTL epitope for T cell stimulation, offering proof of principle for a 
possible vaccine approach. 
Al. 5 Discussion 
YF17D infects DCs in Ca2+dependent fashion 
Recent reports have identified the receptors for related flaviviruses West Nile 
virus and dengue virus as avp3 and DC-SIGN, respectively92'9398. In addition, the 
presence of an RGD motif in the ectodomain of the YF17D envelope protein 
suggests a mechanism for interaction with integrins276. Both integrins and DC-
SIGN require divalent cations for structural and functional integrity. Consistent 
with these findings, our data suggest that YF infection is Ca2+-dependent (Fig. 
A1.3); however, direct investigation of the role of avp3 as well as numerous other 
integrins using blocking antibodies failed to inhibit infection. Cyclo-RGD 
peptides also do not competitively block YF infection which is consistent with 
data suggesting that RGD motif in the envelope domain is not required for viral 
spread; however, this does not formally rule out the RGD motif from playing a 
role. The RGD motif in the envelope protein does not exist in YF Asibi262'276—this 
motif was acquired as a result of mutation during passage in chicken embryos. 
The characterization of YF Asibi interaction with DCs may offer insight into the 
role of this motif and integrins in DC infection. 
Furthermore, our results, as well as other's92, suggest that, in contrast to 
dengue, YF17D infection of DCs is not mediated by DC-SIGN. One explanation 
for this difference may be the differential glycosylation of the envelope proteins. 
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In contrast to dengue virus envelope protein which contains one or two N-linked 
gly cans, the envelope protein of YF17D-204 used in these experiments is not 
glycosylated277. Although other YF17D substrains (YF17DD and YF17D-213) 
may be glycosylated, our data indicate that DC-SIGN interaction is not necessary 
for infection and that YF17D interacts with DCs via mechanisms distinct from 
related flaviviruses. 
DC maturation prevents YF-induced cytopathogenicity 
Many viruses have been suggested to play an active role in immune 
evasion via inhibition of DC maturation. Our data, however, suggest that YF17D 
does not inhibit maturation (Fig. A1.4). These results suggest therefore, that in 
the context of YF17D vaccination, release of inflammatory cytokines in 
peripheral tissue may play an important role in triggering DC maturation; this 
will allow for DC migration to the lymph node and subsequent T cell 
engagement and priming (Fig. A1.7). Consistent with this model, an increase in 
TNFa has been detected in subjects vaccinated with YF17D278. 
The ability to undergo functional maturation plays an important role in 
preventing YF-induced cytopathogenicity. This resistance to cytopathogenicity 
could play an important role in allowing infected DCs to remain alive for 
trafficking to lymph node and priming of T cell responses. It will be interesting 
to evaluate the effect of pathogenic YF Asibi on DC maturation and 
cytophathogenicity. 
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Figure A1.7. Schematic for DC/YF interaction in generating T cell 
immunity. In the periphery, iDCs may interact with various. 
Calcium-dependent infection of DCs does not itself mature the DCs; 
however, infection does not block normal maturation by other 
inflammatory signals. Maturation prevents the cytopathic effects of 
YF, enabling migration to the lymph node and priming of T cells. 
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Infected mature DCs present antigen for T cell activation 
The ability of maturation to protect DCs infected in the periphery from 
apoptosis enables antigen loaded DCs to traffic to lymph nodes for T cell 
engagement. In vitro analysis indicates that these DCs are fully capable to 
present antigen for CD8+ and CD4+ T cell activation (Fig. A1.6). Although the 
mechanism of processing and presentation of endogenous CD4 epitopes remains 
poorly characterized, the YF17D epitopes presented may be derived from the 
small percentage of dying infected cells or by alternative mechanisms of 
processing 279. Similarly, infected DCs can process and present heterologous 
epitopes from chimeric viruses indicating that that DC infection may be a potent 
mechanism for robust immunity seen in vivo. These data indicate that YF17D 
vector is capable of delivering endogenous and recombinant epitopes to the 
surface of the DC enabling specific T cell activation. In the presence of a 
maturation stimulus produced in infected tissue, we therefore propose that Ca2+-
dependent direct infection of human DCs may offer a mechanism for the robust 
and long-lasting immunity associated with the YF17D vaccine. 
More questions remain for YF 
It is surprising that even at after 100 years since the discovery of YF, the 
mechanisms associated with its pathogenesis and immunity are not well 
understood. In light of the interactions of other flaviviruses with DCs, we 
designed these experiments to explore the interaction of YF17D with DCs. 
Although infection of DCs is robust, selective, and Ca2+-dependent, the 
receptor(s) affording these characteristics remain elusive. A better 
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understanding of the surface proteins involved in this infection may identify 
target molecules on DCs for vaccine delivery. Interestingly, the majority of 
amino acid changes between YF17D and pathogenic YF Asibi exist in the 
envelope protein262. Thus, a better understanding of the molecules involved in 
infection may offer insight into tropism differences between YF17D and Asibi 
that result in immunity versus disease. 
Mouse models are of limited significance since mice are not a true host for 
YF. As such, it is crucial to evaluate these questions in human models. Of 
particular note, is the nature of the infection of YF in the skin (during natural 
transmission by the mosquito) as well as in the subcutaneous tissue (during 
immunization). While we have made an attempt to evaluate the infectivity of 
DDCs and LCs using CD34+ derived cells (Fig. A1.2), these experiments need to 
be performed in skin ex vivo to understand YF interaction with resident skin DCs 
in both immunity and disease. 
Finally, the efficacy of YF as a vaccine vector needs further clarification. 
Although we have shown proof of principle that human DCs can process and 
present the minimal Ml epitope inserted into the the NS2B/3 site, the 
components of this process have yet to be defined. The role of the viral protease, 
host proteasome, length of flanking regions, and site of insertion in mediating 
efficient presentation by DCs will offer tremendous insight into vaccine vector 
design. 
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Appendix 2: T h e D C database 
As mentioned in chapter 3, transcriptional changes associated with maturation 
and IFNa/p treatment were monitored by affymetrix analysis using human 
U133A microarrays. The amount data obtained in these experiments is 
enormous and we are still only beginning to harness this resource. In order to 
manage such a large amount of data, I adapted a database provide by our 
collaborator Dr. Nir Hacohen at MIT to facilitate searching and navigation of the 
data. Our initial work with the database has offered us important insight into 
DCs regulation of IFNa/p signaling (Chapter 3) as well as novel regulation of 
indoleamine 2,3-deoxygenase activity in DCs280. 
Preparing the database 
Biotinylated cRNA for hybridization was prepared as per Affymetrix Manual 
(see Chapter 2, Materials and Methods) and loaded onto the U133A microarray. 
This array analyzes expression of 18,400 transcripts and variants, 14,000 of which 
are well characterized genes. Each array is chemically loaded with over 22,000 
probe sets. Each probe is a 25-mer chosen to allow selectivity for the gene of 
interest. For each gene probe a 'mismatch probe' exist with a single base pair 
mismatch in the middle of the 25-mer. This allows for a quantitative index of 
signal to noise. MAS5.0 analysis software calculates the p-value for the intensity 
signal of the specific probe versus that of the mismatch probe. p<0.05 is used to 
determine if the gene expression is present (P) above the noise or absent (A) 
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below the level of detection. Notably, background depends on the specific probe 
so the absolute level of signal intensity only indicates relative expression. 
The data generated following MAS5.0 analysis was exported to Excel and 
the comparisons of interest were created. For example, comparison of mDC 
signal to iDC signal intensity was generated for the whole list of genes. Both 
forward (mDC / iDC) and reverse (iDC / mDC) ratios were created to facilitate 
searching. These data were then imported into Filemaker pro according to the 
specific donor preparation. Data from individual donors were linked for 
multiple donor comparisons using the Affymetrix ID numbers. A master 
template was created with search criteria for various comparisons used in our 
analysis (Fig. A2.1). Searches can be performed based on gene name/symbols, 
comparison ratios (using >, <, or = functions), absolute value (using >, <, or — 
functions), and/or absent/present calls (using "a" or "p," respectively). Another 
template was created to allow for quick scanning of search results (Fig. A2.2). 
This list displays gene symbol, genename, and absolute signal values. Of note, 
not all the probes have been associated with defined genes and may therefore 
appear without a gene name. As the gene names become available, the database 
can be update with new lists linked to the Affy ID. 
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Figure A2.1. D C Database. Affymetrix data from individual donors 
(indicated by color). The top panel indicates gene symbol, name, and 
Affy ID. Searches may be performed for any of the fields. The 
middle panel shows comparison ratios of samples indicated in the 
left hand column. Both forward and reverse ratios are shown. 
Searches can be performed using >, <, or = functions in these fields. 
The bottom panel shows absolute signal value, A/P calls, and p-
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Figure A2.2. Genes upregulated upon TNFo/PGE-2 maturation. 
The top 45 genes with the highest comparison ratios of m D C / iDC 
over multiple runs are displayed in a table in filemaker database. 
This arrangement allow quick scanning of gene names (pink and 
green), absolute signal for iDC (beige) and m D C (tan), and gene 
regulation during CD40L engagement (orange). 
216 
Transcriptional Profiles of iDCs verus mDCs: the gift that keeps giving 
One important analysis performed is the set of genes regulated during DC 
maturation (Fig. A2.2 and A2.3). The majority of genes do not change by greater 
than 2-fold during maturation providing an important internal control. 
However, a significant number of genes are either up or down regulated during 
maturation. Many of these transcriptional changes are consistent with known 
phenotypic and functional changes associated with maturation (Fig. A2.3). For 
example, iDCs express high levels of TLRs and antigen capture receptors to 
allow them to respond to PAMPs and capture antigen for initiating an immune 
response. Upon maturation, chemokine receptor (CCR) 7 is upregulated 
allowing migration to the lymph node. mDCs also upregulate important 
cytokines such as IL-12 and characteristic maturation marker such as CD83. 
The transcriptional profiles associated with maturation have been very 
important for our analysis. These data were mined extensively to provide a 
candidate list of genes responsible for the dual effects of IFNa/p described in 
chapter 3. Furthermore, we have made an effort to characterize the role of 
several interesting genes whose role in DC maturation is not well understood. 
Deborah Braun, a post-doc in Matthew Albert's lab, tackled the question of 
indoleamine 2,3-dioxygenase (IDO) upregulation in mDCs. IDO is an enzyme 
involved in tryptophan catabolism and is implicated in T cell tolerance281. Her 
work showed that while PGE-2 induces the expression of IDO mRNA, a second 
signal by TNF-R or TLR engagement is required to induce IDO activity (Fig. 
A2.4)280. 
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The database allows us to continue to push our functional findings to molecular 
mechanism in a relatively systematic fashion. For example, several genes have 
been identified as potential candidates in the regulation of IFNa/|3 signaling in 
DCs based on the expression profile and likely interactions with STAT signaling 
molecules. We are currently evaluating various technologies such as retroviral 
shRNA to identify the importance of these genes in our functional assays. As we 
learn more about the interconnectedness of these signaling pathways, I believe 
that the database will continue to be a very important tool in aiding these 
discoveries. 
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Appendix 3: CRI-0505 
During my thesis work, I had the unique opportunity to write and participate in 
a clinical protocol in collaboration with Andy Talal. As I mentioned in chapter 2, 
our desire to define the function of circulating DCs required larger quantities of 
PBMCs. As such, we wrote clinical protocol CRI-0505 in order to use 
leukapheresis to obtain large amounts of PBMCs. This experience was important 
for me for two reasons. 
First, as an MD/PhD student, it gave me my first experience with 
translational research. This type of research is not easy. The following document 
shows the preparation that goes into coordinating this type of study. Research 
on human samples involves numerous concerns and must be extensively 
reviewed both scientifically and ethically. Once the protocol is approved, 
technical difficulties exist in physically obtaining samples. Sometimes patients 
cannot give detailed histories; sometimes you get a smaller sample than you 
would like; sometimes appropriate controls are not available; and sometimes you 
get no sample at all. However, for many diseases in which animal models are 
not available, we must perform the highest quality science with human samples 
in order to gain insight into human diseases. Despite these difficulties, I was 
extremely fortunate to have the opportunity to do this work in collaboration with 
the staff at the Rockefeller University Hospital (RUH). The infrastructure setup 
at RUH removes a significant amount of administrative and technical problems 
associated with human research. I am very grateful for the professional and 
courtesy help of all the staff, nurses, and doctors at RUH. 
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Secondly, this work served as a constant reminder of why I do this 
research—to help the people affected by HCV. I was involved in coordinating 
each leukapheresis and had the opportunity to explain to most of the donors the 
goals of our research. I am very grateful for their generous contributions. 
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Abstract, Rationale of Study, Research Plan and Procedures. 
a) Abstract 
Hepatitis C virus (HCV) infects approximately 200 million people 
worldwide. Current estimates indicate that 30% of infected individuals 
spontaneously resolve the infection. Both resolution and protection correlate 
with the presence of HCV-specific T cell responses. In the 70% of individuals 
that progress to chronic H C V infection, pegylated interferon alfa (IFNa) and 
ribavirin enables -50% of individuals to sustain virologic responses after 
treatment is discontinued. The role for HCV-specific T cell responses and 
IFNa highlight the importance of understanding D C function during H C V 
infection as myeloid DCs are required for priming T cells in vivo and 
plasmacytoid DCs (pDCs) are the principle cell type responsible for 
endogenous IFNa production. In this study, w e characterize the phenotype 
and function of these DCs in vivo. Furthermore, w e evaluate mechanism of 
H C V antigen presentation by DCs as well as adaptive and innate signals 
which regulate the immunologic outcome of antigen presentation (T cell 
activation, tolerance, or ignorance). This study will offer insight into the 
pathogenesis of H C V and effective immunotherapy strategies. 
b) Overview 
Hepatitis C virus (HCV) infects more than 100 million people worldwide 
posing a significant public health risk. Approximately 3 0 % of people 
infected with H C V resolve infection while 7 0 % progress to chronic 
infection. Many studies have explored the mechanisms by which the virus 
is able to circumvent both humoral and cell-mediated immune responses. 
Although an HCV-specific humoral response is commonly seen in H C V -
infected chimpanzees and humans, HCV-specific antibodies are not 
capable of conferring protection34. Instead, protection in chimpanzees has 
been shown to correspond with expanded populations of HCV-reactive 
CD8+ T cell responses. Similarly in humans, tetramer analysis of CD8+ T 
cells from successful resolvers indicates the presence of HCV-specific 
CD8+ T cells, which are absent in chronically infected patients40. To better 
define these distinct immunologic outcomes, and gain insight into the 
pathogenesis of chronic H C V infection, w e propose to explore the role of 
dendritic cells (DCs) in H C V infected patients across the spectrum of 
disease. 
b) Hypothesis 
i. Circulating populations of dendritic cell in HCV patients are 
phenotypically and functionally normal. 
ii. H C V encoded proteins modulate D C function through direct 
interaction with surface receptors (e.g. CD81 or DC-SIGN) or through 
engagement of intracellular signaling proteins (e.g. PKR), thus 
resulting in the selective inactivation of HCV-reactive CD8+ T cells. 
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c) Aims 
i. To enumerate and characterize circulating populations of DCs in 
patients with HCV. This will be performed on fresh blood or PBMCs 
isolated from a leukapheresis sample. W e will focus our attention on 
the rare CDllc+ myeloid D C and the CD123+ plasmacytoidal D C 
(approximately 0.2 - 0.5% of the P B M C fraction), as w e believe the 
study of such cells will provide better insight into D C function in the 
native state. 
ii. To identify HCV-mediated points of dysregulation whereby 
dendritic cell / T cell interactions result in the selective tolerization of 
HCV-reactive T cells. 
Aim 1. To investigate phenotypic and functional characteristics of circulating DCs. 
Using Miltenyi Bead technology, w e will isolate CDllc+ myeloid and 
CD123+ plasmacytoidal DCs. Briefly, using the Miltenyi microbeads, cells 
can be separated from complex cell mixtures to very high purity within 
minutes. They are specifically labeled with super-paramagnetic M A C S 
MicroBeads. After magnetic labeling, the cells are passed through a 
separation column that is placed in a strong permanent magnet. The column 
matrix serves to create a high-gradient magnetic field. The magnetically 
labeled cells are retained in the column while non-labeled cells pass through. 
After removal of the column from the magnetic field, the magnetically 
retained cells are eluted. Both labeled and non-labeled fractions can be 
completely recovered. Using this approach it will be possible to isolate the 
respective D C populations to >95% purity. 
We will employ antibodies specific for the BDCA-2 antigen for the 
isolation of CDllcCD123+ plasmacytoid dendritic cells in blood15*151. BDCA-
2+ DCs show a plasmacytoid morphology, express the pre-T cell receptor a-
chain and are CD45RA+, CD14- and CD2-. They express neither myeloid 
lineage markers like CD13 and CD33, nor Fc receptors like CD32, CD64 or 
FceRI, and are negative for BDCA-3 and CDlc (BDCA-1). 
Use of the antibody specific for CDlc will be used for isolation of 
circulating myeloid DCs. CDlc is specifically expressed on dendritic cells 
which are CDHc1"8*1 CD123low and they represent the major subset of 
myeloid dendritic cells in blood150. CDlc+ dendritic cells show a monocytoid 
morphology and express myeloid markers such as CD13 and CD33 as well 
as Fc receptors such as CD32, CD64 and FceRI. Furthermore, they were 
determined to be CD4+, Lin, CD2+ and CD45ROA In blood, in addition to 
dendritic cells, a subset of B cells also expresses CDlc. For this reason, w e 
will first deplete the P B M C fraction using CD19 for negative selection, 
followed by isolation of the CDllc+ myeloid DCs. 
Cells will be analyzed phenotypically by flow cytometry; their ability 
to undergo normal maturation will be assessed by placing them in culture 
for 24-36 hrs; and their ability to prime allogeneic T lymphocytes will be 
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assessed. Additional studies will include analysis of cells for negative and 
positive strand H C V R N A ; and quantification of IFN-a released in the 
respective cell populations in response to H C V patient versus control 
plasma. 
This study is designed for the collection of large numbers of PBMCs, thus 
allowing us to study circulating populations of DCs—CDllc+ myeloid 
D C and CD123+ plasmacytoidal DCs. Note, these populations constitute 
<0.5% of the PBMCs; therefore to perform functional studies, >250cc of 
blood are required. This has been difficult to obtain by blood draw and as 
proposed below, leukapheresis will yield enough material to run replicate 
studies. 
If our hypothesis is incorrect and there is indeed a defect in a subset of 
dendritic cells that distinguishes patients who resolve vs. those that progress 
with chronic H C V infection, w e will re-focus our efforts to characterize this 
finding. 
Aim 2. To monitor the presence of HCV-specific memory T cells with DCs cross-
presenting cell associated H C V proteins. 
Tetramer analysis has identified HCV-specific T cells in patients who 
successfully resolve the virus. While useful reagents, this method for T cell 
characterization is limited to those patients with common M H C alleles 
and viral epitopes that have been defines as strong binders of the 
respective M H C molecule. As M H C molecules are highly polymorphic 
and the H C V genome is itself variable across patient populations, w e 
propose to use antigen cross-presentation assays for the screening of 
HCV-reactive T cells. In these experiments, w e will use an osteosarcoma 
cell line with tetracycline-repressible H C V protein expression. These cells 
express full length H C V , genotype lb. W e will monitor the presentation of 
H C V antigen by patient DCs, whereby antigen is derived from 
internalized apoptotic osteosarcoma cells. The activation of patient T cells 
will be monitored using IFN-y ELISPOT assays. As a positive control 
antigen in these cross-presentation studies, the osteosarcoma cell line will 
be infected with influenza virus allowing us to monitor influenza reactive 
cells present in the patient population. 
Cross-presentation of antigen derived from HCV-expressing cell lines. W e have 
previously analyzed the response of HCV-expressing tumor cell lines to 
apoptotic-inducing stimuli. W e have also assessed the phagocytosis of the 
apoptotic cell lines by D C s and demonstrated their ability to transfer 
antigen for the loading of M H C I/peptide complexes and the activation of 
influenza-reactive CD8+ T cells. These assays have been estalished in 
normal control individuals. With large quantities of P B M C s from H C V 
patients, w e now propose to look at responders versus non-responders, 
comparing the frequency of HCV-specific T lymphocytes. W e hypothesize 
that there will be a qualitative difference in T cell reactivity, present in 
patients w h o resolved H C V and absent in those w h o progress to chronic 
infection. As previously described193,282, apoptotic cells will be exposed to 
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DCs and cultured with patient T cells to evaluate the responsiveness to 
H C V antigen. Assays for monitoring T cell activity will include ELISPOT 
and intracellular cytokine stimulation assays. 
Regarding the use of the osteosarcoma cell line, our previous results have 
demonstrated that there is no baseline allo-reactivity in normal 
individuals. As a result, these cells may be used as a vehicle for the 
delivery of viral antigen. 
In addition to characterizing CD8+ T cells responses, w e will also screen 
for the presence of HCV-reactive CD4+ T cells. Insight into the helper T 
cell immune repertoire will aid in the testing of our hypotheses regarding 
cell-mediated HCV-specific T cell tolerance. Positive controls for the CD4+ 
T cell assays will include reactivity to H C V peptides. W e will also employ 
influenza antigen as a non-modulated antigen control for both the CD4+ 
and CD8+ T cell immune assays. 
d) Primary outcomes 
Demonstration of phenotypic and functionally normal DCs in the circulation 
of H C V patients as detailed above. Briefly, >95% of the isolated circulating 
DCs will take on a CD83+ HLA-DRm mature phenotype after 24-36 hours in 
culture. These cells will be able to stimulate an allogeneic T cell response 
with >100,000 counts per minute at a ratio of 100 T cells : 1 DC, as measured 
in a thymidine incorporation assay. 
e) Secondary outcomes 
A secondary outcome of this study will be the identification of 
HCV-reactive T cells in patients w h o have resolved their H C V infection. A 
positive T cell response will be defined as >50 SFCs / IO6 CD8+ T cells. 
f) Study design 
This is an observational study. Subjects with chronic or resolved H C V 
infection as defined below are eligible. In this study, w e will enroll a total 
of 10 patients with chronic H C V and 10 patients who resolved infection. 
All patients will be leukapheresed for purposes of harvesting white blood 
cells and plasma for immunologic study. Prior to the leukapheresis, 
patients will be enrolled by a study investigator or a clinical collaborator; 
two red-top tubes will be collected at that time for pre-screening of 
patients for HBV, HIV and syphilis. 
W e will obtain peripheral blood by leukaperesis, but venipuncture will be 
offered as an alternative to this procedure. 
Initial screening of patients will occur at either The Rockefeller University 
Hospital or by the collaborating physician. All leukapheresis procedures 
will take place at The R U H . 
i) Identification of Patients 
Patients will be identified by collaborating physicians. 
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ii) Leukapheresis and Blood collections 
All patients will be leukapheresed at The Rockefeller University Hospital. 
Samples will be stored at room temperature. 
iii) Schedule of events 
Screening. Screening will be completed within 10 days, but no greater 
than 30 days, and at least 24 hours prior, to study entry. 
Medical History: The Principal Investigator's designee will perform a 
pertinent medical history. A detailed medical history will be provided by 
the collaborating physician. 
Complete Physical Examination: The Principal Investigator's designee 
will perform a complete physical exam at the indicated times. 
If any laboratory result is outside the reference range and is considered to 
be clinically relevant by the designee of the PI, the test will be repeated at 
appropriate time intervals until it returns to baseline or becomes a 
clinically insignificant finding. 
Complete Blood Count: including differential white blood cell count, 
absolute neutrophil count, hemoglobin and platelet count. 
Hematologic Tests: PT/PTT. 
Blood Chemistries: Calcium, prior to leukapheresis. 
Viral screens: Hepatitis B surface antigen, HIV antibodies, Syphilis screen. 
H L A haplotype: complete H L A haplotype is obtained as part of the 
patient database, but is not used as a clinical screening parameter. Results 
of H L A haplotyping do not need to be available prior to leukapheresis at 
week 0. 
g) Statistical model 
The primary variables will be the enumeration of D C subsets and 
determination of myeloid and plasmacytoid D C phenotype and function. In 
preliminary data, two tailed non-parametric comparisons (Mann-Whitney 
test) were used to calculate p values for differences in myeloid and 
plasmacytoid D C enumeration, as well as total IFNa production by PBMCs, 
as this method allows for data with a non-Gaussian distribution, p values for 
data normalized on a per cell basis (e.g. IFNa production per plasmacytoid 
DC) was evaluated with a two-tailed parametric comparison (unpaired t 
test, Welch corrected). 
Statistical significance will be set using 95% confidence intervals (p value 
0.05). Based on preliminary standard deviations for n=17 chronic H C V 
patients (myeloid D C SD = 0.40 and plasmacytoid D C SD = 0.17), 20 patients 
will give us 95% power to detect a difference in means of 0.47 for myeloid 
DCs and 0.20 for plasmacytoid DCs. As with preliminary data from myeloid 
DCs, it is possible to obtain "statistically significant" results with very low 
power. Failure to reject the null hypothesis will be complemented with 
equivalence testing to evaluate the lack of difference between H C V and 
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normal populations. Briefly, if addtition of one standard deviation 
statistically increases the H C V population relative to normal controls while 
subtraction of one standard deviation statistically decreases it, equivalence 
will be concluded provided the power is significant. 
10. Subjects of Study: 
Study group: Subjects for study will be chosen on the basis of a definitive 
diagnosis of prior or ongoing H C V infection as based on seropositivity and/or 
viral load. These patients are expected to fall into three distinct groups based on 
the natural course of disease: complete resolvers, with no plasma H C V titers; 
sustained responders, whose H C V titer drops below the level of detection for 
>6months post-IFN-a and ribavirin therapy; and chronically infected, patients 
who have persistent high-titer plasma HCV. For purposes of this study w e 
combine groups 1 and 2 as both populations have cleared infection and 
presumably harbor HCV-specific T lymphocytes40. All H C V patients will 
receive leukapheresis or whole blood donation (360cc). 
Inclusion/exclusion criteria 
Screening to determine eligibility (with the exception of H L A haplotyping) will 
be completed within 10 days and not less than 24 hours prior to study entry. 
—Disease Characteristics— 
1. Confirmed H C V infection based on serologic studies and /or plasma H C V 
titers 
—Prior /Concurrent Therapy— 
1. Recovered from toxicity of any prior therapy 
2. Biologic therapy: 
N o concurrent immunotherapy 
Greater than 6 months post IFN-a and Ribavirin therapy 
3. Chemotherapy: 
At least one year post-chemotherapy for other medical condition. 
4. Endocrine evaluation/therapy: 
At least 4 weeks since corticosteroid treatment 
5. Radiotherapy: 
At least 4 weeks since radiotherapy 
N o concurrent radiotherapy 
6. Surgery: 
Prior surgery allowed 
—Patient Characteristics— 
1. Age: 18 and over, able to give written informed consent. 
2. Performance status: Karnofsky 70-100% 
3. Life expectancy: At least 12 months 
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4. Hematopoietic: 
W B C greater than 3,800 
Absolute lymphocytes greater than 1,500 
Platelets greater than 120,000 
H b at least 9.5 g/dl 
INR<1.5 
5. Hepatic: 
N o patients with decompensated cirrhosis. 
6. Cardiovascular: 
N o N Y H A class III/IV status 
7. Pulmonary: 
N o severe debilitating pulmonary disease 
8. Other: 
N o active infection requiring antibiotics 
Not HIV, syphilis, or hepatitis B; anti-HIV and HbsAg antibody 
negative obtained within 90 days prior to study entry 
N o serious uncontrolled medical illness 
N o currently active second malignancy other than non-melanoma skin 
cancer (note: a patient is N O T considered to have currently active 
malignancy if they have completed therapy and are now 
considered by their physician to be at less than 30% risk for 
relapse) 
N o history of vasculitis, including but not limited to systemic 
necrotizing vasculitides (polyarteritis nodosa group), 
hypersensitivity vasculitis, Wegener's granulomatosis. 
N o receipt of immune modulators or suppressors within 30 days 
prior to study entry, including but not limited to interferons 
and thalidomide. N o active requirement for corticosteroids; 
prior use is acceptable. 
N o psychiatric illness or social condition that, in the opinion of the 
investigator, would interfere with adherence to study 
requirements. 
N o alcohol or drug use or dependence that, in the opinion of the 
investigator, would interfere with adherence to study 
requirements. 
No patient will be excluded who wants to enter this study, except for the 
reasons detailed above. All women and minority patients will be encouraged to 
participate. All referrals will be accepted after screening and when appropriate, 
entered into the study. 
Control Group: Normative data will be obtained from individuals without 
Hepatitis C or other known disease. Initially, buffy coat material obtained from 
anonymous normal donors will serve as a control population. These samples 
will be purchased from the The N e w York Blood Center. Depending on the 
results for Aim #1, w e may wish to include H B V or HIV / H C V co-infected 
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individuals in this study. At that time, an addendum to the current protocol will 
be submitted. 
11. Recruitment and Consent Procedures: 
All H C V patients that are not otherwise medically excluded, will be eligible for 
entry into the study. Recruitment will be performed in an office or hospital 
setting with patient and family present; recruiters include Drs. Andrew Talal, 
Ira Jacobson, Matthew Albert and Charles Rice. Consent will be obtained by 
Drs. Andrew Talal, Ira Jacobson Matthew Albert, Randy Longman or 
collaborating physicians. Information regarding the current expected prognosis 
of H C V infection will be offered exclusively by the treating physician. Grounds 
for exclusion from study will be solely medical. 
12. Risks and Alternative Methods: 
Risks associated with enrollment into this study include the discomfort 
associated with phlebotomy and leukapheresis. Bruising at the site where the 
needles are inserted may occur, particularly post-leukapheresis. All of these 
procedures, in which needles are inserted into the body, have a minor risk of 
introducing an infection, or causing bleeding in the area if needle insertion. 
Leukapheresis is a means of drawing blood meant to save the subject large 
amounts of blood draws. In leukapheresis, a procedure very much like blood 
donation for the subject, one needle is placed in each arm, and blood is collected 
in the blood bank. Unlike blood donation, however, the patient's own red blood 
cells (one component of the blood) are returned to the patient, in an effort to 
prevent anemia sometimes associated with blood donation. Only a fraction of 
the patient's serum and the white blood cells are kept for clinical study; the 
white blood cells are replaced completely by the patient within a short period of 
time through trafficking of cells out of the lymph nodes and spleen (minutes). 
At no time during or after the leukopheresis is the patient 
immunocompromised28*284. 
The risks involve the use of an invasive needle, which may lead to bruising of 
the arms where the needle is placed. There is a minor risk of bleeding from 
anticoagulants given during the procedure; this anticoagulant (citrate) is 
broken down by the body within one minute, any bleeding will be stopped 
by terminating the leukapheresis. The use of the citrate anticoagulant may 
result in hypocalcemia. This is readily detected as the patients lips will begin 
to tingle. Turns™ will be administered prophylactically and additional 
Turns™ will be given as per needed. Rarely, patients may faint (suffer 
hypotension due to a vasovagal reaction) during leukapheresis; for this 
reason patients lie down during the procedure and are accompanied at all 
times by medical staff. The leukapheresis will be temporarily stopped and it 
the patient continues to feel faint, the procedure will be ended prematurely. 
Patients sometimes feel chilled during leukapheresis; if they do, they will be 
given blankets to keep warm. 
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Alternative methods: A n alternative to leukapheresis is a standard blood draw. 
To obtain a sufficient number of cells for study, approximately 360cc of blood 
would need to be drawn (3/4 unit of blood in a standard blood donation; 
note however that in some patients, only 30-50cc total blood will be drawn). 
Leukapheresis is essentially the same for the patient, but has the advantages 
of providing more cells for study while not depleting the patient of their o w n 
red blood cells. Thus wherever possible, leukapheresis will be preferred over 
standard blood drawing to obtain cells for study when large numbers of cells 
are required. 
13. Data and Safety Monitoring Plan: 
a. Level of Risk: This project entails moderate risk to subjects. 
Monitoring will be conducted by the Principal Investigator (PI), a 
credentialed co-investigator, and the Rockefeller University 
Institutional Review Board (IRB), through annual reports of progress 
and by immediate notification of adverse events by the PI to the IRB, 
the G A C , and any federal regulatory agency (e.g. F D A ) when 
appropriate or required. 
b. Data and Safety Monitoring Board: This protocol comprises the 
collection of patient samples, does not expose participants to 
substantial risk, does not involve blinding, and does not involve 
vulnerable populations. It will therefore not need a Data and Safety 
Monitoring Board. Monitoring will be conducted by the PI and the 
monitoring group (see below, 14.e.) and the Rockefeller University 
IRB, through annual reports of progress. 
c. Safety review plan: Routine and safety lab tests will be reviewed in 
real time by the PI and/or co-investigators, as they are returned from 
the laboratory. Abnormal results will be evaluated for clinical 
significance and so documented. Clinically significant abnormalities 
will be followed up by the investigator or referred for care as 
appropriate. The only "safety data" that will be collected are the CBC, 
calcium and PT/PTT prior to leukapheresis. These results will be 
reviewed immediately upon receipt by the physician of record. 
Patients will not be leukapheresed if any of these tests are outside 
normal limits. Additionally, the nurse w h o is performing the 
leukapheresis will be given study personnel contact information so 
that any unexpected symptoms may be reported to the study clinicians 
as they occur. The common toxicity criteria version 2.0 will be used as 
guidelines to monitor toxicities and adverse events 
(http://ctep.inof.nih.gov). Adverse events will be reviewed in real 
time and documented in the medical record of each patient, and then 
entered into a separate A E log for that patient. On-line adverse event 
reports generated by the G C R C nursing staff will also be reviewed as 
they are received and any not already entered in the log will be added. 
This A E log will be used for tabulation of adverse events in the annual 
report to the IRB. 
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d. Serious Adverse Events (SAE): A serious adverse event or reaction is 
any untoward medical occurrence that at any dose results in death, is 
life-threatening, requires in-patient hopitalization or prolongation of 
existing hospitalization, results in persistent or significant 
disability/incapacity, or is a congenital anomaly/birth defect. All 
serious adverse events will be conveyed to the PI immediately by the 
G C R C nursing staff or a study team member. Medical intervention will 
be initiated as appropriate and the patient referred for further care as 
necessary. All unanticipated AEs of NCI grade 3 or higher occurring 
during inpatient stay or within 10 days of discharge will be reported to 
the Rockefeller University IRB and the G C R C Clinical Research Officer 
within 48 hours. All adverse events tabulated from the A E log 
(including severity and attribution), as well as total enrollment, 
demographics of enrollment, reasons for attrition, significant protocol 
violations, current status of subjects (completed, ongoing, dropout), 
and any available research data will be reported in the annual progress 
report to the IRB. The PI will maintain documentation of adverse event 
(AE) reports, all source documents, research records, and IRB 
documents. 
e. Data management and Patient Confidentiality: Data will be collected 
in a password-protected dedicated computer file and labeled with a 
patient ID number only. A standard form for the input of patient data 
will be used for all patient clinical data and to store the results of 
antibody assays, gene expression studies, and T cell assays. Laboratory 
data will be collected into bound laboratory notebooks. This data will 
then be transcribed into an electronic database. This database will 
electronically date and time stamp entries and will maintain an audit 
trail. This database will be backed up daily by the Laboratory 
Administrator. Data records will be reviewed at regular intervals in 
accordance with the monitoring plan to ensure that data is recorded 
accurately and properly. 
f. Study monitoring: The monitoring group will meet every two months 
to review the Q A data. The monitoring group will consist of Dr. Rice, 
Dr. Albert and Dr. Talal. Medical records of up to three patients will be 
randomly selected and reviewed for completeness of documentation 
and to confirm informed consent, eligibility, enrollment note, accurate 
transcription in to the A E log, and the proper conduct of the protocol. 
Research laboratory results of up to three patients will be randomly 
selected and reviewed for SOP compliance. Occurrence of these record 
and data reviews will be noted in a monitoring log. The monitoring 
group will also review the A E log for completeness (grading, expected 
or unexpected, attribution, outcome), and will review for appropriate 
reporting to the IRB. 
g. CLIA laboratory certification: Laboratory tests performed as part of 
this study are not CLIA or CLEP certified. Therefore, no laboratory 
tests run in the laboratory as part of this research protocol will be 
communicated to the patient, given to referring physicians, or 
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influence decisions about the research participants' treatment. 
14. Procedures to Minimize Risks: 
Leukapheresis or venipuncture will be performed by professional licensed staff 
at The Rockefeller Hospital or by certified phlebotomy laboratories. 
15. Potential Benefits: 
There is no direct benefit to participants in this study. The potential benefits are 
the identification of the immune defect in patients with chronic H C V infection 
that is in part responsible for the inability to clear the virus. This study might 
ultimately be useful in identifying surrogate markers for effective anti-viral 
protocols. 
16. Risk to Benefit Ratio: 
The balance of the risks versus benefits involved in participation are judged by 
the investigators to be clearly in favor of the benefits derived from participation. 
The risks are judged overall to be moderate, but are not anticipated to include 
serious adverse reactions. This is an observational research study, and the 
potential benefit of this study is entirely unknown. If the hypothesis proves to 
be correct, this study will be offer the opportunity to derived new insight into 
the development of anti-viral protocols aimed at achieving cures in chronic 
H C V patients. 
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17. Compensations: 
Patients will receive compensation for the leukapheresis procedure, 
$300/donation. 
Principal Investigator's Assurance: 
As Principal Investigator of this study, I assure the IRB that, as required by 
federal regulations: 
Proposed changes in approved studies will be presented to the IRB for 
review and approval prior to initiation except where necessary to eliminate 
apparent immediate hazards to the subjects. 
The IRB, appropriate institutional officials, the Office for Protection from 
Research Risks (OPRR) and the FDA, if applicable, will be promptly 
informed of any unanticipated problems involving risks to subjects or others 
and research related injuries. 
The informed consent of the subject will be obtained by the investigator in 
the manner and format approved by the IRB prior to the initiation of the 
studies. 
The study will be resubmitted to the IRB for continuing review at the 
interval determined by the IRB to be appropriate to the risk, but not less 
than once a year. 
(Signature of Principal Investigator) 
(Date) 
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Conflict of Interest 
D o you, your spouse or dependent children or any Professional Personnel* listed 
on the application, have any Significant Financial Interest* (as defined by the 
federal regulations): 
(A) that would reasonably appear to be affected by the research? 
Yes N o 
(B) in any entities whose financial interest would reasonably appear to be 
affected by the research? 
Yes N o 
(If you answered "Yes" for either (A) or (B), the Principal Investigator and/or 
appropriate Professional Personnel must provide a confidential statement 
describing the possible conflict of interest in the sealed envelope marked 
"Confidential" and addressed to the IRB Chair). 
Signed Date 
Investigator 
* NOTES: 
Professional Personnel means any other person responsible for the design, 
conduct, or reporting of this research. 
Significant Financial Interest means anything of monetary value, including but 
not limited to salary or other payment for services (e.g., consulting fees or 
honoraria); equity interest (e.g., stock, stock options, or other ownership 
interests); and intellectual property rights (e.g., patents, copyrights, and royalties 
from such rights). This term does not include: 
(i) Salary, royalties, or other remuneration from the institution; 
(ii) Any ownership interests in the institution, if the institution is the 
applicant under the SBIR Program; 
(iii) Income from seminars, lectures, or teaching engagements sponsored by 
public or nonprofit entities; 
(iv) Income from service on advisory committees or review panels for public 
or nonprofit entities; 
(v) A n equity interest which meets both of the following tests: does not 
exceed $10,000 in value as determined through references to public prices 
or other reasonable measures of fair market value when aggregated for 
the investigator and the investigator's spouse and dependent children; 
and constitutes more than a 5 percent ownership interest in any single 
entity when aggregated in the same manner; or 
(vi) Salary, royalties or other payments that are not reasonably expected to 
exceed $10,000 per annum from any single entity when aggregated for the 
investigator and the investigator's spouse and dependent children. 
However, the exclusions in paragraphs (i), (v) and (vi) shall not apply if the 
compensation or transfer of an equity interest is conditioned upon a particular 
outcome in the PHS-funded research. 
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